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Abstract
ETV6 (TEL1) is a member of the ETS family of transcriptional regulators, 
characterised by a conserved DNA-binding ETS domain and a PNT domain that mediate 
interaction with other proteins. Chromosomal translocations, deletions and mutations of the
ETV6 gene occur frequently in hematological malignancies. Moreover, a detailed 
understanding of the normal function of ETV6 has remained incomplete due to the 
embryonic lethality of Etv6-knockout mice. This thesis has employed zebrafish as a relevant 
model to investigate the role of ETV6 and the contribution of ETV6 fusions, and truncations 
to its perturbation during embryonic hematopoiesis.
Zebrafish possessed a single conserved etv6 orthologue that was expressed from 12 hpf in 
the lateral plate mesoderm, and later in hematopoietic, vascular and other tissues. 
Morpholino-mediated gene knockdown of etv6 revealed a complex contribution of this gene 
toward embryonic hematopoiesis. During primitive hematopoiesis, etv6 knockdown resulted 
in reduced levels of progenitor cells, erythrocyte and macrophage populations, but increased 
numbers of incompletely differentiated heterophils. During definitive hematopoiesis, etv6
knockdown decreased HSCs, erythrocytes and myeloid cells, but resulted in enhanced 
lymphopoiesis. This suggests that ETV6 plays a broader and more complex role in early 
hematopoiesis than previously thought, impacting on the development of multiple lineages. 
Chromosomal translocations resulting in alternative fusions of the human ETV6 and 
JAK2 genes have been observed in cases of acute lymphoblastic leukemia and chronic 
myelogenous leukemia, but a full understanding of their role in disease etiology has remained 
elusive. ETV6-JAK2 fusion types derived from both T-cell acute lymphoblastic leukemia and 
atypical chronic myelogenous leukemia were generated using the corresponding zebrafish 
xiii
etv6 and jak2a genes and placed under the control of either the white blood cell-specific spi1
promoter or the ubiquitously-expressed cytomegalovirus promoter.
Injection of the T-cell acute lymphoblastic leukemia-derived etv6-jak2a significantly 
perturbed lymphopoiesis with a lesser effect on myelopoiesis in zebrafish embryos. In 
contrast, injection of the atypical chronic myelogenous leukemia-derived etv6-jak2a resulted 
in significant perturbation of the myeloid compartment. These phenotypes were observed 
regardless of whether expressed in a white blood cell-specific or ubiquitous manner, with no 
overt cellular proliferation outside of the hematopoietic cells. Functional studies revealed 
subtle differences between the alternative forms, with the acute lymphoblastic leukemia 
variant showing higher activity, but reduced downstream signal transducer and activator of 
transcription activation and decreased sensitivity to JAK2 inhibition. JAK2 activity was 
required to mediate the effects of both variants on zebrafish hematopoiesis. This indicates 
that the molecular structure of alternative ETV6-JAK2 fusions likely contributes to the 
etiology of disease. The data further suggest that this class of oncogene exerts its effects in a 
cell lineage-specific manner, which may be due to differences in downstream signalling.
Finally, the ETV6 gene can be mutated to yield truncated isoforms lacking different 
ETV6 functional domains in cases with myelodysplastic syndrome, acute myeloblastic 
leukemia and acute lymphoblastic leukemia. In this study, truncated forms of zebrafish etv6 
with either the PNT or ETS domain deleted were generated. Injection of either mutant 
mimicked etv6 knockdown, resulting in reduced levels of progenitor cells and erythrocytes 
during primitive hematopoiesis. During definitive hematopoiesis these mutants reduced c-
myb+ cells but enhanced monocytic and lymphocytic populations. In contrast, expression of 
full-length etv6 increased primitive progenitor cells and erythrocytes and reduced definitive 
monocytes and lymphocytes. However, when truncated forms were co-injected with full-
xiv
length etv6, decreased erythroid populations were observed. This confirms observations that 
the loss of PNT or ETS domains of ETV6 can result in a dominant negative effect on ETV6 
function and extends these to a relevant in vivo model. This further attests to a potential role 
for these mutations in the etiology of leukemia.
xv
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Chapter 1. Introduction
1.1 Hematopoiesis and its control
1.1.1 Blood and immune cell overview
Blood and immune cells are essential for life. They comprise erythrocytes (red blood 
cells or RBC), megakaryocytes and their platelet products, and various leukocytes or white 
blood cells (WBC) (Orkin and Zon, 2008). 
RBCs are the most numerous blood cells, with their main physiological role being to 
transfer oxygen and carbon dioxide between respiratory surfaces and metabolising tissues 
(Jensen, 2009; Wickramasinghe et al., 2003). Platelets or thrombocytes are small cell 
fragments which lack a nucleus. They are involved in hemostasis, which mediates blood clot 
formation, and inflammation (Wagner and Burger, 2003; Wickramasinghe and McCullough, 
2003), and are also a source of growth factors that can stimulate angiogenesis (Kisucka et al., 
2006) and tissue remodelling (Artitua et al., 2004).
WBCs include granulocytes (neutrophils, eosinophils, basophils), lymphocytes (B-
cells, T-cells), monocytes, and natural killer cells. The major function of WBCs is to protect 
against microbial infections and other insults, and they achieve this in different ways
according to the WBC type. WBCs carry out their antimicrobial roles in the extracellular 
space, so they must be able to pass the vessel wall (Cavenagh, 2007). 
Granulocytes contain a segmented nucleus separated by fine filaments, and granules 
within their cytoplasm. The different staining characteristic of these granules is used to define 
the three types of granulocyte: the neutrophil, basophil and eosinophil (Cavenagh, 2007). 
Neutrophils are the most numerous leukocyte in mammals. They are phagocytic cells that can 
traverse through capillary walls to engulf and kill organisms encountered in the tissue. 
Eosinophils and basophils are rare cells in the blood but represent significant population in 
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the tissues. Eosinophils are involved in antiparasitic activity (Cavenagh, 2007), whereas 
basophils play key roles in mucosal immune responses and intermediate-type hypersensivity 
reactions (Franco et al., 2006).
Monocytes exist in the blood but can leave the circulation and migrate into tissues 
where they undergo transformation into various macrophages population. Both monocytes 
and macrophages are phagocytic cells similar to neutrophils, and can protect the body against 
intracellular organisms such as mycobacteria, listeria, and some type of fungi. Macrophages 
also play roles in tumour immunity, antigen presentation, tissue remodelling and removal of 
dead cells and debris (Cavenagh, 2007). 
Lymphocytes (B-cells and T-cells) are specialist cells that function in adaptive 
immunity. B-cells are involved in antibody production against pathogenic antigens, and they 
are characterized by the expression of B-cell receptors (BCR) on their surface 
(Wickramasinghe and McCullough, 2003; Blom and Spits, 2006). B-cell precursors migrate 
to the lymph nodes, where they differentiate into plasma cells and memory cells following 
interaction with an antigen (Hartenstein, 2006; Wickramasinghe and McCullough, 2003; 
Blom and Spits, 2006). T-cells are responsible for cellular immunity. T-cell precursors 
mature in the thymus (Hartenstein, 2006; Hansen and Zapata, 1998; Schlenner and 
Rodewald, 2010), then migrate to peripheral lymphoid organs via circulation to protect 
against invading microorganisms and tumour cells. Interaction of specific T-cell receptors 
(TCR) with major histocompatibility complexes (MHC) on antigen-presenting cells (APCs) 
represents the underlying mechanism for triggering T-cell function. This mediates the 
recruitment of innate immune cells - including neutrophils and macrophages - to sites of 
tissue damage, destruction of infected cells, and stimulation of B-cells to produce antibodies 
(Wickramasinghe and McCullough, 2003; Blom and Spits, 2006). T-cells can be sub-grouped 
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into helper T (Th) cells, including Th1, Th2 and Th17, cytotoxic T (Tc) and regulatory T 
(Treg) each with specialised functions (Blom and Spits, 2006). Th1 cells mediate cellular 
immune response against intracellular pathogens (Mosmann et al., 2005), Th2 cells are 
involved in humoral immune response against extracellular pathogens by induction of B-cell 
antibody class switching (Bettelli et al., 2007), Th17 cells are mainly involved in protection 
against extracellular bacteria (Maloy and Powrie, 2001; Harrington et al., 2005), Tc cells are 
able to kill infected cells as well as tumour cells (McCullough and Summerfield, 2005), while 
Treg cells suppress excessive immune responses to inhibit autoimmunity (Sakaguchi et al., 
2008).
1.1.2 Hematopoiesis
Hematopoiesis describes the process of blood cell formation. All blood cells arise 
from a small number of common progenitors, called hematopoietic stem cells (HSC). Most 
HSCs are quiescent and comprise the reserve stem cell pool. At any one time, a small fraction 
of HSCs are active, dividing asymmetrically to produce more HSC, to maintain the HSC 
pool, and daughter cells, which differentiate and replicate to generate the large number and 
wide diversity of blood cells (Pietras et al., 2011; Beckmann et al., 2007).
An important part of hematopoiesis involves lineage commitment through a 
succession of progenitor cells with increasingly restricted potential to form the specific cell 
type. Firstly, HSC commit to either lymphoid or myeloid lineage. Subsequently, theses 
common lymphoid and myeloid progenitors (CLP and CMP respectively) become more 
committed. Myeloid progenitors can give rise to basophils, eosinophils, neutrophils, 
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monocytes, erythrocytes or thrombocytes. Instead, lymphoid progenitors give rise to B-cells 
and T-cells (Akashi et al., 2000; Kondo et al., 1997) (Fig. 1.1).
Two distinct waves of hematopoiesis have been identified during the life span of 
mammals, called primitive and definitive hematopoiesis. Primitive hematopoiesis occurs in 
blood islands of the yolk sac located outside the embryo (Hansen and Zapata, 1998, Palis and 
Yoder, 2001; Shizuru et al., 2005). Definitive hematopoiesis begins latter in the aorta-ganad-
mesonephros (AGM) region of the embryo (Orkin, 2000; Pietil et al., 2005). The HSCs 
generated then migrate firstly to the fetal liver (Hansen and Zapata, 1998), and then the bone 
marrow, which is the major site of definitive hematopoiesis after birth, where erythroid and 
myeloid cell lineages are consistently produced. Although both B-cells and T-cells are also 
produced in bone marrow, they mature in different sites. B precursors mature in lymph nodes, 
spleen and other secondary sites (Brendolan et al., 2007; Hartenstein, 2006), but T precursors 
migrate to the thymus to produce the different T-cell lineages (Hansen and Zapata, 1998; 
McGrath et al., 2003). Both steady-state hematopoiesis and the emergency hematopoiesis that 
occurs in response to physiological stress such as hypoxia, bleeding, and infection are tightly 
regulated through numerous mechanisms (Takizawa et al., 2012).
1.1.3 Regulators of hematopoiesis
Cytokines are the main extrinsic regulator of hematopoiesis which act via downstream 
signalling pathways, while transcription factors represent the major intrinsic regulators. 
Collectively, they determine lineage fate decisions and flux through each lineage (Fig. 1.1) 
(Robb, 2007; Orkin, 1995).
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Figure 1.1. Hematopoiesis and its key regulators
Schematic representation of the process by which common blood cell progenitors undergo 
increasing lineage commitment to generate the complete repertoire of blood and immune 
cells. Some key lineage-specific cytokines and transcription factors that serve to regulate this 
process are shown in green and red, respectively.  HSC: hematopoietic stem cell, CMP: 
common myeloid progenitor, CLP: common lymphoid progenitor, BP: basophil progenitor, 
EP: eosinophil progenitor, GMP: granulocyte-monocyte progenitor, EMP: erythroid-
megakaryocyte progenitor, Baso: basophil, Eos: eosinophil, Neut: neutrophil, Mono: 
monocyte, Mac: macrophage, Mk: megakaryocyte, Ery: erythrocyte, Plt: platelet,  SCF: Stem 
cell factor, IL: Interleukin, GM-CSF: Granulocyte-macrophage colony stimulating factor, G-
CSF: Granulocyte-colony stimulating factor,  M-CSF: Macrophage-colony stimulating factor,
TPO:  Thrombopoietin, EPO:  Erythropoietin
6
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1.1.3.1 Cytokines
Cytokines are small proteins secreted by various cells in response to developmental 
and environmental stimuli. These include stem cell factor (SCF), which acts on HSCs,
erythropoietin (EPO), which induces erythroid production (Grover et al., 2014), 
thrombopoietin (TPO), which regulates megakaryocyte expansion (de Graaf and Metcalf, 
2011), and granulocyte colony-stimulating factor (G-CSF), which preferentially stimulate the 
formation of granulocytes (Metcalf, 1986). There are also numerous interleukins (IL) such as 
IL-3 which is implicated in proliferation and differentiation of myeloid cells and IL-2, IL-7
etc which are involved in lymphopoiesis (Metcalf et al., 1986; Fry and Mackhall, 2005). They 
act via cognate receptor on the surface of responsive cells, and initiate a cascade of 
intracellular signalling events, which eventually modulate the transcription of key target 
genes (Baker et al., 2007). Perhaps the most important signalling pathway used by 
hematologically important cytokines is the JAK-STAT pathway (Ward et al., 2000).
Following binding to its receptor, associated Janus kinases (JAKs) are transiently activated
which leads to autophosphorylation of the JAKs and subsequent phosphorylation of specific 
tyrosine residues on the cytoplasmic domain of the receptor. SH2-containing signalling 
molecules, including the signal transducer and activator of transcription (STAT) proteins, are 
able to bind to these phosphorylated tyrosine motifs. Subsequent tyrosine phosphorylation of 
the STATs by the JAKs releases them from the receptor, inducing homo or heterodimer 
formation, and then nuclear translocation. Here the STATs bind to specific sequences within 
the promoters of target genes to activate their expression (Fig.1.2) (Kisseleva et al., 2002; 
Levy and Darnell, 2002).
Mammals possess four JAKs (JAK 1, 2, 3 and TYK2) and seven STATs (STAT 1, 2, 
3, 4, 5A, 5B, 6) (Yamashita et al., 1998). All JAK proteins share seven JAK Homology (JH) 
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structural domains, JH1-7. The JH1 domain lies at the carboxy-terminal end and possess 
tyrosine-kinase activity. The JH2 domain represents a pseudokinase domain without any 
enzymatic activity, but serves a regulatory function for JAK kinase activity. The amino-
terminal JH3-JH7 domains mediate association with receptors (Hubbard and Till, 2000; 
Schindler, 2002; Kisseleva et al., 2002). Different cytokine receptors engage with a specific 
combination of JAKs (and STATs) (Barker et al., 2007). JAK2 is an important mediator for 
EPO, IL-3, GM-CSF, IL-5 and TPO induced biological responses (Kisseleva et al., 2002). Its 
corresponding gene is located on chromosome 9p23-24.
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Figure 1.2. Cytokine receptor signalling via the JAK-STAT pathway.
Schematic drawing showing the sequential activation of the JAK-STAT pathway following 
ligand binding to its receptor. This results in conformation changes leading to transactivation 
of JAKs, which then phosphorylate the receptor and subsequently STATs that dock to these 
sites. The phosphorylated STAT molecules dimerise and translocate to the nucleus to activate 
transcription (Levy and Darnell, 2002).
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1.1.3.2 Transcription factors
Transcription factors are sequence-specific DNA binding proteins that control gene 
expression by interaction with either promoter or enhancer regions of responsive genes
(Latchman, 1997; Karin, 1990). Transcription factors use a variety of mechanisms to 
modulate gene expression, including affecting the binding of RNA polymerase to DNA, 
catalysing the acetylation and deacetylation of histone proteins, and recruiting corepressor or 
coactivator proteins (Gill, 2001; Narlikar et al., 2002; Xu and Glass, 1999 ). 
Differentiation of HSC into specific hematopoietic progenitors is regulated by the 
transcription factors SCL and c-MYB. Lymphoid progenitor differentiation into B and T cells 
is regulated by transcription factors such as Ikaros and related proteins. SPI1 is one of the key 
transcription factors in myeloid cell differentiation as well as being introduced in lymphoid 
progenitor differentiation into B cells, while formation of erythrocytes from erythroid 
progenitor cells is regulated by the GATA-1 transcription factor. These hematopoietic 
transcription factors can be classified into groups according to their DNA binding motif: for 
example, helix-loop-helix for SCL, zinc finger for Ikaros and GATA1, and ETS for SPI1 and 
ETV6 (Davidson and Zon, 2004).
1.1.4 Perturbation of hematopoiesis
1.1.4.1 Diseases of hematopoiesis
Any alterations to the regulation of blood cell production and differentiation can result 
in blood deficiencies or malignancies. A decrease in erythrocytes or haemoglobin is known as 
anemia and results in impaired ability of blood to transfer oxygen to the tissues. Three main 
causes of anemia include (i) decreased erythrocyte production such as in iron deficiency 
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anemia; (ii) increased erythrocyte destruction or hemolysis such as in sickle cell anemia, 
thalassemia or G6PD deficiency; and (iii) blood loss such as gastrointestinal bleeding or 
trauma (Janz et al., 2013). In contrast, abnormally reduced numbers of leukocytes in blood is 
defined as leukopenia, which may be due to reduced production or increased utilization and 
destruction of leukocytes, or both. Infection, malignancy and drugs are responsible for most 
cases of leukopenia (Ing, 1984).
In contrast, leukemia is recognised by the accumulation of abnormal WBCs in bone 
marrow and blood, which may then spread in to different organs and fluid. Leukemic 
disorders can be divided into lymphoid and myeloid according to the cell lineage the 
malignancy develops from. They can also be classified into acute and chronic forms. Acute 
leukemias are characterised by rapid accumulation of immature blood cells, whereas chronic 
leukemia refers to sustained increase of relatively mature blood cells. Therefore, leukemic 
disorders are classified into 4 major groups: acute myelogenous leukemia (AML), acute 
lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and chronic 
lymphocytic leukemia (CLL) (Pokharel, 2012).
According to the WHO classification from 2001, CML is considered a part of the 
myeloproliferative neoplasms (MPN). Theses represent of clonal hematological malignancies 
characterized by chronic expansion of some or all of the myeloid lineages. Polycythemia vera 
(PV) and essential thrombocythemia (ET), which are manifested by increased erythrocytes 
and platelets, respectively, and  primary myelofibrosis (PM), which is the formation of 
fibrous tissue in the bone marrow as a result of abnormal myelopoiesis, are among other 
members of this group (Tefferi and Vardiman, 2008). 
There are three phases of CML: chronic-phase (CML-CP), accelerated-phase (CML-
AP) and blastic-phase (CML-BP). These phases are determined by the number of blast cells 
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in the blood and bone marrow and the severity of symptoms. CML-CP is characterized by 
less than 10% blasts in the blood and bone marrow. These patients have mild symptoms and 
respond well to standard treatments. In CML-AP, there are 10% to 19% blasts in the blood 
and bone marrow, and are less responsive to treatments. In CML-BP, there is 20% or more 
blasts in the blood and bone marrow with poor responsiveness (Cortes et al., 2006).
AML is divided into 7 subtypes according to WHO classification: AML with 
rcurrent genetic abnormalities (incluing t(8;21), t(9;11), t(15;17) or M3, t(6;9), t (1;22), inv 
(16) and inv (3)), AML with myelodysplastic-related changes, therapy-related myeloid 
neoplasms, NOS (not otherwise specified) AML (including AML with minimal 
differentiation (M0), AML without maturation (M1), AML with maturation (M2), acute 
myelomonocytic leukemia (M4), acute erythroid leukemia (M6), acute megakaryoblastic 
leukemia (M7), acute basophilic leukemia and acute panmyelosis with myelofibrosis),
myeloid sarcoma, myeloid proliferation related to Down syndrome and blastic plasmacytoid 
dendritic cell neoplasm (Vardiman et al.,2009).
Myelodysplastic syndromes (MDS) are a group of hematological disorders recognised 
by ineffective production of myeloid cells in bone marrow, which can progress into AML. 
MDSs are classified into five categories according to the proportion of myeloblasts in the 
bone marrow: refractory anemia (RA) and refractory anemia with ring sideroblasts (RARS) 
with less than 5% myeloblasts in both cases, refractory anemia with excess blasts (RAEB) 
with 5-20% myeloblasts, refractory anemia with excess blasts in transformation (RAEB-T) 
with 21-30% myeloblasts, and chronic myelomonocytic leukemia (CMML) with 0-20% 
myoblasts. Moreover, in RARS more than 15% of erythroid precursors are ring sideroblasts 
(Tefferi and Vardiman, 2009).
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1.1.4.2 Molecular basis of hematopoietic disease
As discussed above, transcription factors are known to be essential for normal 
hematopoiesis. Thus, mutations of genes encoding transcription factors can cause leukemia 
(Enver et al., 1998). For instance, mutation of genes encoding Ikaros, and SPI1 have been 
implicated in ALL and AML, respectively (Kastner et al., 2013; Mueller et al., 2002). 
Similarly, chromosomal translocations creating chimeric transcription factor fusions can be 
involved. For example, MN1-ETV6 and AML1-ETO fusion proteins block normal 
hematopoiesis and cause AML (van Wely et al., 2007; Dowing et al., 1999; Melnick et al., 
2000). Finally, dysregulation of signalling components have also been found in variety of 
hematological malignancies. For example, constitutive activation of JAK2 due to a V617F 
mutation was identified in the majority of patients with polycythemia vera (James et al., 
2005).
1.2 ETV6 and ETV7
1.2.1 Overview
ETV6 (ETS variant 6) also known as TEL1 (Translocating E26 transforming-specific 
leukemia 1) and the related ETV7 or TEL2 are members of the evolutionarily-conserved ETS
(E26-transforming specific) family of transcription factors, which have been implicated in a 
variety of cellular development and differentiation processes (Dittmer and Nordheim, 1998; 
Ghysdael and Boureux, 1997; Sharrocks et al., 1997). All ETS proteins share an extensively 
conserved domain of about 85 amino acids, which binds to purine-rich sequences of 
GGAA/T, flanked by 5-8 nucleotides that determines the specificity of each family member, 
found within the promoters or enhancers of target genes (Graves and Petersen, 1998; 
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Janknecht and Nordheim, 1993). This so-called ETS domain represents a winged helix-turn-
KHOL[GRPDLQFRPSRVHGRIĮ-helixes and 4 ȕ-sheets arranged in the order Į-ȕ-ȕ-Į-Į-
ȕ-ȕ.RGDQGDSDQi, 1996; Donaldson et al., 1996). Another evolutionary conserved domain 
shared by a subset of ETS family members is the pointed (PNT) domain, which is in the form 
of a modified helix-loop-helix (HLH) structure for mediating protein-protein interactions
(Kim et al., 2001). Although some ETS family members are expressed ubiquitously, other are 
predominantly expressed in a tissue-specific manner (Potter and Buijs, et al., 2000), including 
in hematopoietic cells where they regulate blood cell development (Bassuk and Leiden, 
1997). 
1.2.2 ETV6 gene and protein structure and function
The human ETV6 gene spans a region of over 240 kb on the short (P) arm of 
chromosome 12 at band 13.1 and consists of 8 exons (Baens et al., 1996). There are two 
isoforms of ETV6 (57 kDa and 53 kDa) arising from alternative start codons at position 1in 
exon 1a and position 43 in exon 1b (Fig. 1.3) (Baens et al., 1996). The PNT domain at its N-
terminus is encoded by exons 3 and 4 and the ETS domain at its C-terminus is encoded by 
exons 6 and 8 flanking a central domain encoded by exon 5 (Fig. 1.3).
The PNT domain is responsible for homo or heterodimerization with a range of proteins, 
including the closely-related ETV7 protein, the ETS family member FLI1 and the ubiquitin-
conjugating enzyme UBC9 (Chakrabarti et al., 1999; Hiebert et al., 1996; Kim et al., 2001; 
Potter et al., 2000). This domain is required for the repression of target genes (Irvin et al., 
2003), and also mediates the nuclear export of ETV6, thereby regulating its activity (Wood et 
al., 2003). The positively charged ETS domain is responsible for binding to DNA (Oikawa 
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and Yamada 2003; Poirel et al., 1997). The less conserved central domain contributes to the 
strong repressional activity of ETV6 (Chakrabarti et al., 1999; Guidez et al., 2000). 
In several studies ETV6 has been identified as a strong transcriptional repressor (Lopez et al., 
1999; Chakrabarti and Nucifora, 1999). This has been mapped to the PNT and central 
domains. PNT domain-mediated repression has been shown to be dependent on interaction 
with the SPM domain of L3MBTL1 (human homolog of the Drosophila Lethal3 Malignant 
brain tumor protein), a member of polycomb group of chromatin-associated proteins, which 
stabilizes the repressive effect of ETV6 on transcription through a HDAC (histone
deacetylase) independent mechanism (Boccuni et al., 2003). In contrast, repression by the 
central domain is mediated through binding of various co-repressors, including SMRT, 
mSin3A, N-CoR and Tip60, which subsequently recruit HDACs to mediate transcriptional 
repression (Chakrabarti et al., 1999; Lopez et al., 1999; Guidez et al., 2000; Wang et al., 
2001; Nordentoft et al., 2003).
While ETV6 would appear to regulate the transcription of genes with ETS consensus 
site in their promoters, only a handful of genes actually targeted by ETV6 are known. These 
include the GPIIb and *3,EĮ genes in myeloid K562 cells induced with TPA (Sakurai et al., 
2003), the TCL1 (T-cell lymphoma 1) oncogene in pre–B-cell acute lymphoblastic leukemic
cells (Fears et al., 2002), the BCL-XL gene in NIH 3T3 cells (Irvin et al., 2003) and ȕ-globin 
in transgenic mice expressing human ETV6 under the control of Gata1 promoter (Eguchi-
lshimae et al., 2009), as well as acting on the stromelysin promoter in Ras-transformed NIH 
3T3 cells (Fenrick et al., 2000)
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Figure 1.3. ETV6 chromosomal location, gene and protein structure.
Schematic representation of the ETV6 gene locus on human chromosome 12 (upper panel), 
the ETV6 gene transcript with numbered boxes corresponding to exons (middle panel), and 
the ETV6 protein with domains indicated and relevant amino acids numbered (lower panel).
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1.2.3 Functions of ETV6 in vivo
ETV6 has been shown to play an important role in normal embryonic development 
and hematopoietic regulation. Targeted knockout of the Etv6 gene in mice led to embryonic 
lethality at day 10.5-11.5 of development due to mesenchymal and neural cell apoptosis 
accompanied by defective angiogenesis in the yolk sac (Wang et al., 1997). Primary 
erythropoiesis at this time was unaffected. However, further analysis of chimeric mice 
consisting of both Etv6 -/- cells and normal (Etv6 +/+) cells revealed that although Etv6 -/-
cells contributed to yolk sac and fetal liver hematopoiesis, they were totally absent from the 
bone marrow. These findings revealed that Etv6 was essential for the establishment of 
definitive hematopoiesis in mice (Wang et al., 1998). Knockdown of etv6 in Xenopus also 
revealed a requirement for this gene in the formation of the first definitive hematopoietic 
stem cells in the dorsal aorta (Ciau-Uitz et al., 2010). Conditional knockouts in adult mice 
indicated that Etv6 was essential for survival of adult HSCs within hematopoietic niches 
(Hock et al., 2004). However, ablation of Etv6 after lineage commitment did not affect adult 
hematopoiesis except for specific maturation defects in the megakaryocyte lineage (Hock et 
al., 2004). In contrast, transgenic mice expressing human ETV6 under the control of Gata1
promoter identified that ETV6 was also involved in both proliferation and differentiation in 
the erythroid lineage, depending on the stage of erythroid development. During the early 
stages of erythropoiesis, ETV6 was found to accelerate proliferation, while in the latter stages 
it increased differentiation including stimulation of hemoglobin synthesis. The latter was
achieved through indirect promotion of ALAS-E transcription and GLUHFW VWLPXODWLRQ RI ȕ-
globin synthesis (Eguchi-Ishimae et al., 2009). This may explain the observation that 
enhanced expression of ETV6 in mouse erythroleukemia cells induced their differentiation 
toward erythrocytes (Waga et al., 2003).
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1.2.4 Role of ETV6 chromosomal translocations in disease
The human ETV6 gene is notable for its frequent involvement in chromosomal 
translocations associated with hematological malignancies. Around 50 translocations 
involving the ETV6 gene have been described, involving around 30 partner genes (De 
Braekeleer et al., 2012). These translocations can be classified according to the type of fusion 
partners namely: tyrosine kinases, transcription factors, and other proteins (Fig. 1.4).
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Figure 1.4. ETV6 fusion partner network.
Graphical representation of the various proteins found fused to ETV6 in malignancy are 
shown by class: tyrosine kinases (blue), transcription factors (green) and other proteins
(orange).
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1.2.4.1 Tyrosine kinases
The ETV6/tyrosine kinase fusions have been detected in a plethora of hematological 
malignancies. In all cases, including fusions with ABL1, ABL2, JAK2, SYK, FRK, LYN, 
FGFR3, PDGFRA, PDGFRB, NTRK3, and FLT3, the PNT domain of ETV6 is fused to the 
tyrosine kinase domain of the fusion partner. In this way the PNT domain mediates 
dimerization of the tyrosine kinase, resulting in its constitutive activation and subsequent 
autophosphorylation and phosphorylation of downstream signal transducing proteins, such as 
STATs (Table 1.1).
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Table 1.1. Tyrosine kinase fusions with ETV6.
Summary of the ETV6 fusions with tyrosine kinases, indicating the disease, translocation, 
ETV6 breakpoint, ETV6 domain involvement (PNT, ETS), functional mechanisms and 
references. AML: acute myelogenous leukemia, ALL: acute lymphocytic leukemia, MPN: 
myeloproliferative neoplasm, CML: chronic myelogenous leukemia, Ph: Philadelphia 
chromosome, CP: chronic phase, BP: blastic phase, aCML: atypical CML, MDS: 
myelodysplastic syndrome, CMML: chronic myelomonocytic leukemia, CIM: chronic 
idiopathic myelofibrosis, Bc: blastic crisis, CEL: chronic eosinophilic leukemia
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Fusion gene        Disease Translocation Breakpoint 
in ETV6
PNT ETS Functional mechanisms References
ETV6-ABL1 AML, B-cell ALL, 
T-cell ALL, MPN, 
CML (Ph 
negative) in CP 
and BP
t(9;12) int 4 or 5 + - • Constitutive activation of 
the PTK domain of ABL1
Golub et al., 1996; La 
Starza et al., 2002; 
Papadopoulos et al., 
1995; Malona et al., 
2010; Van Limbergen 
et al., 2001;  Nand et 
al., 2009; Barbouti at 
al., 2003; Kelly et al., 
2009
ETV6-ABL2 AML-M4, M3, T-
cell ALL
t(1;12) int 5 + - • Constitutive activation of 
the PTK domain of ABL2
Cazzaniga et al., 1999; 
Iijima et al., 2000; 
Griesinger et al., 2002
ETV6-JAK2 Pre-B cell ALL, 
aCML, T-cell ALL
t(9;12) int 4 or 5 + - • Constitutive activation of 
the PTK domain of JAK2
Peeters et al., 1997a;
Lacronique et al., 1997
ETV6-FGFR3 Peripheral T-cell 
lymphoma
t(4;12) int 5 + - • Constitutive activation of 
the PTK domain of FGFR3
Yagasaki et al., 2001
ETV6-SYK MDS t(9;12) int 5 + - • Constitutive activation of 
the PTK domain of SYK
Kuno et al., 2001
ETV6-FRK AML-M4 t(6;12) int 4 + - • Constitutive activation of 
the PTK domain of FRK
Hosoya et al., 2005
ETV6-LYN Primary 
myelofibrosis
Ins(12;8) int 5 + - • Constitutive activation of 
the PTK domain of LYN
Tanaka et al., 2009
ETV6-
PDGFRA
MPN t(4;12) int 6 + - • Constitutive activation of 
the PTK domain of 
PDGFRA
Curtis et al., 2007
ETV6-
PDGFRB
CMML, AML-M0 
on CIM, AML-
M2, aCML in Bc
t(5;12) int 4 or 7 + - • Constitutive activation of 
the PTK domain of 
PDGFRB
Golub et al., 1994; 
Tokita et al., 2007; 
Yahata et al., 1998; 
Curtis et al., 2007
ETV6-NTRK3 AML-M2, M0, 
CEL
t(12;15) int 4 or 5 + - • Constitutive activation of 
the PTK domain of 
NTRK3
Eguchi et al., 1999; 
Kralik et al., 2011; 
Forghieri et al., 2011
ETV6-FLT3 MPN with 
hypereosinophilia, 
T-lymphoblastic 
lymphoma
t(12;13) int 4 or 5 + - • Constitutive activation of 
the PTK domain of FLT3
Vu et al., 2006; Walz 
et al., 2011
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1.2.4.2 Transcription factors
ETV6/transcription factor fusions have been implicated in variety of leukemias. In 
these cases, the fusion modifies the transcription activity of ETV6 and/or the fusion partner 
by converting a transcriptional repressor into an activator or vice versa, which can be 
achieved in three different ways. Fusions with involvement of the PNT domain of ETV6, 
such as fusions with RUNX1 and ARNT, results in a dominant-negative effect of the fusion 
protein over the normal function of the fusion partner. However, in fusions that involve both 
PNT and ETS domains of ETV6, such as fusions with MN1, PAX5 and HLXB9, the chimeric 
protein appears to act as an aberrant transcription factor and results in modification of both 
ETV6 and partner gene transcription activity. Finally, in fusions that involve the promoter -
rather than a functional domain - of ETV6, such as with EVI1 and CDX2, ectopic expression 
of the fusion partner genes in hematopoietic cells has been suggested to mediate 
leukemogenesis.
27
Chapter 1. Introduction
Table 1.2. Transcription factor fusion partners of ETV6: 
Summary of the ETV6 fusions with other transcription factors, as detailed in Table 1.1. ALL: 
acute lymphocytic leukemia, AML: acute myelogenous leukemia, RAEB: refractory anemia 
with excess of blasts, MDS: myelodisplastic syndrome, aCML: atypical chronic myelogenous 
leukemia, Bc-CML: blastic crises of CML
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Fusion gene     Disease Translocation Breakpoint 
in ETV6
PNT ETS Functional mechanisms References
ETV6-
RUNX1
B-cell ALL t(12;21) int 4 or 5 + - • Dominant negative 
effect of the fusion 
protein over wild type 
ETV6 allele
• Repression of RUNX1 
target genes
Romana et al., 1995a; 
Golub et al., 1995; 
Romana et al., 1995b; 
Zaliova et al., 2011
MN1-ETV6 AML-M0, M2, 
M4, CML, 
RAEB, AML on 
MDS
t(12;22) int 2 or 3 + + • Activation of ETV6 
target genes, 
• Repression of retinoic 
acid mediated 
transcription
• Dominant negative 
effect of the fusion 
protein over wild type 
MN1 allele
Buijs et al., 1995;
Nakazato et al., 2001;
Chen et al., 2007a;
Nofrini et al., 2011; 
Van Wely et al., 2007; 
Buijs et al., 2000; Van 
Wely et al, 2003
ETV6-ARNT AML-M2, T-
cell ALL
t(1;12) int 4 + - • Dominant negative 
effect of the fusion 
protein over wild type 
ETV6 allele
• Modification of ARNT 
into a transcriptional 
repressor.
Salomon-Nguyen et 
al., 2000; Otsubo et al., 
2010
ETV6-EVI1 aCML, Bc-
CML, RAEB, 
AML-M0
t(3;12) int 2 - - • Ectopic expression of 
EVI1 
Peeters et al., 1997b; 
Nishimura et al., 2000; 
Nakamura et al., 2002
ETV6-CDX2 AML-M1 t(12;13) int 2 - - • Ectopic expression of 
CDX2
Chase et al., 1999;
Rawat et al., 2004
PAX5-ETV6 B-cell ALL t(9;12) int 2 + + • Modification of ETV6
and/or PAX5 
transcription activity
Cazzaniga et al., 2001; 
Strehl et al., 2003
HLXB9-
ETV6
AML-M0, M1, 
M2,  M3, M7
t(7;12) int 2 + + • Modification of ETV6
and/or HLXB9 
transcription activity?
Beverloo et al., 2001; 
Von Bergh et al., 
2006; Hauer et al., 
2008; Taketani et al., 
2008
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1.2.4.3 Other proteins
Other ETV6 translocations not involving tyrosine kinases or transcription factors have 
been reported in variety of leukemias. In most of these cases, just the first two (non-coding) 
exons of ETV6 are involved in the translocation. It is believed that in these cases, involving 
fusions to CHIC2, MDS2, TTL, STL, ACS2 and PER1, the overexpression of a neighbouring 
gene is the critical pathogenic mechanism of the translocation (Table 1.3).
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Table 1.3. Other protein fusion partners of ETV6:
Summary of ETV6 fusions with other proteins as detailed in Table 1.1. AML: acute 
myelogenous leukemia, RAEB: refractory anemia with excess of blasts, ALL: acute 
lymphocytic leukemia, CMML: chronic myelomonocytic leukemia, MDS: myelodysplastic 
syndrome, AEL: acute eosinophilic leukemia, PV: polycythemia vera, CML: chronic 
myelogenous leukemia, RA: refractory anemia, RAEB: refractory anemia with excess of 
blasts. *OSTL (or opposite STL) shares the first exon with STL but is transcribed in the 
opposite direction.
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Fusion gene        Disease Translocation Breakpoint 
in ETV6
PNT ETS Functional mechanisms References
CHIC2-ETV6 AML-
M0,M1,M2
M/NK cell L, 
RAEB
t(4;12) int 1 or 2 - - • Overexpression of 
adjacent gene (GSX2)
Cools et al., 1999; Cools et 
al., 2002; Kuchenbauer et 
al., 2005; Chen et al., 
2005; Silva et al., 2008
ETV6-MDS2 RAEB t(1;12) int 2 - - • Overexpression of 
adjacent gene (PRL11)
Odero et al., 2002
ETV6-TTL or
TTL-ETV6
Pre B-cell ALL t(12;13) int 1 -
+
-
+
• Loss of function of 
ETV6 or/and TTL
• Over-expression of 
adjacent genes (p27 and 
FOXO1A)?
Qiao et al., 2003
ETV6-STL or
STL-ETV6-s or 
STL-ETV6-L, 
M
Pre-B ALL t(6;12) int 2 -
+
-
-
+
-
• Deregulation of 
adjacent gene (OSTL*)
• Loss of ETV6 function
Suto et al., 1997; Krause et 
al., 2003
ETV6-PER1 AML on CMML t(12;17) int 1 - - • Over expression of 
adjacent gene (HES7 or 
STK12)
Penas et al., 2003
ETV6-ACS2 RAEB, MDS, 
AML, AEL, PV, 
CML
t(5;12) int 1 or 2 - - • Over-expression of 
adjacent gene (IL-3)
Katsura et al., 2007; 
Yagasaki et al., 1999; 
Murati et al., 2006; Cools 
et al., 2002; Erben et al., 
2010
ETV6-PTPRR AML-M2 inv(12) int 4 + - • Dominant negative 
effect of the fusion 
protein over wild type 
ETV6 allele
Nakamura et al., 2005
ETV6-NCOA2 AML-M2, ALL t(8;12) int 4 or 5 + - • Constitutive activation 
of ETV6 target genes
• modification of 
transcriptional activity of 
CBP-dependent 
activators
Strehl et al., 2008
ETV6-BAZ2A Pre B-cell ALL t(12;12) int 2 - - • Haploinsufficiency of 
ETV6 and/or BAZ2A?
• Deregulation of 
BAZ2A or a gene in 
vicinity of BAZ2A?
Panagopoulos et al., 2006
ETV6-GOT1 RA, RAEB t(10;12) int 2 or 3 - - • Dominant negative 
effect of fusion protein 
over both GOT and 
ETV6
Janssen et al., 2006;
Struski et al., 2008
ETV6-FCHO2 AML-M1 t(5;12;22) int 2 - - • Haploinsufficiency of 
ETV6 and/or FCHO2
Belloni et al., 2004
ETV6-IGH Pre B-cell ALL t(12;14) ? ? ? ? Lu et al., 2002
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1.2.5 Tumor suppressor function of ETV6
Besides being involved in a vast number of translocations associated with 
malignancies, there are other studies supporting the notion that ETV6 functions as a tumor 
suppressor gene. The short arm of chromosome 12 is a hot spot for chromosomal 
abnormalities in various malignancies. These include interstitial deletions that lead to the loss 
of genetic material from 12p which has been mapped to a small locus containing the ETV6 
and KIP1 genes (Wlodarsk et al., 1996; Sato et al., 1995; Wlodarsk et al., 1996). In many 
cases of childhood ALL carrying t(12;21) the wild-type ETV6 allele is deleted (Golub et al., 
1995; Patel et al., 2003; Raynaud et al., 1996). Interestingly, in cells harbouring these 
translocations, consistent loss of ETV6 expression was observed even in the absence of 
detectable ETV6 deletion, suggesting that secondary structural abnormalities and epigenetic 
modifications may lead to the silencing of ETV6 allele (Patel et al., 2003). Frequent point 
mutations of ETV6 have been reported in T-ALL and AML leading to truncated forms of 
ETV6 which exerted a dominant-negative effect to abolish wild type ETV6 function (Van 
Doorn et al., 2005; Van Vlierberghe et al., 2011, Zhang et al., 2011). Furthermore, in several 
cases of leukemia including ETV6 translocations, neither functional fusion protein was 
identified nor was ectopic expression of a neighbouring proto-oncogene reported. In these 
cases, haploinsufficiency of ETV6 has been raised as a contributing factor to the etiology of 
leukemia (Belloni et al., 2004; Panagopoulos et al., 2006).
Additional evidence of a potential tumor suppressor role for ETV6 comes from its 
functional studies.  A transient increase in endogenous ETV6 expression was reported during 
the first 3 days of differentiation of mouse erythroleukemia (MEL) cells (Waga et al., 2003). 
Overexpression of ETV6 in these cells enhanced erythroid differentiation while introducing a 
dominant-negative mutants of ETV6 completely blocked this process with cells continuing to 
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proliferate. Enforced expression of ETV6 also inhibited cell growth in Ras-transformed cells 
(Fenrick et al., 2000) and retarded proliferation of both primary wild type and immortalized 
cells possibly through inducing G1 arrest (Rompaey et al., 2000) or decreasing survival via 
direct repression of the Bcl-XL promoter (Irvin et al., 2003). It has also been demonstrated 
that ETV6 overexpression slowed Ras-induced tumor formation in nude mice (Rompaey et 
al., 2000).
1.2.6 ETV7
The ETV7 gene is located on human chromosome 6p21 with 8 exons across 21 kb of 
DNA. There is striking similarity between the genomic organisation of ETV7 and ETV6 with 
nearly identical exon sizes, except exon 5, encoding homologous region of each protein. 
There are also 2 isoforms of ETV7 starting from ATG codons at positions 17 and 82. 
ETV7 can bind to the same DNA binding sequence recognised by ETV6 through its 
ETS domain. It is also able to self-associate and also interact with ETV6 through its PNT 
domain. However, unlike the ubiquitously expressed ETV6, this protein is predominantly 
expressed in hematopoietic tissues, including bone marrow and fetal liver in human (Potter et 
al., 2000) and kidney in zebrafish (Quintana et al., 2013). 
Interestingly, ETV7 is not present in most rodent species, including mice, but it is conserved 
in other vertebrates such as zebrafish. It has been shown that forced expression of ETV7 in 
mouse bone marrow causes leukemia (Cardone et al., 2005; Carella et al., 2006). ETV7 
expression was also down-regulated during monocytic differentiation induced by vitamin D3 
in U937 human monocytic cell line (Kawagoe et al., 2004). A recent study in zebrafish 
reported a role for etv7 in normal red blood cell development which is mediated through the 
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cholesterol synthesis pathway (Quintana et al., 2013). Collectively, these data support the 
idea that ETV7 is involved in hematopoiesis and might have some overlapping functions with 
ETV6. However, there are likely to be significant differences since ETV7 is known as an 
oncogene (Carella et al., 2006), while ETV6 appears to act as a tumor suppressor gene 
(Fenrick et al., 2000).
1.3 Zebrafish and its application
1.3.1 Zebrafish as an alternative vertebrate model 
Zebrafish has become established as a useful alternative experimental model. It 
possesses a set of unique properties compared to other vertebrate models, which makes it a 
powerful tool to understand the role of genes during development and its perturbation. This 
includes the external fertilization and development of its transparent embryos, short 
generation interval (about 2-3 months), small size, high productivity (about 200 eggs/week), 
rapid development, low impact housing and maintenance. Importantly, the molecular 
mechanisms of development and cellular biology are highly similar between zebrafish and 
mammals, facilitating comparative studies (Kari et al., 2007). Moreover, the zebrafish 
genome has been sequenced and extensive genome resources are available to zebrafish 
investigators, including the widely accessed Zebrafish Model Organism Database 
(www.zfin.org), Sanger Danio rerio sequencing project 
(http://www.sanger.ac.uk/Projects/D_rerio/) and the National Centre for Biotechnology 
Danio rerio database 
(http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=7955). 
35
Chapter 1. Introduction
Zebrafish genes can be easily ablated using morpholino mediated gene knockdown 
(Bill et al., 2009), ZFN (zinc finger nuclease) (Foley et al., 2009), TALEN (transcription 
activator-like effector nuclease) (Cade et al., 2012), and CRISPR (clustered regularly 
interspaced short palindromic repeats) (Hwang et al., 2013) knockout technologies or 
randomly mutated with chemical or transposon-mediated approaches. Alternatively, genes 
can be transiently over-expressed by introducing mRNA (de Jong et al., 2010) or DNA 
(Nixon et al., 2009) encoding the protein of interest. Collectively, this makes zebrafish 
genetically amenable, readily accessible and relatively inexpensive.
1.3.1.1 Morpholinos
Morpholinos are synthetic DNA analogues with a modified backbone, in which the 
deoxyribose rings and anionic phosphate linkages are replaced by morpholino rings and non-
ionic phosphorodiamidate linkages, respectively (Summerton and Weller, 1997). This altered 
structure of morpholinos stabilises them against nuclease digestion, as well as inhibiting non
selective interaction of morpholinos with cellular proteins (Corey and Abrams, 2001). They 
are delivered into the cell cytoplasm by microinjection of one to eight cell stage embryos, 
where they can transiently block transcript processing or translation by binding to 
complementary RNA target sequences (Summerton and Weller, 1997).
1.3.2 Zebrafish hematopoiesis
Zebrafish has proven a particularly advantageous model to study of hematopoiesis. 
Not only are the key genes and signalling pathways involved in hematopoiesis conserved 
between zebrafish and humans, but also zebrafish possess all major blood cell types, which 
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are generated by similar developmental pathways, although both zebrafish primitive and adult 
erythrocytes remain nucleated (Traver et al., 2003; Chen and Zon, 2009). Zebrafish 
hematopoiesis, like other vertebrates, occurs in two waves, primitive and definitive.
1.3.2.1 Primitive hematopoiesis
During the segmentation period at around 10 hpf (hours post fertilisation) the ventral 
lateral mesoderm gives rise to hemangioblast cells, which become further specified in to both 
hematopoietic and endothelial cells (Paik and Zon, 2010). Primitive hematopoiesis then 
commences intraembryonically in two locations, the anterior lateral mesoderm (ALM), which 
gives rise to primitive myeloid cells, and the posterior lateral mesoderm (PLM) that later 
forms intermediate cellular mass (ICM), which generates mostly primitive erythrocytes and 
some myeloid cells (Fig. 1.5) (Davidson et al., 2003; Detrich et al., 1995).
The transcription profile during primitive hematopoiesis is highly conserved between 
zebrafish and mammals. At 10 hpf bipotent hemangioblasts in both the ALM and PLM
express scl, lmo2, gata2, and vascular transcription factors including flk1 and fli1 (Dooley et 
al 2005). Hemangioblast cells in the PLM give rise to predominantly gata1+ erythroid 
precursors by 12 hpf, as well as flk+ endothelial cells (Davidson and Zon, 2004). After 
entering circulation around 24 hpf, primitive erythroid precursors develop into mature 
erythrocytes by expressing the erythroid specific genes alas2, globin, and carbonic 
anhydrase (Brownlie et al., 2003). The only circulating red blood cells during the first 4 dpf 
in zebrafish embryos are primitive erythrocytes, despite primitive erythropoiesis ceasing by 
24 hpf (Chen et al., 2009). At 16-20 hpf spi1 is coexpressed with gata1 in the ICM and the 
equilibrium between these two factors regulates the balance between primitive myeloid and 
erythroid production in this region (Berman et al., 2005; Galloway et al., 2005).
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In contrast, the hemangioblasts in the ALM diverge into spi1+ myeloid precursors or 
flk1+ endothelial cells (Bennett et al., 2001, Lieschke et al., 2002). These spi1+ cells migrate 
rostrally and then laterally across the yolk sac, and mature into two distinct myeloid 
populations according to the expression of l-plastin, a myeloid specific actin binding protein 
marker, and myeloperoxidase (mpo), a granulocytic enzyme. Thus, mpo+/l-plastin+ cells 
represent granulocytes, while mpo-/l-plastin+ cells represent monocyte/macrophages (Bennett 
et al., 2001).
Around 26 hpf, when circulation begins, hematopoiesis shifts from the ALM and ICM 
to the posterior blood island (PBI). This so called transient wave of hematopoiesis is 
recognised by the emergence of bipotent erythromyeloid progenitors (EMP) in the PBI. 
Although EMPs do not have the self-renewing property, they can differentiate into gata1+
erythroid and spi1+ myeloid cells (Fig. 1.5) (Bennett et al., 2001; Bertrand et al., 2007).
1.3.2.2 Definitive hematopoiesis
Definitive hematopoietic stem cells (HSC) are initially formed at around 33 hpf by 
budding from the hemogenic endothelium on the ventral wall of dorsal aorta, which is 
equivalent to the aorta-gonad-mesonephros (AGM) in mammals (Burns et al., 2002; Kalev-
Zylinska et al., 2002). Transcription factors expressed by definitive HSCs are runx1 and c-
myb (Burns et al., 2002; Kalev-Zylinska et al., 2002).
From 48 hpf, a subset of these c-myb+ HSCs migrate from the AGM to the caudal 
hematopoietic tissue (CHT), which is equivalent to the fetal liver in mammals. Erythropoiesis 
commences at 3.5 dpf in the CHT and can be identified by expression of embryonic globin
and gata1 in this region, with the erythrocytes produced gradually replacing the circulating 
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primitive erythrocytes (Zhang et al., 2007; Jin et al., 2009). Definitive myelopoiesis similarly 
begins around 3 dpf in the CHT as recognised by l-plastin expression (Galloway et al., 2005).
By 54 hpf, some of the HSCs also migrate directly from the AGM to seed the thymus, 
the initial site of lymphopoiesis (Kissa et al., 2008). Immature lymphoblasts expressing 
ikaros appear in thymus around 3 dpf (Willett et al., 2001). Then, by 4 dpf these cells begin 
to express rag1 which is essential for lymphoid differentiation (Willett et al., 1997). Mature 
lymphocytes are found in thymus by 7 dpf (Trede et al., 2001).  
Finally, between 48-96 hpf, HSCs from the AGM and CHT seed the developing 
kidney, the site of definitive hematopoiesis, which is the equivalent mammalian bone marrow 
(Murayama et al., 2006; Bertrand et al., 2008). By 5 dpf erythropoiesis shifts to the kidney 
(Jin et al., 2009), and regulated by the scl and gata1 transcription factors (Davidson et al., 
2003; Dooley et al., 2005) along with the cytokine erythropoietin (epo) (Paffett-Lugassy et 
al., 2007). Myelopoiesis transitions from the CHT to the kidney by 4 dpf (Galloway et al., 
2005). This process is regulated by spi1 along with granulocyte colony-stimulating factor 
(gcsf) (Liongue et al., 2009). The zebrafish kidney is the on-going site of common lymphoid 
progenitors production, with these progenitors maturing to T-cells in thymus and B-cells in 
the kidney (Chen et al., 2009). The thymus and kidney continue to generate hematopoietic 
cells throughout the life of zebrafish (Paik and Zon, 2010).
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Figure 1.5. Zebrafish hematopoiesis and its key regulators.
Schematic representation of the area of hematopoiesis in zebrafish. The primitive wave 
commences in two locations, the anterior lateral mesoderm (ALM) (orange), which gives rise 
to primitive monocytes, and the intermediate cellular mass (ICM) (violet), which generates 
mostly primitive erythrocytes before 24 hpf, and later shifts to the posterior blood island 
(PBI) where both erythrocytes and heterophil are formed (grey). Definitive hematopoietic 
stem cells are initially formed by budding from the hemogenic endothelium on the ventral 
wall of dorsal aorta (blue). A subset of these HSCs migrate to the caudal hematopoietic tissue 
(CHT) (yellow) to produce several cell lineages, and also thymus (purple), where T-
lymphocyte production occurs. Finally, HSCs seed the developing kidney (green), the final 
site of definitive hematopoiesis where erythroid, myeloid and B-lymphocyte production 
occurs. The lineage specific transcription factors that serve to regulate this process are red. 
HSC: hematopoietic stem cell, HPC: hematopoietic progenitor cells, LSC:  lymphoid stem 
cell, MSC: myeloid stem cell, MP: myeloid progenitor, EP: erythroid progenitor, Hetero:
heterophil, Mono: monocyte, RBC: red blood cells, GMP: granulocyte-monocyte progenitor, 
TP: T-cell progenitor, BP: B-cell progenitor. 
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1.3.3 Use of zebrafish to study hematopoiesis and its perturbation
Zebrafish has become an important model for the study of hematopoiesis and its 
perturbation. A number of zebrafish hematopoietic mutations have been identified in different 
genetic screens that have provided considerable insight to hematopoietic development. For 
example, the cloche mutant, which lacks both hematopoietic and vasculature lineages 
illustrated the presence of a common precursor, the hemangioblast (Thompson et al., 1998).
Other zebrafish mutants possessed phenotypes similar to that of human disorders, which 
makes these mutations invaluable disease models. This is the case for the sauternes mutation, 
ZKLFK DIIHFWHG WKH HU\WKURLG VSHFLILF LVRIRUP RI į-aminolevulinic acid synthase (ALAS2) 
gene. These mutants represented the first model for the human congenital sideroblastic 
anemia (CSA) (Brownlie et al., 1998).
Zebrafish has also proven a useful model system for leukemogenesis and related 
disorders, which has increased knowledge of the oncogenic process (Table 1.4). For example, 
fish over-expressing Myc under the control of the rag2 promoter developed T-ALL in thymus 
which closely mimicked the human disease (Langenau et al., 2005; Feng et al., 2007). Other 
studies have identified loss-of-function mutations of zebrafish pten or constitutive activation 
of the Akt signalling pathway were sufficient for maintenance of T-ALL transformation 
(Gutierrez et al., 2011). Transgenic zebrafish expressing the human RUNX1-ETO oncogene 
recapitulated aspects of human AML including fate changes of myeloerythroid progenitors 
toward granulocytes and accumulation of immature granulocytes in the PBI (Yel et al., 2008). 
Subsequent studies have shown physical interaction between RUNX1-(72DQG&%)ȕFRUH
ELQGLQJ IDFWRUȕ VXEXQLW DQGDOVR WKHGRZQVWUHDPPHGLDWRUF\FORR[\JHQDVH &2; WREH
critical for the leukemogenetic properties of RUNX1-ETO fusion. Inhibition of this 
interaction by Benzodiazepine or COX2 inhibitor blocked its effects (Cunningham et al., 
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2012; Yeh et al., 2009; Zhang et al., 2013). Moreover, the histone deacetylase inhibitor 
Trichostatin A was able to suppress the in vivo effects of RUNX1-ETO (Yeh et al., 2008).
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Table 1.4. Zebrafish models of leukemia and myeloproliferative disorders. 
Overview of models, showing gene, mode of expression and references. Hs: Homo sapiens,
Mm: Mus musculus, Dr: Danio rerio, ALL: acute lymphocytic leukemia, CML: chronic 
myelogenous leukemia, PV: Polycythemia vera, AML: acute myelogenous leukemia, MPD: 
myeloproliferative disorder
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Disease         Gene Expression References
Pre-B
ALL
Hs ETV6-RUNX1 Ubiquitous Sabaawy et al., 2006
T-ALL Mm Myc Lymphoid Langenau et al., 2003; Langenau et al., 2005; Feng et al., 2007; 
Smith et al., 2010; Mizgirev et al 2010; Feng et al. 2010; Blackburn 
et al., 2012; Langenau et al., 2008
Hs MYC Lymphoid Gutierrez et al., 2011; Gutierrez et al., 2014; Chen et al., 2007b
Dr ALL-derived etv6-
jak2a
Lymphoid Onnebo et al., 2012
AML Dr spi1G242D Ubiquitous Sun et al., 2013
Mm Mycn Ubiquitous Shen et al., 2013
Hs NPM1 Ubiquitous Bolli et al., 2010
Hs MOZ/TIF2 Myeloid Zhuravleva et al., 2008
Hs RUNX1-ETO Ubiquitous Kalev-Zylinska et al., 2002
CML Dr-CML derived etv6-
jak2a
Myeloid Onnebo et al., 2005; Onnebo et al., 2012
PV Dr jak2aV581F mutation Ubiquitous Ma et al., 2009
Other 
MPDs
Hs NUP98-HOXA9 Myeloid Forrester et al., 2011 
Hs kRASG12D Ubiquitous Le et al., 2007
Hs HRASG12V Endothelial Alghisi et al., 2013
Dr eena Myeloid Le et al., 2008 
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1.4 Rationale, aims and hypothesis
ETV6 is a member of the ETS family of transcriptional regulators, characterised by a 
conserved DNA-binding ETS domain and a PNT domain that mediate interaction with other 
proteins. Chromosomal translocations involving fusions of the ETV6 gene occur frequently in 
hematological malignancies with around 50 different translocations have been reported.
Interestingly, in many cases, leukemic cells harbouring ETV6 translocations possess no 
functional ETV6 protein due to consistent deletion or mutation of the wild type ETV6 allele. 
This suggests that the normal ETV6 protein may act as a tumour suppressor to retard or block 
the development of leukaemia, and also function during blood cell formation. The aim of this 
Project is to further investigate the function of ETV6 in both blood cell development and its 
disruption in disease. 
Zebrafish has been previously used as a model for studying blood cell development 
and leukemogenesis. This Project will exploit this model for the study of ETV6 and its 
perturbation during embryogenesis. This will be achieved by using anti-sense morpholino 
mediated gene knock-down as well as overexpression studies, followed by analysis of blood 
lineage specific markers using in situ hybridisation, qRT-PCR and histochemical staining 
where needed. It is anticipated that this Project will provide new molecular insights into 
haematopoiesis and its control and how this is perturbed in leukaemia.  This will potentially 
reveal new strategies for treating this disease.
46
Chapter 2. Materials and methods
Chapter 2:
Materials and methods
47
Chapter 2. Materials and methods
2.1 Materials
The following companies supplied reagents and equipment used in this work: 
Ambion, Austin, TX, USA
American Type Tissue Culture, Cryosite, NSW, Australia 
Amersham Biosciences, Piscataway, NJ, USA 
Amresco, Solan, OH, USA
Applied Biosystems, Warrington, UK 
Astral Scientific, Gymea, NSW, Australia 
BD Biosciences, North Ryde, NSW, Australia 
BDH Laboratory Supplies, Poole, UK
Bio-Rad Laboratories, Hercules, CA, USA
Cell Signaling, Danvers, MA, USA 
Chem-Supply, Port Adelaide, SA, Australia
Eppendorf, Hamburg, Germany 
5 PRIME, Hamburg, Germany
Gene Tools, LLC, Philomath, OR, USA
Gilson, Guelph, Canada
Invitrogen, Mount Waverley, VIC, Australia 
Leica Microsystems GmbH, Wetzlar, Germany 
Life Technologies, Rockville, MD, USA
Merck-Calbiochem, Darmstadt, Germany 
Millipore, Billerica, MA, USA 
New England Biolabs, Beverly, MA, USA
Olympus, Shinjuku, Tokyo, Japan 
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Promega, Annandale, NSW, Australia 
Qiagen, Melbourne, VIC, Australia
Roche Molecular Biochemicals, Indianapolis, IN, USA
Sigma-Aldrich, Castle Hill, NSW, Australia 
Sigma Chemical Co., St Louis, MO, USA
Thermo Scientific, Waltham, MA, USA
Zebrafish International Resource Center, Eugene, OR, USA
2.1.1 Oligonucleotides
Oligonucleotides used for reverse transcription-polymerase chain reaction (RT-PCR), 
quantitative real time-RT-PCR (qRT-PCR) and sequencing were designed using the NCBI 
Primer-BLAST design tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) or NetPrimer 
primer analysis software (http://www.premierbiosoft.com/netprimer/index.html). These 
oligonucleotides were synthesized by Sigma-Aldrich and are listed in Table 2.1.
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Table 2.1. List of oligonucleotides used in this study
Number Description Ori Sequence 5’-3’ Application
AW024 ȕ-actin S TGGCATCACACCTTCTAC qRT-PCR, RT-PCR
AW025 ȕ-actin AS AGACCATCACCAGAGTCC qRT-PCR, RT-PCR
AW216 T3 promoter S AATTAACCCTCACTAAAGGGA Sequencing
AW217 SP6 promoter S AATTAGGTGACACTATAG Sequencing
AW218 T7 promoter AS TAATACGACTCACTATAGGG Sequencing
AW465 epor S GCCCTGTTCTTCACCTCTCTGG qRT-PCR
AW466 epor AS CTTCTGCTCTGGTGTTGGTATGTC qRT-PCR
AW728 gata1 S CTCCTCTGAGCCTTCTCGTTGG qRT-PCR
AW729 gata1 AS GTCTGATGAGGGGTCTGTTCTGGC qRT-PCR
AW761 mmp9 S GCTGCTCATGAGTTTGGACA qRT-PCR
AW762 mmp9 AS GGTGGAAGCAGTGGTTGTTT qRT-PCR
AW837 runx 1 S AGAAGCCGGATGAAGCAGTA qRT-PCR
AW838 runx1 AS ATACGACCAGGATGGAGACG qRT-PCR
AW839 epo S TACTGCTGATGGTGCTGGAG qRT-PCR
AW840 epo AS GACTGGACCTCCTGAGCTTG qRT-PCR
AW841 ȕ-e-g AS GCATAGGTGGCCTTGATGTT qRT-PCR
AW842 ȕ-e-g S ATCTTCGCCAAGGCTGACTA qRT-PCR
AW890 etv6 (exon I) S CCGGAAGGTGTTAACCATCG RT-PCR
AW891 etv6 (exon III) AS GAGGAAGTGGAGTTTGGCAGTG RT-PCR
AW1040 c-myb S GGTCCTCATGCCAAGTCAG qRT-PCR, RT-PCR
AW1041 c-myb AS CGGAGTTGGGCTGACTTTAG qRT-PCR, RT-PCR
AW1096 etv6 (exon VII) AS TCTTTGCGGATGATGTTGAG RT-PCR
AW1194 ikaros S AAGCGAAGTCACACTGAAGAAAG qRT-PCR
AW1195 ikaros AS CAGATGTCCAGTGAGAGCGTC qRT-PCR
AW1196 rag1 S ACACTGCCTTAACCATTACCG qRT-PCR
AW1197 rag1 AS GTCAAACACACAGACTTCACATC qRT-PCR
AW1230 lyz S ACTGGGACGCTGTGATGTTTAC qRT-PCR
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AW1231 lyz AS GTAAGAATCCCAGGTTTCCCAT qRT-PCR
AW1358 EcoRI-Flag-etv6 S AAGAATTCATGGATTACAAGGATGACGAC
GATAAGATGTCCGATTCCCCCTCGCA
PCR, Cloning 
AW1359 XbaI-etv6 AS CTTAATCTAGATCAACACTCCTCCTTCACG
T
PCR, Cloning 
AW1360 EcoRI-Flag-etv6 
(ETS)
S AAGAATTCATGGATTACAAGGATGACGAC
GATAAGCCCATGGGACGCATCGCAGA
PCR, Cloning
AW1361 XbaI-etv6 (PNT) AS CTTAATCTAGATCAGGGCGTGGCCTGCTC
ATCCT
PCR, Cloning
AW1378 prdm16 S AACCTGGAAGATGAGCAAATG qRT-PCR
AW1379 prdm16 AS CCCACCTTATCACAGTTTTCAC qRT-PCR
AW1380 cd33 S GACAATGGGAAGGAGCTGAC qRT-PCR
AW1381 cd33 AS TAGCCACCCTTTTTGTTGAC qRT-PCR
AW1382 hox13A S GGAAGGGTTCACAGGAGGTA qRT-PCR
AW1383 hox13A AS GCAGTAGACCTGTCCGTTCC qRT-PCR
AW1384 hox13B S TCTATGACAACGGTTTGGATG qRT-PCR
AW1385 hox13B AS TGACTGTGTTTGATCTTTCGG qRT-PCR
AW1386 ptena S CCGAAACAACATTGATGACG qRT-PCR
AW1387 ptena AS ATGGGCAAAGTCTGGAACAC qRT-PCR
AW1388 ptenb S AAGGAGATACCAAGAAGACGG qRT-PCR
AW1389 ptenb AS AGGTTTGTACTCCAGCTTATTCC qRT-PCR
AW1390 tie1 S CTTCTCCACGAAACGTCCAG qRT-PCR
AW1391 tie1 AS TGCTGAGTGGTGGGAATAAAG qRT-PCR
AW1406 Flag S GATTACAAGGATGACGACGATAAG RT-PCR
AW1429 KpnI-Mmp3 S AAGGTACCCACTGTATTCAGCTTTGACTTC PCR, Cloning 
AW1430 SacI-Mmp3 AS TTGAGCTCTTTCATTTCCACTGGCTTC PCR, Cloning 
Ori = orientation, S = sense, AS = antisense
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2.1.2 Morpholinos
Morpholinos used for in vivo gene knockdowns were designed using the Gene Tools 
morpholino design service (http://www.gene-tools.com) and synthesized by Gene Tools 
(Philomath, USA).  Two morpholinos (Gene Tools, Philomath, USA) targeting zebrafish etv6
were used in this study, a splice site blocking morpholino targeting the exon II/intron II splice 
junction (SSmo: 5’-ACACAGAAAATGCAGATTTACCTTA) and one targeting the 5’ 
untranslated region  (UTRmo: 5’-TCTTGTGTTTCCACTTTCCTCTCCT), as well as a 
control scrambled morpholino (Co: 5’-CCTCTTACCTCAGTTACAATTTATA).
2.1.3 Plasmids and RNA probes 
Details of plasmids and probes used for whole mount in situ hybridization (WISH) are 
provided in Table 2.2.
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Table 2.2 plasmids used in this study 
Number Description Application Source of plasmid
pA006 pGL3 Transfection of HEK293T cells,
luciferase assay
Promega
pA011 pCS2+ Transfection of HEK293T cells,
Western blot, luciferase assay
Addgene
AW204 runx 1 WISH Kalev-Zylinska et al., 2002
pA207 Etv6 WISH IMAGE cDNA clone AI626760
pA212 lyz WISH Liu and Wen, 2002
pA232 spi1 WISH Lieschke et al., 2002
pA343 ȕH3-globin WISH Brownlie et al. 2003
pA408 Flag all tel-jak in 
pCS2+
Microinjection into zebrafish 
embryos, transfection of HEK293T 
cells, Western blot, luciferase assay
This study
pA409 Flag cml tel-jak2 in 
pCS2+
Microinjection into zebrafish 
embryos, transfection of HEK293T 
cells, Western blot, luciferase assay
Onnebo et al., 2005
pA410 Flag all tel-jak in 
pA308
Microinjection into zebrafish 
embryos
This study
pA411 Flag cml tel-jak in 
pA308
Microinjection into zebrafish 
embryos
Onnebo et al., 2005
pA441 mmp9 WISH Yoong et al., 2007
pA451 rag1 WISH Willet et al., 1997
pA455 ikaros WISH Willet et al., 2001
pA457 gata1 WISH Kobayashi et al., 2001
pA466 scl WISH Gering et al., 1998
pA900 Stat5 (ȕ-cas)-luciferase Transfection of HEK293T cells,
luciferase assay
van de Geijn et al., 2004
pA902 Stat 3 (m67)-luciferase Transfection of HEK293T cells, 
luciferase assay
van de Geijn et al., 2004
pA1135 Flag-etv6 in pCS2 Microinjection into zebrafish 
embryos, transfection of HEK293T 
cells, Western blot, luciferase assay
This study
pA1136 Flag-PNT etv6 in pCS2 Microinjection into zebrafish 
embryos, transfection of HEK293T 
cells, Western blot, luciferase assay
This study
pA1138 Flag-ETS etv6 in pCS2 Microinjection into zebrafish 
embryos, transfection of HEK293T 
cells, Western blot, luciferase assay
This study
pA1196 Mmp3 in SV40
luciferase
transfection of HEK293T cells,
luciferase assay
This study
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2.2 Methods 
2.2.1 Bioinformatics
Human ETV6 was used in a tBLASTn search of zebrafish and pufferfish EST 
databases that identified putative etv6 sequences (GenBank Acc. No. AY693994 and 
AF340230.1, respectively). Nucleotide sequences were assembled using Sequencher 4.10.1 
(Gene Codes Corporation) and intron/exon boundaries determined by alignment of cDNA 
and genomic sequences, applying the GT-AG splice rule where possible (32). Multiple 
protein sequences were aligned using ClustalX 1.83 (33), which was also utilized to create 
bootstrapped phylogenetic trees of 1000 replicates using the Neighbor-Joining algorithm 
Njplot (http://pbil.univ-lyon1.fr/software/njplot.html), which were viewed in Treeview 1.6.6 
(http://taxonomy.zoology.gla.ac.uk/rod/treeview.html). The sequences used for alignment 
were ETV6: human (NP_001978), mouse (NP_031987), zebrafish (AAH65661) and 
pufferfish (AAK54061) and ETV7: human (NP_057219), zebrafish (NP_001076493) and 
pufferfish (XP_003963363). Ensembl (http://www.ensembl.org) was used to perform synteny 
analysis using the Japanese pufferfish (Takifugu rubripes) (FUGU4) and human (Homo 
sapiens) (GRCh37) genome assemblies.
2.2.2 RNA methods
2.2.2.1 Isolation of total RNA
For RT-PCR and qRT-PCR applications, at least 30 zebrafish embryos were 
homogenized in 1 ml Trizol reagent (Invitrogen) and the phases separated by the addition of 
200 μl chloroform. After a brief incubation at room temperature, the Trizol-chloroform mix 
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was centrifuged at 12000×g for 10 min at 4ºC. RNA was precipitated with the addition of 500 
μl isopropanol and incubation at room temperature (RT) for 10 min, followed by 
centrifugation at 12000×g for 10 min at 4ºC. The RNA pellet was washed with 75% (v/v) 
ethanol and centrifuged at 7500×g for 10 min at 4ºC, with the purified RNA subsequently 
resuspended in an appropriate volume (20-25 μl) of sterile nuclease-free water (Ambion) 
depending on the size of RNA pellet. 
2.2.2.2 In vitro RNA synthesis
Digoxygenin (DIG)-labelled RNA probes for in situ hybridisation were produced by 
incubating linearised template DNA (1-ȝJZLWKî',*ODEHOOLQJPL[P0HDFKRI$73
CTP, GTP, 0.65 mM UTP, 0.35 mM DIG-11-UTP ) (Roche), 1×Transcription buffer (40 mM 
Tris-HCl (pH 8.0), 6 mM MgCl2, 10 mM dithiotreitol (DTT), 2 mM spermidine) (Roche), 2 
U/μl RNase inhibitor (Roche) and 2 U/μl RNA polymerase in nuclease free water (Ambion). 
Reactions were incubated at 37°C for 2 h after which 10 U/μl DNase I (Roche) was added 
and reactions incubated at 37°C for a further 15 min. The reactions were then terminated by 
DGGLQJ  ȝO RI  0 ('7$ S+  Capped RNA for injection was produced using 
mMessage mMachine Kit (Ambion) following the manufacturer’s recommendations.
2.2.2.3 Purification of RNA 
DIG-labelled RNA and capped RNA were purified from unincorporated nucleotides 
using G-50 size gel filtration exclusion microcolumns (GE Health) following the 
manufacturer’s guidelines.
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2.2.2.4 RNA electrophoresis 
RNA products were analysed on 1.2% (w/v) agarose gels prepared using a
Formaldehyde-Free RNA Gel Kit (Amresco), as per the manufacturer’s protocol. 
Electrophoresis was carried out at 80 V for between 1-1.5 h in a mini-tank apparatus 
(Biorad). Gels were poststained in SYBR®Safe (Invitrogen), with RNA fragments visualised 
under UV illumination on a ChemiDoc XRS (BioRad).
2.2.3 DNA methods
2.2.3.1 DNA minipreps 
Plasmid DNA was purified using the Wizard Plus Miniprep DNA Purification System 
Kit (Promega), following the manufacturer’s recommendations, with elution in nuclease-free 
water.
2.2.3.2 Restriction endonuclease digestion 
Plasmid DNA was digested using relevant restriction endonucleases (5-10 U) for 2-4
h. Manufacturer’s directions were followed with regards to appropriate buffers and 
incubation temperatures.
2.2.3.3 Purification of DNA fragments 
Digested DNA and PCR reaction products were purified using the QIAquick PCR 
Purification Kit (Qiagen), following the manufacturer’s instructions. DNA fragments excised 
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from agarose gels were purified using the QIAquick Gel Clean-up Kit (Qiagen), following 
the manufacturer’s instructions.
2.2.3.4 DNA electrophoresis
To separate DNA fragments by size, electrophoretic analysis was performed on 1%
(w/v) agarose gels, containing 1×TAE buffer (40 mM Tris-HCl, 190 mM glacial acetic acid, 
10 mM EDTA; pH 8.0) (BioRad) and 0.2 μg/ml ethidium bromide in a mini-tank apparatus 
(BioRad) at 70-100 V for 60-100 min, as appropriate. DNA fragments were visualised under 
UV illumination (excitation 480 nm, emission 620 nm) on a ChemiDoc XRS (BioRad).
2.2.3.5 Ultraviolet spectrophotometry
UV spectrophotometry with a NanoVue Plus Spectrophotometer (GE Heathcare) was 
used to determine nucleic acid concentrations, using the relationships that 1 A260 absorbance 
unit equals 50 μg/μl DNA and 40 μg/μl RNA, with confirmation of purify based on the 
following ratios: Abs (260 nm)/ Abs (280 nm) = 1.8 (DNA) and 2.0 (RNA)
2.2.3.6 DNA ligation
Standard sticky HQG OLJDWLRQ UHDFWLRQVXVHG7'1$ OLJDVH 8ȝO 3URPHJD LQ
1×T4 ligase buffer (30 mM Tris-HCl pH 7.8, 10 mM MgCl2, 10 mM DTT, 1 mM ATP 5% 
polyethylene glycol) (Promega) with a 3:1 insert (excised fragment) to linearized vector ratio. 
Reactions were incubated overnight at 15°C.
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2.2.3.7 Bacterial transformation of plasmid DNA
Heat shock transformation of ligation products was performed using competent One 
6KRW0$;(IILFLHQF\'+Į-T1 cells (Invitrogen) following the manufacturer’s guidelines.
2.2.3.8 Sequencing of DNA fragments
Sequencing of purified PCR amplified and double-stranded plasmid DNA was 
performed by the Australian Genome Research Facility utilising BigDye Terminator 
sequencing (Applied Biosystems) and capillary separation on a 3730xl 96-capillary sequencer 
(Applied Biosystems).
2.2.3.9 Reverse Transcription – Polymerase Chain Reaction (RT-PCR) and quantitive 
RT-PCR (qRT-PCR)
Total RNA (200 ng) was reverse transcribed to complementary DNA (cDNA) with an 
iScript cDNA Synthesis Kit (BioRad) according to the manufacturer’s guidelines. A 2 μl 
aliquot of this was used in a PCR reaction containing GoTaq Green Master Mix (Promega) 
and 0.4 μM each gene-specific oligonucleotide (Sigma Aldrich) (Table 2.2). Typical PCR 
conditions were an initial 2 min cycle of 95°C, followed by 35 cycles at 95°C for 1 min, 55°C 
for 30 sec and 72°C for 2 min. This was followed by 1 cycle at 72°C for 10 min, after which 
the sample was held at 4°C.
qRT-PCR was performed on the cDNA using iQ SYBR Green (Bio-Rad) Supermix
and 0.1 μM each gene-specific oligonucleotide. All reactions were performed with 5 
replicates using the Agilent Strategene MX3000P system, with data analysed using the Livak 
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method (Livak et al. 2001) and expressed as a fold-change. The ȕ-actin gene was used as 
housekeeping gene to normalise the relative expression between samples.
2.2.4 Zebrafish methods
2.2.4.1 Zebrafish breeding and embryo collection 
Zebrafish were housed in an Aquatic Habitats aquarium facility at the Deakin 
University Upper Animal House, which functions on a 14 h light/10 h dark light-cycle. Fish 
were fed several times daily on a diet that included brine shrimp and high protein pellets. 
Spawning was stimulated at the beginning of the light cycle with resultant embryos manually 
collected and allowed to develop in egg-water (2.5% (w/v) Na2HPO4; PH 6.0-6.3) at 28.5°C. 
Embryos required for various staining methodologies were transferred to system water
containing 0.003% (w/v) 1-phenyl-2-thiourea (PTU) at 9 hpf to inhibit pigment formation, 
thereby enhancing embryo transparency. 
2.2.4.2 Microinjection 
Needles used for microinjection were pulled from filamented 1.0 mm glass capillary 
tubes (SDR Scientific) on a Flaming Brown micropipette puller model P-87 (Sutter 
Instruments) using the following settings: heat 339, pull 45, velocity 80 and time 150; and 
then modelled manually to fit the injection apparatus. Morholinos were diluted to 1-5 mM in 
1×Danieau buffer (58 mM NaCl, 0.7 mM KCl, 0.4 mM MgSO4, 0.6 mM CaCl2, 5.0 mM 
HEPES; pH 9) containing 1% (w/v) phenol red and the optimal concentration for each 
morpholino was determined by monitoring the phenotypic penetrance and extent of 
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knockdown if appropriate. RNA for microinjection was diluted to 300 ng/μL in 1×Danieau 
buffer. For control injections, standard control morpholino or mock RNA was used at the 
same concentration as the test morpholino or RNA.
The prepared solutions were loaded into needles and they were mounted into a Narishige 
MN-151 micromanipulator attached to a Nikon SMZ 645 dissecting microscope. Embryos at 
the 1-2 cell stage were held with watchmakers’ forceps and positioned so that the needle 
entered the yolk through the cell mass. An aliquot of morpholino, DNA or RNA were 
injected using an ASI MPPI 2 pressure injector. Typical conditions included a pulse duration 
of 0.3 sec and a gas pressure of 400 kPa that resulted in 2 nL injected. Injected embryos were 
then incubated in an incubator set to 28.5°C until they had reached the required 
developmental stage or until transferred to the aquarium to be reared to adulthood.
2.2.4.3 Embryo fixation 
Embryos were euthanized using 1 mg/L benzocaine (Sigma) prior to fixation in 4% 
(w/v) paraformaldehyde (PFA) in phosphate-buffered saline (PBS) (137 mM NaCl, 2.7 mM 
KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4). Fixed embryos were stored at 4°C for a 
minimum of 1 day, after which embryos were dehydrated with 100% (v/v) methanol for long-
term storage at -20°C. 
2.2.4.4 Whole-mount in situ hybridisation (WISH) and double WISH
Fixed embryos (stored in 100% (v/v) methanol) were rehydrated via a series of 5 min 
washes in 50% (v/v) methanol, 30% (v/v) methanol and PBS-T (1×) before re-fixing for 20 
min in 4% PFA/PBS followed by two washes in PBS-T. Embryos older than 24 hpf were 
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then incubated at RT in PBS-T containing proteinase K: 24-36 hpf with 10 μg/ml proteinase 
K for 10 min; 36 hpf-7 dpf with 20 μg/ml proteinase K for 20-30 min. In situ hybridization 
with DIG-labelled probes was performed using a previously described method (Bennett et al. 
2001; Yoong et al. 2007).
Double WISH was carried out essentially as described (Jowett, 2001). Briefly, 
embryos were hybridized with a scl probe labelled with fluorescein-UTP and an etv6 probe 
labelled with DIG-UTP. The scl probe was detected first using an anti-FITC alkaline 
phosphatase conjugate (Roche) and Fast Red (Roche) as a substrate. After removing the first 
antibody with acid treatment (0.1 M glycine-HCl pH 2.2, 0.1% Tween-20), the etv6 probe 
was then detected using an anti-DIG alkaline phosphatase conjugate (Roche) and NBT/BCIP 
(Roche) as a substrate.
Whole mount in situ stained embryos were imaged on an MVX10 microscope 
(Olympus) using a DP72 camera (Olympus). Individual cells were manually counted or an 
area of staining quantified using CellSens Dimensions 1.6 software (Olympus).
2.2.4.5 Sectioning embryos
Embryos were subjected to 2 × 15 min washes in 1×PBS, followed by a series of 15 
min ethanol washes (30% (v/v), 50% (v/v), 70% (v/v), 90% (v/v), 95% (v/v), 100% (v/v), 
100% (v/v), 100% (v/v)) to dehydrate embryos. This was followed by 2 × 30 min washes in 
100% (v/v) Histosolve (Chem-Supply). Embryos were then subjected to a 2 h and then an 
overnight wash in 100% (v/v) paraffin at 60oC. Samples were then embedded in 100% (v/v) 
SDUDIILQDQGDOORZHGWRVHW6HFWLRQVZHUHWKHQFXWWRȝPXVLQJPLFURWRPH/HLFD50
RTS) and mounted on standard glass slides. 
61
Chapter 2. Materials and methods
2.2.4.6 Nuclear Fast Red 
Mounted paraffin-embedded sectioned embryos were stained with Nuclear Fast Red 
(Sigma). Slides were washed 3 times for 5, 3, and 1 min respectively in 100% (v/v) 
Histosolve, followed by 3 × 1 min washes in 100% (v/v) ethanol. Slides were then rinsed in 
dH2O and incubated in Nuclear Fast Red solution for 15 min. Following this slides were 
rinsed in dH2O, washed 3 × 1 min in 100% (v/v) ethanol and 3 × 1 min in 100% (v/v) 
Histosolve before being coverslipped with dopexamine hydrochloride. 
2.2.4.7 Histochemical analysis
2.2.4.7.1 Hemoglobin stain
O-dianisidine staining of whole embryos were performed by incubation of euthanised 
embryos in 0.5 mg/ml O-dianisidine (Sigma-Aldrich), 40% (v/v) ethanol, 6% (v/v) H2O2
(BDH), 0.01 M NaOH) for 15 min in the dark. This was followed by 3 × 5 min 1×PBS-T
washes before fixation in 4% PFA/PBS-T.
2.2.4.7.2 Blood cell stains
Sudan black B and myeloperoxidase staining of whole embryos was performed 
according to the manufacturer’s protocol (Sigma-Aldrich), except that the incubation time for 
the latter was decreased to 7 min. For differential cell counts, blood was pooled from 
embryos by nicking the ventral part of the trunk in PBS containing 1 mM EDTA and 2% 
(v/v) FCS, and smears prepared by centrifugation at 7000 rpm for 5 min using a Cytospin 4 
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(Thermo Scientific). Slides were fixed and stained with Wright-Geimsa according to the 
manufacturer’s protocol.
Slides were viewed on a Leica DME stereomicroscope and images captured on a Leica 
DFC290 digital camera controlled by the Leica Application Suite for Windows (Leica 
Microsystems). For quantitation purposes, randomly selected low and high power fields from 
representative embryos were enumerated with regard to specific blood cell populations. 
2.2.4.7.3 Proliferation analysis
To detect proliferation, embryos were incubated in 10 mM BrdU (Sigma) in Danieau 
water at 4°C for 20 min, rinsed and incubated at 28.5°C for 5 min, before staining for BrdU 
incorporation, as described (Verduzco and Amatruda, 2011).
2.2.4.7.4 Apoptosis analysis
7RGHWHFWDSRSWRWLFFHOOVHPEU\RVZHUHLQFXEDWHGLQȝJPODFULGLQHRUDQJH6LJPD
for 20 min, washed 8 times in egg-water and examined immediately under UV light  or 
subjected to staining with anti-caspase 3 (BD Bioscience), as described (Verduzco and 
Amatruda, 2011; Sorrells et al., 2013).  
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2.2.5 Protein methods
2.2.5.1 Cell line maintenance 
Human 293T cells were taken from liquid nitrogen and slowly thawed in 
approximately 1 ml of DMEM medium. The cells were then centrifuged at 2500 rpm for 5 
min, the supernatant removed and the cell pellet resuspended in fresh medium. Cells were 
then transferred to a culture flask, which was maintained at 37°C and 5% (v/v) CO2 in an air-
jacketed incubator.
2.2.5.2 Subculturing 
Cells were sub-cultured at about 80% confluence. The culture medium was removed 
and the cells were washed twice with PBS-EDTA (1x) (Ameresco) before trypsinisation with 
0.25% (1×) Trypsin–EDTA (Invitrogen) for 3-5 min at 37°C. Once cells were detached, fresh 
medium was added to suspend the cells, which were centrifuged at 100 g for 5 min, the cell 
pellet was resuspended in fresh medium, cells were counted using hemocytometer and a fixed 
number of cells were seeded into an appropriate flask or plate.
2.2.5.3 Cell freezing 
Prior to freezing a single cell suspension was prepared as above and then transferred 
to cryovials and centrifuged at 100 g for 5 min. The supernatant was removed and to the 
pellet was added DSSUR[LPDWHO\ȝORI IUHH]LQJPL[WXUH FRQWDLQLQJ UHOHYDQWPHGLD DQG
DMSO in ratio of 9:1). Cryovials were labeled, sealed and stored in Mister Frosty™ (Thermo 
Scientific) overnight at -80oC, before being transferred to liquid nitrogen for longer storage.
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2.2.5.4 Transfection
Cells were plated one day before transfection at 50-80% confluency using a 3:1 ratio
of FuGENE HD Transfection Reagent (μl) (Roche) to DNA (μg), respectively. Transfection 
complexes containing 300 μl serum free DMEM media, 2 μg DNA, and 10 μl Fugene were 
incubated at RT for 15 min and then added to the cells in a drop-wise manner. After an 
incubation time of 48 h post-transfection, cells were harvested for protein analysis.
2.2.5.5 Protein isolation 
Approximately two million cells were harvested in 0.5 mL of RIPA Lysis Buffer 
containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% 
(v/v) NP-  YY VRGLXP GHR[\FKRODWH  P0 VRGLXP S\URSKRVSKDWH  P0 ȕ-
glycerophosphate, 1 mM Na3VO4  ȝJP/ leupeptin (Sigma) and phosphatase inhibitor 
cocktail (5 mg/mL). The cells were scraped and suspended by pipetting. After a brief 
incubation of 5 min on ice, the lysate were centrifuged at 14,000 g for 15 min at 4°C. The 
supernatant, which contains extracted proteins, was collected and stored at -80oC. 
2.2.5.6 Protein concentration determination
The total protein content was determined using a Pierce-BCA Protein Determination 
Kit (Pierce) following the manufacturer’s instructions, with bovine serum albumin as the 
standard and reading the absorbance at a wavelength of 570 nm using a PerkinElmer 
VICTOR X Multilabel Plate Reader. 
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2.2.5.7 SDS-PAGE
Protein lysates were denatured by using SDS-PAGE loading buffer, heating at 100oC
for about 5 min then immediate cooling on ice for 5 min before separation on a 10% Tris-HCl 
Polyacrylamide gel (1.5M Tris Buffer, Acrylamide /Bis-acrylamid 30% /0.8 w/v, water, 10% 
w/v APS and TEMED).
2.2.5.8 Western blotting 
Following electrophoresis, proteins were electroblotted to Odyssey nitrocellulose 
membrane (Millennium Science) in 20% (v/v) methanol, 25 mM Tris base, 192 mM glycine, 
pH 8.0. The membranes were then blocked with 5% (w/v) dried milk in 0.1% TBST, pH 7.6 
(20 mM Tris base, 200 mM NaCl, and 0.05% (v/v) Tween-20), then incubated with primary 
antibodies (Cell Signalling and Sigma) at appropriate concentrations, according to the 
manufacturer’s instruction overnight at 4oC. Membranes were then washed and incubated 
with IRDye secondary antibody (Millennium Science), and proteins were detected using an 
Odyssey Infrared imaging system.
2.2.5.9 Immunoprecipitation
A 50 μL aliquot of protein G-coupled agarose beads (Sigma) were incubated with 300
μL of cell extract, and 1 μL of antibody for the protein of interest at 4oC under rotary 
agitation overnight to bind the protein of interest from the rest of the sample. The next day, 
excess antibody and antigen existed in supernatant were excluded by 3× washes with 1% 
TBST at 4oC. IP samples then were eluted from beads with the addition of 1× SDS-PAGE
loading buffer prior to being analysed by SDS-PAGE.
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2.2.5.10 Electromobility shift assay (EMSA)
Nuclear extracts were prepared from human 293T cells transfected with relevant 
constructs and EMSA were performed using 32P-labelled E74 binding site probe as 
previously described (Ward et al., 1999).
2.2.5.11 Luciferase assay
Lysates from human 293T cells transiently transfected with relevant luciferase 
reporter vectors were harvested using a Dual Luciferase Kit (Promega), following the 
manufacturer’s recommendations. Samples were subsequently analysed using a single tube 
luminometer (Berthold Technologies Lumat LB 9507) with Firefly luciferase reporter 
activities normalized to the level of Renilla luciferase activity.
2.2.5.12 Immunofluorescence
Cells on chambered coverglass (Thermo scientific) were transfected for 48 h before 
being briefly washed with PBS and fixed with 4% PFA/PBS. Cells were then permeabilized 
with 0.5% Triton X-100 in PBS. Following by 3× PBS washes, cells were blocked with 1% 
BSA in PBS to suppress non-specific binding of antibody. Cells then were incubated with 20 
μg/ml anti-Flag antibody (Sigma) at 4oC overnight followed by incubation with a 1/2000 
dilution of Alexa Fluor 568 goat anti-mouse IgG (Invitrogen) for 1 h. Excess antibodies were 
washed away by PBS. Finally, cells were subjected to nuclear staining with 1 μg/mL of DAPI 
(4ƍ-Diamidino-2-phenylindole dihydrochloride) stain (Sigma), and were visualised with an 
Olympus FluoView FV10i self-contained confocal laser scanning microscope system.
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2.2.6 Statistical analysis
All statistical analyses were performed using GraphPad Prism software version 4. 
Statistical significances between wild type and morphant embryos was determined using an 
unpaired independent Student t test. Probability (p) values less than 0.05 were considered 
significant. Sample populations in each group were at least 30.
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3.1 Introduction
The ETV6 gene encodes a nuclear phosphoprotein that plays important roles in a 
diverse range of cellular processes, including proliferation, differentiation, apoptosis and 
transformation (Oikawa and Yamada, 2003). ETV6 is widely expressed during embryonic 
development, with higher levels of expression observed in the developing kidney, liver and 
lung, as well as the cranial nerve ganglia, dorsal root ganglia and the ventral region of the 
caudal neural tube (Wang et al., 1997), and shows broad expression in the adult, including in 
various hematopoietic cells (Wang et al., 1997). 
The human ETV6 gene is frequently involved in chromosomal translocations 
associated with hematologic malignancies. Interestingly, in many cases leukemic cells 
harbouring ETV6 translocations possess no functional ETV6 protein due to deletion of the 
wild type ETV6 allele (Golub et al., 1995; Patel et al., 2003; Romana et al., 1995; Raynaud et 
al., 1996), specific point mutations leading to truncated unstable forms of ETV6 (Barjasteh 
van Waalwijk van Doorn-Khosravani et al., 2005; Van Vlierberghe et al., 2011), or dominant 
negative effects of the fusion protein over normal ETV6 function (De Braekeleer et al.,
2012). Therefore, investigation into a potential negative regulatory role for ETV6 within the 
hematopoietic transcriptional hierarchy was waranted.
Previous studies have shown that zebrafish is susceptible to the effects of ETV6-JAK2
Onnebo et al., 2005) and ETV6-AML1 (Sabaawy et al., 2006) oncogenes, which has validated 
zebrafish as a useful model for the study of leukemogenesis as well as ETV6. This Chapter
has taken further advantage of this model to investigate the function of ETV6 during 
embryogenesis.
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3.2 Characterization of teleost etv6 genes
Consistent with other studies (Montpetit et al., 2001; Liu and Patient, 2008), extensive 
bioinformatics analyses identified a single etv6 gene in both zebrafish and pufferfish, which 
showed high conservation to mammalian ETV6 proteins, particularly within the PNT and 
ETS domains where overall identity was >80% and >90%, respectively (Fig. 3.1A).
Zebrafish etv6 gene is located on chromosome 4. However, its genomic construct was not 
found, possibly due to repetitive elements within the genomic region for etv6 that make 
automatic assembly of genomic sequences difficult. We were able to find whole genome 
shotgun traces for the corresponding exon and adjacent intronic sequences of zebrafish etv6. 
Attempts to manually create a genome construct for etv6 using WGS traces also failed. 
Therefore, due to their close evolutionary relationship, another teleost, takifugu, was used to 
determine the genomic organisation and structure of etv6. Teleost etv6 genes showed 
conserved splicing (Fig. 3.1B) and synteny (Fig. 3.1C) with human ETV6, with the encoded 
etv6 proteins forming a clade with other vertebrate ETV6 proteins, which was distinct from 
the closely related ETV7 and SPDEF (SAM pointed domain containing ETS transcription 
factor) (Fig. 3.1D).
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Figure 3.1. Characterization of teleost ETV6 genes. 
A. Alignment of ETV6 proteins from human (Homo sapiens, Hs ETV6), mouse (Mus 
musculus, Mm Etv6), zebrafish (Danio rerio, Dr etv6) and pufferfish (Takifugu rubripes, Tr 
etv6). The identical, conserved, and semi-conserved residues are denoted by asterices, colons, 
and periods, respectively. The boxes demarcate the highly conserved PNT and ETS domains. 
B. Splicing structure of human (Hs) ETV6 and pufferfish (Tr) etv6 genes, with exons 
represented by numbered rectangles and coding regions shaded.
C. Synteny analysis of human (Hs) ETV6 and pufferfish (Tr) etv6 gene loci, with adjacent 
conserved genes color-matched. 
D. Phylogenic analysis of ETV6 proteins and related ETS family members, ETV7 and 
SPDEF, from human (Hs), mouse (Mm), chicken (Gallus gallus, Gg), zebrafish (Dr) and 
pufferfish (Tr). Bootstrap values (n=1000) for each branch are indicated with the ETV6 clade 
shaded.
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3.3 Embryonic expression profile of etv6 gene in zebrafish
To gain further insights into the role of ETV6 during embryogenesis, the spatio-
temporal expression profile of zebrafish etv6 was investigated by whole-mount in situ
hybridization. Transcripts of etv6 were first evident in 1-cell stage embryos (Fig. 3.2A), 
indicative of maternal derivation. By 12 hpf this was replaced by zygotic expression that was 
restricted to bilateral stripes corresponding to the lateral plate mesoderm (LPM) (Fig. 3.2B), 
which contains precursors for both blood and vasculature (Davidson et al., 2004). By 18 hpf 
staining was seen in the LPM-derived anterior lateral mesoderm (ALM) and posterior 
intermediate cell mass (pICM) (Fig. 3.2C-D), the site of myeloid and erythromyeloid 
progenitor production, respectively, during the transient primitive wave of zebrafish 
hematopoiesis (Bertrand et al., 2007). The observed etv6 expression pattern was similar to 
that previously described for scl (Gering et al., 1998; Weber et al., 2005). Therefore, double 
in situ hybridisation was performed with probes for both etv6 and scl. This indicated that etv6 
was expressed in a subset of scl positive cells at this time point (Fig. 3.2E1-E3). A similar 
pattern of expression was observed at 24 hpf (Fig. 3.2F), but extending to the nascent pICM-
derived posterior blood island (PBI). From 48 hpf, etv6 expression was detected in the 
vasculature, particularly the inter-segmental vessels between successive somites, the caudal 
hematopoietic tissue (CHT), a transient secondary site of hematopoiesis, as well as anteriorly 
(Fig. 3.2G-H). By 72 hpf, etv6 expression was mostly anterior, including in the tectum, 
cerebellum, thymus, as well as in the developing kidney, gut and caudal hematopoietic tissue, 
a secondary site of definitive hematopoiesis (Fig. 3.2I-J). This pattern was largely maintained 
up to 6 dpf when additional expression was also observed within optic sensory epithelium 
(Fig. 3.2K). No staining was observed using a sense probe as a control (Fig. 3.2L-N). Blood 
and vasculature are derived from a common precursor, the hemangioblast (Patterson et al., 
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2007), which can be specifically ablated with a morpholino targeting lycat (Xiong et al., 
2008). Injection of this morpholino resulted in a drastic reduction in the level of both scl (Fig. 
3.2O-P) and etv6 (Fig. 3.2Q-T), the latter quantified by Q-RT-PCR at 3.6-fold (p<10-4). This 
collectively suggests that etv6 is expressed in hemangioblast-derived cells and likely 
participates in zebrafish embryonic development, including hematopoiesis.
3.4 Targeted knockdown of zebrafish etv6
To investigate the potential involvement of etv6 during zebrafish embryogenesis, an 
anti-sense morpholino mediated gene knockdown strategy was used. Two independent 
morpholinos were used to verify the specificity of the phenotypes observed: one targeting 
sequences upstream of the etv6 start codon (UTRmo) and the other targeting the donor splice-
site for exon 2 (SSmo) (Fig. 3.2U). RT-PCR using primers for exon 1 and 3 confirmed robust 
inhibition of splicing in the SSmo-injected embryos (Fig. 3.2V), with Q-RT-PCR quantifying 
this as a highly-significant 10.4-fold decrease (p < 10-14). An alternatively-spliced product 
was also detected, the sequencing of which revealed it to represent a complex splice product 
with retained intronic sequence and use of an alternate exon, which would encode just the 
first 12 residues of etv6, followed by 35 novel residues before a stop codon (Fig. 3.2W).
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Figure 3.2. Expression of the zebrafish etv6 gene during embryonic development and its 
targeted knockdown using morpholinos. 
A-Q. Whole-mount in situ hybridization analysis of etv6 expression. Zebrafish embryos, 
either wild-type (A-N) or injected with control morpholino (Co mo) (O, Q, S) or lycat mo 
(lyc mo) (P, R, T), were hybridized separately with anti-sense etv6 probes (A-D, F-J, P-Q), 
control (con) sense etv6 probes (K-M) and scl probes (N-O), or co-stained for scl (in red) and 
etv6 (blue) (E1-E3). panels A, C, F, G, I, K, M-P, S-T are lateral views; panels B, J and L are 
dorsal views with rostral to the left; panels Q-R oblique lateral views; and panels D and E1-
E3 represent dorsal views of flat-mount embryos, while panel H is a cross-section. Specific 
structures are labelled as follows: LPM (lateral plate mesoderm), ALM (anterior lateral 
mesoderm), PND (pronephric duct), pICM (posterior intermediate cell mass), PBI (posterior 
blood island), v (vessels), CHT (caudal hematopoietic tissue), DA (dorsal aorta), AV (axial 
vein), t (tectum), c (cerebellum), th (thymus), k (kidney), g (gut) and os (optic sensory 
epithelium).
U-W. Morpholino-mediated knockdown of etv6. Schematic representation of the zebrafish 
etv6 locus (middle) and its targeting with specific anti-sense morpholinos directed to the 
5’UTR (UTRmo, upper), and exon 2/intron 2 splice-site (SSmo, lower) (U). Exonic sequence 
is displayed in upper case and intronic sequence in lower case, with binding sites for 
morpholinos shaded. The relevant encoded amino acids are shown below with numbering. 
Arrows show the location of primers used for RT-PCR analysis of total RNA extracted from 
SSmo-injected (SSmo) and control (Co) embryos using specific primers for etv6 and ȕ-actin
as indicated (V). The arrow and arrowhead indicate the positions of wild type and novel etv6
transcripts, respectively, relative to a size marker. The structure of the alternatively-spliced 
transcript is shown, including relevant nucleotide and encoded amino acid sequences derived 
from an extended exon 2 and the use of the alternate exon 1b (W).
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3.5 Zebrafish etv6 is involved in primitive haematopoiesis
Embryos injected with either morpholino produced no overt developmental disruption 
compared to control embryos, apart from a mild anemia. To further investigate the role of 
etv6 during hematopoiesis, specific blood lineage markers were investigated. At 14 hpf, etv6
morphant embryos showed equivalent expression of scl (Fig. 3.3A-B), a marker of 
hemangioblasts (Liao et al., 1998), and gata1 (Fig. 3.3C-F), an early erythroid marker (Long 
et al., 1997; Kobayashi et al., 2001). However, by 20 hpf the scl expression pattern was 
altered in etv6 morphant embryos, with increased expression rostrally and dorsally (Fig. 
3.3G-I, W), but reduced expression in the pICM (Fig. 3.3K-M, X). Both of these phenotypes 
were able to be rescued by co-injection of morpholino-resistant etv6 mRNA (Fig. 3.3J, N, W-
X). A significant decrease in gata1 expression was also observed within the pICM at the 
same time point (Fig. 3.3O-Q), which could also be rescued (Fig. 3.3R, Y). Finally, ȕ-
embryonic globin (ȕ-e-g), a late erythroid marker (Brownlie et al., 2003) was similarly 
reduced in morphant embryos (Fig. 3.3S-U, Z). Quantitative RT-PCR (Q-RT-PCR) 
expression analysis confirmed significantly reduced expression of both gata1 and ȕ-e-g, but 
also revealed increased expression of erythropoietin (epo), indicating that defective epo 
signalling was not responsible (Fig. 3.3V).
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Figure 3.3. Knockdown of zebrafish etv6 disrupts primitive hematopoiesis.
A-U, W-Y. WISH analysis of control (Co), morphant (SSmo, UTRmo) and rescued (Res) 
embryos for expression of scl (A-B,G-N,W-X), gata1 (C-F,O-R,Y), ȕ-e-g (S-U,Z) at the 
times indicated, with quantitation of dorsal scl (W), caudal scl (X), total gata1 (Y) and total 
ȕ-e-g (Z) at 20 hpf expressed as mean relative area of expression ± SEM (*: p < 0.05). 
Regions of altered staining are indicated with the arrows and arrowheads.
V. Q-RT-PCR analysis of RNA extracted from control and SSmo-injected embryos for the 
expression of gata1, ȕ-e-g and epo at 20 hpf, expressed as mean fold change in morphant 
relative to control embryos ± SEM from 5 replicates (*: p < 0.05).
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At 36 hpf, morphant embryos showed significantly increased expression of gata1
(Fig. 3.4A-C), but ȕ-e-g expression (Fig. 3.4D-F) and O-dianisidine staining of haemoglobin 
(Fig. 3.4G-I) were both decreased. Analysis with Q-RT-PCR confirmed the increased gata1
and reduced ȕ-e-g levels at this time point, with epo levels no longer statistically different to 
controls (Fig. 3.4J). Differential blood cell counts at 48 hpf indicated a statistically-
significant increase in pro-erythroblasts (Fig. 3.4K), but no alterations in morphology were 
observed (Fig. 3.4L).
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Figure 3.4 Effect of etv6 knockdown on erythroid and other blood cells.
A-I. WISH and histochemical analysis of control (Co) and morphant (SSmo, UTRmo) 
embryos for expression of gata1 (A-C) and ȕ-e-g (D-F) and O-dianisidine staining of 
hemoglobin (G-I) at 36 hpf, with the proportion of embryos affected shown.
J. Q-RT-PCR analysis of RNA extracted from control and SSmo-injected embryos for the 
expression of epo, ȕ-e-g and gata1 at 36 hpf.
K-L. Analysis of Wright-Giemsa stained blood smears from 48 hpf SSmo-injected and 
control embryos by differential quantitation (K) and light microscopy (L): Erythro 
(erythrocytes), proEB (pro-erythroblasts), Mono/Mac (monocyte/macrophages) and Hetero 
(heterophils) (*: p < 0.05). 
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The myeloid compartment was examined by analysis of spi1, an early pan-myeloid 
marker (Lieschke et al., 2002), lysozyme (lyz), a marker of early macrophages that develop 
rostrally and later heterophils (Liu and Wen, 2002), and mmp9, a marker of various cell 
populations including heterophils (Yoong et al., 2007). At 14 hpf, spi1 expression was 
normal in etv6 morphants (Fig. 3.5A-D). However, by 20 hpf there was a significant decrease 
in the number of cells expressing spi1 (Fig. 3.5E-H) or lyz (Fig. 3.5I-L) in the rostral part of 
the embryo. In contrast, a substantial increase in expression of mmp9 in the region around the 
cloaca was observed (Fig. 3.5M-P). Histochemical analysis for myeloperoxidase (Fig. 3.5Q-
S), and Sudan Black (Fig. 3.5T-V), which specifically stain heterophils (Lieschke et al, 2001; 
Le Guyader et al., 2008), confirmed increased numbers of these cells at 31 hpf. Analysis of 
blood smears revealed an increased proportion of heterophils in morphants (Fig. 3.4K), 
although a large proportion of these showed incomplete differentiation (Fig. 3.5W-X). 
84
Chapter 3. ETV6 regulates embryonic hematopoiesis in zebrafish
Figure 3.5 Knockdown of etv6 disrupts primitive myelopoiesis.
A-P. WISH analysis of morphant and control embryos for expression of spi1 at 14 hpf (A-D) 
and 20 hpf (E-H), lyz and mmp9 at 20 hpf (I-L and M-P, respectively), with quantitation of 
relative expression area of spi1 at 14 hpf (D), the number of positive cells for spi1 and lyz
expression at 20 hpf (H and L, respectively) and expression area of mmp9 at 20 hpf (P), 
presented as mean ± SEM (*: p < 0.05).
Q-V. Histochemical staining for myeloperoxidase activity (mpx) (Q-S) and Sudan Black B 
(SBB) (T-V) at 31 hpf on SSmo-injected and control embryos, with the number of positive 
cells presented as mean ± SEM (S and V, respectively) (*: p < 0.05). 
W-X. Morphological characterization of heterophils. Stages of heterophil differentiation 
observed in 48 hpf blood smears by light microscopy (W: i-iv), and their quantitation in 
SSmo injected and control embryos (X).
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3.6 Zebrafish ETV6 affects definitive hematopoiesis
To explore the role of etv6 during definitive hematopoiesis, etv6 morphants were 
examined using a range of specific molecular markers. Knockdown of etv6 led to increased 
expression of the hematopoietic stem cell markers runx1 (Lam et al., 2010) at 36 hpf (Fig.
3.6A-B, I’) that reached significance at 48 hpf (Fig. 3.6C-D, I’) and c-myb (Murayama et al., 
2006) from 36 hpf to 3 dpf (Fig. 3.6E-H, I-K, I’), when c-myb positive precursors migrate 
from the CHT to the thymus. Q-RT-PCR analysis performed separately for the rostral and 
caudal regions of embryo showed that the increased expression was restricted to the caudal 
region (Fig. 3.6J’). Conversely, by 5 dpf, c-myb was slightly reduced in the CHT, thymus and 
kidney of morphant embryos (Fig. 3.6L-N, J’), indicative of a disruption of progenitor cells.
Morphant embryos were also overtly anemic by light microscopy, which was confirmed by 
reduced O-dianisidine staining at 4 dpf (Fig. 3.6O-Q) and ȕ-e-g expression at 5 dpf (Fig.
3.6U-W, J’). Interestingly, this was despite increased gata1 at 5 dpf (Fig. 3.6R-T), confirmed 
by Q-RT-PCR at 5 dpf when epo expression was also increased and epor expression was 
normal (Fig. 3.6J’), confirming the reduced erythroid differentiation was not due to defective 
epo signaling. Morphant embryos maintained significantly increased numbers of circulating 
pro-erythroblasts (Fig. 3.6K’-L’), although these are largely derived from primitive 
erythropoiesis at this timepoint (Paik and Zon, 2010). Analysis of BrdU incorporation 
revealed increased proliferation within the CHT at 3 dpf (Fig. 3.6X-B’), whereas staining 
with acridine orange (Fig. 5C’-D’) and ani-caspase 3 (Fig. 5E’-H’) indicated enhanced
apoptosis in this region at 4-5 dpf (Fig. 3.6C’-F’).
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Figure 3.6. Knockdown of etv6 affects definitive HSC and erythroid compartments.
A-N, R-W. WISH analysis of the indicated morphant and control embryos for the expression 
of runx1 at 36 hpf (A-B) and 48 hpf (C-D), c-myb at 36 hpf (E-F), 48 hpf (G-H), 3 dpf (I-K) 
and 5 dpf (L-N), gata1 (R-T) and ȕ-e-g (U-W) at 5 dpf.
O-Q, X-F’. Histochemical staining of the indicated morphant and control embryos to detect 
haemoglobin using O-dianisidine (O-dia) (O-Q), proliferation using BrdU incorporation (X-
B’) and apoptosis using acridine orange (AO) (C’-D’) and anti-caspase 3 (E’-H’) at the times 
shown, with the number of BrdU-positive cells ± SEM shown (B’).
I’-J’. Q-RT-PCR analysis of runx1 and c-myb at 36 hpf and 48 hpf, total (I’), and rostral and 
caudal c-myb at 3 dpf, total c-myb at 4 dpf, and c-myb, gata1, epo and epor at 5 dpf (J’), 
expressed as fold change in SSmo-injected relative to control embryos ± SEM from 5 
replicates (*: p < 0.05).
K’-L’. Analysis of Wright-Giemsa stained blood smears from 5 dpf morphant and control 
embryos by differential quantitation (K’) and light microscopy (L’): designations as 
described for Figure 3K, with the addition of Lympho (lymphocytes) (*: p < 0.05).
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To examine the role of etv6 in definitive myeloid cell development, the myeloid 
specific markers lyz and mmp9 were also examined at 5 dpf. Interestingly, morphant embryos 
showed a modest expansion of lyz+ cells (Fig. 3.7A-C, E), which could be rescued by co-
injection of morpholino-resistant etv6 mRNA (Fig. 3.7D-E). In contrast, there was a 
reduction of mmp9+ cells (Fig. 3.7F-I), with this differential effect confirmed by Q-RT-PCR 
analysis of the respective genes (Fig. 3.7W). Blood examination at 5 dpf revealed elevated 
numbers of monocyte/macrophages in morphant embryos compared to controls, while in 
contrast circulating heterophils were lessened in morphants, although this did not reach 
significance (Fig. 3.7I’-J’). Finally, lymphopoiesis was investigated through evaluation of the 
lymphoid markers ikaros (Willett et al., 2001) and rag1 (Willett et al., 1997). In etv6
morphant embryos expression of ikaros was increased at 3 dpf (Fig. 3.7J-M) and 5 dpf (Fig.
3.7N-Q). Expression of the late lymphoid marker rag1 was also increased at 5 dpf (Fig. 3.7R-
T, V), with this phenotype able to be rescued by morpholino-resistant etv6 mRNA (Fig. 3.7U-
V). The increased expression of lymphoid genes in morphants was confirmed by Q-RT-PCR 
analysis (Fig. 3.7X). In addition, morphant embryos showed higher lymphocyte numbers in 
peripheral blood smears at 5 dpf (Fig. 3.7K’-L’). Moreover, no difference was observed in 
expansion of the thymic epithelium marker foxn1 (Fig. 6Y-Z). This collectively indicates 
enhanced lymphopoiesis in etv6 morphants.
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Figure 3.7. Knockdown of etv6 affects definitive myeloid and lymphoid compartments.
A-V, Y-Z. WISH analysis of control, morphant and rescued embryos showing representative 
expression of lyz in the tail (A-E) and mmp9 in the tail (F-I) at 5 dpf, as well as ikaros at 3 
dpf (J-M) and 5 dpf (N-Q), rag1 at 5 dpf (R-V), and foxn1 at 5 dpf (Y-Z) in the thymus. The 
total number of lyz+ and mmp9+ cells in the embryos are presented as mean ± SEM (E and I, 
respectively), and the area of ikaros and rag1 staining quantified relative to eye size, and 
expressed as mean ± SEM (M, Q and U, respectively) (*: p < 0.05).
W-X. Q-RT-PCR analysis of morphant and control embryos for the expression of mmp9 and 
lyz at 5 dpf (W) or ikaros and rag1 at 3 or 5 dpf as indicated (X), expressed as fold change in 
SSmo-injected relative to control embryos ± SEM from 5 repeats (*: p < 0.05).
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3.7 Discussion
Despite the frequent involvement of ETV6 in hematological malignancies, much 
remains to be learned about the role of ETV6 during normal hematopoietic development. This 
is partly related to the embryonic lethality of Etv6-knockout mice due to a failure in 
angiogenesis (Wang et al., 1997; Hock et al., 2004), which has complicated more detailed 
studies. Since embryonic development in zebrafish is not dependent on vasculogenesis, this 
Chapter investigated the hypothesis that this organism would be a useful alternative for 
investigating the function of ETV6 during embryogenesis. This Chapter has characterized the 
zebrafish etv6 gene, and delineated its role during embryonic hematopoiesis, where it acts at 
multiple levels to influence the production of blood and immune cells. 
In agreement with other work (Montpetit and Sinnett, 2001; Liu and Patient, 2008)
bioinformatic analysis revealed that the zebrafish possessed a single etv6 protein with high 
sequence homology with other vertebrate ETV6 proteins, especially within the PNT and ETS 
domains, indicating functional conservation. Expression studies showed zebrafish etv6 
transcripts were found to be initially maternally-derived, with specific zygotic expression 
evident from 12 hpf in the LPM in a subset of scl positive hemangioblasts (Davidson et al., 
2004). By 18 hpf, expression was seen in the anterior lateral mesoderm (ALM) and posterior 
intermediate cell mass (pICM), the sites of primitive myelopoiesis and erythropoiesis
(Bertrand et al., 2007), and by 24 hpf staining was also observed in the nascent posterior 
blood island (PBI), and later in vessels. At 3 dpf, etv6 expression was evident in the thymus, 
the site of lymphopoiesis, and later in the developing kidney, the site of definitive 
hematopoiesis. Expression was drastically reduced in embryos in which hemangioblasts were 
ablated. This is consistent with the expression studies in Xenopus (Ciau-Uitz et al., 2010)
mice (Wang et al., 1998), and in various hematopoietic cell lines (Wang et al., 1998),
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suggesting a conserved role in blood and immune cell development across vertebrates. 
Expression also overlapped with that for the related etv7 gene (Quinta na et al., 2014).
The earliest zebrafish hematopoietic cells are derived from hemangioblasts in the 
LPM at 12 hpf (Davidson and Zon, 2004), characterized by the expression of markers for 
hematopoietic progenitors, such as scl, as well as those for early myeloid (spi1) and erythroid 
(gata1) populations (Patterson et al., 2007; Lieschke et al., 2002; Long et al., 1997).
Morpholino-mediated knockdown of etv6 did not alter the expression of early hematopoietic 
markers, suggesting that hematopoietic cell specification was etv6-independent. However, at 
20 hpf there was differential effect on scl populations, with an increase within ventral, non-
hematopoietic tissue, but a reduction of caudal expression in hematopoietic tissue, suggesting 
that etv6 may influence the early hematopoietic progenitor compartment. This would 
potentially explain the reduced levels of early (spi1) and late (lyz) myeloid cells rostrally, and 
reduced early (gata1) and late (ȕ-e-g) erythroid cells caudally. Interestingly, there was a 
specific increase in the mmp9+ cells caudally, suggesting that etv6 might also influence 
lineage choice during primitive hematopoiesis in this region. This is the first study 
demonstrating the involvement of ETV6 during primitive hematopoiesis, and is in contrast 
with previous studies that have been reported unaffected yolk sac and fetal liver 
hematopoiesis in Etv6-/- mice (Wang et al., 1997; Hock et al., 2004), which may represent a 
genuine difference between the two species.
Definitive HSCs in zebrafish originate in the dorsal aorta and migrate first to the CHT 
before seeding the kidney and thymus (Paik et al., 2010). Morphant embryos showed a 
significant increase in cells expressing runx1 and c-myb within the dorsal aorta and CHT, 
which correlated with increased proliferation in the latter. However, by 5 dpf, etv6 morphants 
showed an overall decrease in c-myb expression, along with increased apoptosis in this 
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region, suggesting etv6 may impact on cell survival. This is consistent with the failure of 
Etv6-/- progenitors to contribute to bone marrow hematopoiesis in chimeric mouse (Wang et 
al., 1998), and the loss of bone marrow HSCs in mice with Etv6 specifically inactivated in the 
hematopoietic compartment (Hock et al., 2004). Interestingly, etv6 morphant Xenopus
embryos exhibited a more severe phenotype, with HSCs completely ablated, although this 
was secondary to a severe defect in artery formation (Ciau-Uitz et al., 2010). An increase in
lymphopoiesis was also observed in zebrafish etv6 morphants concomitant with the loss of c-
myb+ cells, suggesting that etv6-deficiency may result in preferential differentiation down 
this lineage. This observation may be of clinical relevance, providing one possible 
explanation for the high propensity of ETV6 fusions in lymphoid malignancies.
The role of ETV6 in erythropoiesis has remained controversial. Previous work has 
shown that selective excision of Etv6 in the erythroid lineage of mice failed to impact on 
erythropoiesis (Hock et al., 2004). However, other data has demonstrated that overexpression 
of ETV6 enhanced erythroid differentiation in cell models (Takahashi et al., 2005), as well as 
leading to increased erythroid precursors, accelerated differentiation and augmented globin 
expression in mice transgenic for ETV6 (Eguchi-Ishimae et al., 2009). The data in this 
Chapter is consistent with the latter studies, with etv6 morphants showing an initial decrease 
in gata1 expression, followed by a sustained increase in expression. However, despite this 
increase in early erythroid cells – and a parallel induction of epo – etv6 morphants remained 
anemic, with decreased ȕ-e-g expression and increased erythroblasts in the blood. This 
collectively suggests a role for etv6 in the regulation of red blood cell maturation. Expression 
of etv7, which also contributes to red blood cell maturation (Quintana et al., 2014), was
reduced in etv6 morphants (data not shown). This suggests the two genes may act co-
ordinately in this process.
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The data presented also revealed that etv6 influences the differentiation of zebrafish 
heterophils, the piscine neutrophil equivalent. Morphant embryos showed incomplete 
heterophil differentiation at 48 hpf and reduced numbers of mmp9+ heterophils at 5 dpf.
Close examination of the published study using chimeric mice revealed that while Etv6-/-
cells were able to contribute to all definitive hematopoietic lineages, the 
granulocyte/macrophage lineage was under represented (Wang et al., 1998), and the study on 
the hematopoietic-specific disruption of Etv6 described reduced neutrophils, despite normal 
red cell and lymphocyte numbers (Hock et al., 2004). A role for ETV6 in regulating myeloid 
differentiation might also be relevant in the context of ETV6 fusions in myeloid 
malignancies.
Finally, ETV6 has been implicated in angiogenesis, with yolk sac angiogenesis 
disrupted in Etv6-/- mice (Wang et al., 1997), and arterial differentiation ablated in etv6
morphant Xenopus embryos due to loss of VEGFA expression (Ciau-Uitz et al., 2010). A 
more subtle defect was recently reported following etv6 knockdown in zebrafish embryos, 
with aberrant trajectories and stalled sprouts observed during intersegmental vessel (ISV) 
formation (Roukens et al., 2010). To verify this, etv6 SSmo was injected into flk:gfp 
transgenic embryos, which resulted in similar subtle ISV defects (Fig. 3.8A-C), confirming 
this distinct angiogenic role, which may be an indirect consequence of the altered scl
expression seen in etv6 morphants. No other vascular defects were observed (data not 
shown). Moreover, overexpression of etv6 had no significant effect on circulation (Fig.
3.8D). Collectively, the data in this chapter suggests that ETV6 participates in both blood and 
– to a lesser extent – vessel development, consistent with their common derivation from the 
hemangioblast, and the expression of ETV6 in both lineages. 
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Figure 3.8. Knockdown of etv6 affects early vessel development.
A-D. Confocal analysis of fli1:GFP embryos injected with control (Co) or etv6-specific 
morpholinos (SSmo, UTRmo) or etv6 mRNA (mRNA) and visualized at 48 hpf. Arrows 
indicate disrupted vessels in morphant embryos.
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4.1 Introduction
The Janus kinase-Signal transducer and activator of transcription (JAK-STAT) 
pathway lies downstream of cytokine receptors where it plays an important role in regulating 
proliferation, differentiation, and function of several cell types, particularly those of the 
immune and hematopoietic systems (Schindler et al., 2007). Not surprisingly, therefore, 
deregulation of this pathway has been associated with various hematological malignancies 
(O'Sullivan et al., 2007). For example, activating JAK1 mutations have been identified in T 
cell acute lymphoblastic leukemia (ALL) (Jeong et al., 2008), where they are associated with 
poor prognosis (Flex et al., 2008), as well as acute myeloid leukemia (AML) (Xiang et al., 
2008), while activating mutations of JAK3 have been observed in acute megakaryoblastic 
leukemia (AMKL) (Walters et al., 2006; Kiyoi et al., 2007). Activating JAK2 mutations have 
been observed in a high percentage of patients with classical myeloproliferative disorders 
(Baxter et al., 2005; Kralovics et al., 2005;James et al., 2005), and at a lower frequency in 
those with AML and chronic neutrophilic leukemia (Steensma et al., 2005; Lee et al., 2006).
JAKs and STATs are also constitutively activated in hematopoietic cell lines transformed 
with different oncogenic kinases and in cells from patients with AML, ALL, chronic 
myelogenous leukemia (CML), and chronic lymphoblastic leukemia (CLL) (Gouilleux-
Gruart et al., 1996; Chai et al., 1997; Ward et al., 2000). In addition, JAK2 has been 
identified as a fusion partner in several leukemic oncogenes (Peeters et al., 1997; Bousquet et 
al., 2005).
ETV6-JAK2 fusions are generated as a result of translocation of the JAK2 locus on 
9p24 to the ETV6/ETV6 locus on 12p13. In cases of ALL this is mediated by either of two 
t(9;12)(p24;p13) translocations: that seen in the pre-B-cell form of the disease creates a 
transcriptional fusion between exon 4 of ETV6 and exon 17 of JAK2, whereas that seen in 
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the T-cell form fuses exon 5 of ETV6 and exon 19 of JAK2. In addition, a case of atypical 
CML has been reported that is the result of a complex t(9;15;12)(p24;q15;p13) translocation 
that creates a fusion between exon 5 of ETV6 and exon 12 of JAK2, with no involvement of 
BCR-ABL or other known oncogenes (Peeters et al., 1997; Lacronique et al., 1997). Each of 
these ETV6-JAK2 variants identified has in common the pointed (PNT) dimerization domain 
of ETV6 fused to the JH1 tyrosine kinase domain of JAK2, resulting in constitutive 
activation of the kinase as well as downstream signalling pathways (Lacronique et al., 1997; 
Schwaller et al., 1998; Carron et al., 2000;Lacronique et al., 2000). However, the CML 
version also contains the complete JH2 pseudokinase domain, which is known to be 
important in regulating kinase activity (Feener et al., 2004; Luo et al., 1997) and recently 
identified as possessing dual-specificity kinase activity (Ungureanu et al., 2011). The 
transformation properties of isolated ETV6-JAK2 fusions have been demonstrated in vitro by 
their ability to enable cytokine-independent growth of murine hematopoietic Ba/F3 cells 
(Lacronique et al., 1997; Schwaller et al., 1998; Ho et al., 1999; Lacronique et al., 2000).
Mice reconstituted with bone marrow cells transduced to express the T-cell ALL-associated 
ETV6-JAK2 oncogene variant developed a fatal mixed myelo- and T-cell-
lymphoproliferative disorder (Schwaller et al., 1998). Moreover, transgenic mice expressing 
ETV6-JAK2 in the lymphoid lineage developed a rapid onset and fatal T-cell leukemia 
(Carron et al., 2000) and B cell lymphoma/leukemia (dos Santos et al., 2006). STAT5 is 
strongly activated by each of the ETV6-JAK2 fusions and its activation is at least partially 
responsible for their transforming properties (Schwaller et al., 2000; Carron et al., 2000).
Conversely, SOCS1, a negative regulator of the JAK-STAT pathway, is induced by ETV6-
JAK2 and can inhibit ETV6-JAK2-mediated transformation (Monni et al., 2001; Frantsve et 
al., 2001; Kamizono et al., 2001; Rottapel et al., 2002). However, possible differences 
between the various ETV6-JAK2 forms have yet to be determined.
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Zebrafish is now established as a useful model for the study of leukemic oncogenes 
(Kalev-Zylinska et al., 2002; Langenau et al., 2003; Onnebo et al., 2005). Indeed, previous 
studies have utilised relevant zebrafish orthologues to recapitulate both an MPD-derived 
JAK2 mutant (Ma et al., 2009) and the atypical CML-derived ETV6-JAK2 fusion (Onnebo et 
al., 2005), and demonstrated their ability to perturb hematopoiesis in zebrafish embryos. This 
Chapter describes further studies using this model to investigate the alternate ETV6-JAK2 
fusions seen in ALL and CML, comparing their effects when expressed either in a white 
blood cell-specific or ubiquitous manner. 
4.2 Construction and expression of etv6-jak2a fusions
A Flag-tagged fusion gene corresponding to the ETV6-JAK2 form seen in T-cell ALL 
(Lacronique et al., 1997) was constructed using zebrafish etv6 and jak2a genes, guided by the 
high level of conservation at the fusion juncture (Fig 4.1A). This was cloned downstream of 
the spi1 promoter, for white blood cell-specific expression (Ward et al., 2003), as previously 
described for the atypical CML-derived etv6-jak2a (Onnebo et al., 2005). Both fusions were 
also cloned downstream of the CMV promoter for ubiquitous expression (Turner et al., 1994)
(Fig 4.1A). The latter constructs were introduced into human 293T cells to verify the 
expression of the expected fusion proteins. Western Blot analysis of total cell lysates using 
anti-Flag identified single bands with the expected molecular weight for each fusion that 
were absent in cells transfected with empty vector with GAPDH used as a loading control 
(Fig 4.1B). 
For in vivo expression, zebrafish embryos were microinjected with each of the four 
expression constructs at the one cell stage. Quantitative reverse transcriptase PCR analysis on 
pooled embryos at 24 hpf revealed higher expression from the CMV promoter compared to
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the spi1 promoter but that the ALL and CML versions were expressed at similar levels in 
each case (Fig S4.1C). Staining of embryos with an anti-Flag antibody showed that those 
injected with spi1.etv6-jak2a ALL or spi1.etv6-jak2a CML possessed discrete Flag-positive 
cells in the posterior intermediate cell mass (pICM) and occasionally across the yolk (Fig 
4.1E, F), a pattern consistent with endogenous spi1 expression (Bennett et al., 2001;Lieschke
et al., 2002 Ward et al., 2003). In contrast, embryos injected with CMV.etv6-jak2a ALL or 
CMV.etv6-jak2a CML showed ubiquitous staining throughout the majority of the embryo 
(Fig 4.1G, H). Only slight background staining was observed in uninjected embryos (Fig
4.1D). This confirmed that all fusion constructs were expressed, and in appropriate cell 
populations. 
103
Chapter 4.Dissection of alternate ETV6-JAK2 fusions in vivo
Figure 4.1. Construction and expression of etv6-jak2a fusions.
A. Schematic representation of constructs expressing the Flag-tagged zebrafish etv6-jak2a 
fusions derived from T cell acute lymphoblastic leukemia (ALL) and atypical chronic 
myelogeneous leukaemia (CML). Segments corresponding to Flag (green), etv6 (blue) and 
jak2a (red) are shown, with the pointed (PNT) domain of etv6, the Jak-homology (JH) 
domains of jak2a and relevant amino acid numbers indicated, and the concordance of 
junctional residues of the zebrafish (zf) fusions with those seen in human (hu) disease shown 
in the corresponding alignments. These were expressed under the control of the spi1 promoter 
for white blood cell specific expression and the CMV promoter for ubiquitous expression. 
B. Expression of Flag-etv6-jak2a in human HEK293T cells. Total cell lysates from 293T 
cells transfected with either empty pCS2+ vector or pCS2+ expressing ALL or CML derived 
Flag-etv6-jak2a ZHUH VXEMHFWHG WR :HVWHUQ EORW DQDO\VLV ZLWK Į-)ODJ DQG Į-GAPDH 
antibodies, with the sizes of the fusions indicated. 
C-I. Expression of Flag-etv6-jak2a fusions in zebrafish embryos. qRT-PCR analysis of etv6-
jak2a transcript levels in uninjected embryos or those injected with the indicated constructs, 
standardised against CMV.etv6-jak2a CML at 100% (C). Whole-mount 
immunohistochemistry using alkaline phosphatase-conjugated anti-Flag antibodies on 
uninjected embryos (uninj: D, G) or embryos injected with spi1.etv6-jak2a ALL (E), 
spi1.etv6-jak2a CML (F), CMV.etv6-jak2a ALL (H) or CMV.etv6-jak2a CML (I) at 24 hpf. 
Single large Flag-positive cells in panels E and F are indicated with arrows.
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4.3 Characterization of injected embryos
Injected embryos were examined for phenotypic perturbation from 24 hpf to 5 dpf and 
compared to uninjected embryos or embryos injected with the relevant empty vector controls 
for the spi1 and CMV promoters (pA308 and pCS2+, respectively). Each construct was 
injected on at least five independent occasions to ensure reproducibility of the results.
Injection of all etv6-jak2a constructs produced phenotypes consistent with severe 
perturbation of the hematopoietic compartment during embryonic development. Ubiquitous 
expression of both etv6-jak2a constructs also caused a number of other phenotypes, including 
head defects as well as occasional disruption of circulation, pigmentation and curvature of the 
tail (Supp. Fig. S4.1 and S4.2). No cellular hyperproliferation was observed outside the 
hematopoietic compartment in any embryos even considering potential mosaicism, this
strongly suggests lineage specificity.
At 24 hpf, all constructs produced an expansion of the posterior intermediate cell 
mass (Fig. 4.2B-E, P), a site of zebrafish hematopoiesis at this time (Detrich et al., 1995),
which was not observed in un injected embryos (Fig. 4.2A, P) or those injected with empty 
vectors (pA308 or pCS2+) (data not shown). This was unrelated to the infrequent circulation 
defects (data not shown). By 48 hpf, increased numbers of large, non-hemoglobinised cells 
were observed in circulation in injected embryos (Fig. 4.2G-J), compared to those not 
injected (Fig. 4.2F). To examine the nature of the large non-hemoglobinised cells in more 
detail, blood smears were prepared and examined histologically. Samples taken from 
embryos injected with any of the etv6-jak2a oncogenes contained significant numbers of 
white blood cells (Fig. 4.2L-O), whereas blood from uninjected embryos contained almost 
exclusively red blood cells (Fig. 4.2K). BrdU incorporation experiments confirmed that the 
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posterior intermediate cell mass expansion observed in etv6-jak2a-expressing embryos was 
due to increased cell proliferation (Fig. 4.2R-U).  
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Figure 4.2. Hematopoietic defects caused by etv6-jak2a fusions. 
(A-J) Light microscopy. Images of uninjected embryos (uninj: A, F) or embryos injected with 
spi1.etv6-jak2a ALL (B, G), spi1.etv6-jak2a CML (C, H), CMV.etv6-jak2a ALL (D, I), or 
CML.etv6-jak2a CML (E, J) at the times indicated. Expanded posterior intermediate cell 
mass regions in panels B-E are indicated by black arrowheads and enlarged pericardia in 
panels G-J indicated by red arrowheads. (K-O) Blood analysis. May-Grünwald stained blood 
smears from 52 hpf embryos, either uninjected (uninj: K), or injected with spi1.etv6-jak2a 
ALL (L), spi1.etv6-jak2a CML (M), CMV.etv6-jak2a ALL (N), or CMV.etv6-jak2a CML
(O). Red arrowheads indicate red blood cells and black arrowheads indicate white blood 
cells. (P) Quantification of posterior intermediate cell mass expansion. (Q-U). Cell 
proliferation. BrdU incorporation in uninjected embryos (Q) or those injected with spi1.etv6-
jak2a ALL (R), spi1.etv6-jak2a CML (S), CMV.etv6-jak2a ALL (T) or CMV.etv6-jak2a 
CML (U).
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4.4. Molecular analysis of hematological compartments
To further investigate the hematologic perturbation apparent in these embryos, in situ
hybridization was performed using specific molecular markers and stains. At 24 hpf, there 
was an increase in cells expressing spi1, an early white blood cell marker (Bennett et al., 
2001; Lieschke et al., 2002), in embryos injected with spi1.etv6-jak2a CML (Fig. 4.3C,N)
and CMV.etv6-jak2a CML (Fig. 4.3E,N), compared to uninjected embryos (Fig. 4.3A,N). 
However, this was restricted to the rostral (anterior) population, with the caudal (posterior) 
population significantly depleted with spi1.etv6-jak2a CML. The spi1.etv6-jak2a CML and 
CMV.etv6-jak2a CML embryos also showed a decrease in cells expressing lysozyme (lyz), a 
marker for mature myeloid cells derived from the rostral compartment (Crosier et al.,2001) 
(Fig. 4.3H,J,O), although cells expressing mmp9 (Yoong et al., 2007) were increased with 
spi1.etv6-jak2a CML (Fig. 4.3M,P), compared to uninjected embryos (Fig 4.3F and Fig 4.3K,
respectively). In contrast, expression of the ALL-derived fusion did not alter the number of 
lyz+ (Fig. 4.3G,I) or mmp9+ (Fig. 4.3L,P) cells, and only CMV.etv6-jak2a ALL led to an 
expansion of spi1+ cell numbers in the posterior intermediate cell mass (Fig. 4.2D,N). This 
suggests that the effects on myelopoiesis were largely specific for the CML-derived etv6-
jak2a fusion gene. In addition, ubiquitous expression of ALL or CML-derived etv6-jak2a
fusions resulted in ectopic expression of spi1 in a range of anterior tissues (Fig. 4.3D, E) at 24 
hpf.
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Figure 4.3. Characterization of myelopoiesis in embryos expressing etv6-jak2a fusions.
Uninjected embryos (uninj: A, F, K) or embryos injected with spi1.etv6-jak2a ALL (B, G, L), 
spi1.etv6-jak2a CML (C, H, M), CMV.etv6-jak2a ALL (D, I) or CMV.etv6-jak2a CML (E, J)
were analyzed at 24 hpf for expression of the specific markers, spi1 (A-E), lysozyme (lyz) (F-
J) and matrix metalloproteinase 9 (mmp9) (K-M), by in situ hybridization. The red arrows 
indicate the position of the yolk sac and the dotted line the area of the posterior intermediate 
cell mass. The numbers of spi1 (N), lyz (O) and mmp9 (P) cells were determined and are 
expressed as the mean ± SEM.
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At 24 hpf, there was a slight increase in the expression of gata1, an early erythroid 
marker (Long et al.,1997; Meng et al., 1997) in embryos injected with spi1.etv6-jak2a CML
(Fig. 4.4C), CMV.etv6-jak2a ALL (Fig. 4.4D), and CMV.etv6-jak2a CML (Fig. 4.4E)
compared to uninjected controls (Fig. 4.4A). In contrast, there was a slight but consistent 
decrease in embryos injected with spi1.etv6-jak2a ALL (Fig. 4.4B). Consistent with a visible 
anemia observed by light microscopy from 48 hpf, a significant decrease in DAF staining 
was seen in embryos injected with spi1.etv6-jak2a ALL (Fig. 4.4G) or spi1.etv6-jak2a CML
(Fig. 4.4H) compared to uninjected controls at 52 hpf (Fig. 4.4F). This was confirmed by O-
dianisidine staining of hemoglobin (Fig. 4.4K-M), ZKLFK FRUUHODWHG ZLWK OHYHOV RI ȕ-
embryonic globin expression (Fig. 4.4N-O, and data not shown). Ubiquitous expression of 
these two etv6-jak2a variants, on the other hand, caused no major differences in the number 
of hemoglobinized cells, although there was some disruption of circulation through the tail 
(Fig. 4.4I, J).
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Figure 4.4. Characterization of erythropoiesis in embryos expressing etv6-jak2a fusions.
Uninjected embryos (uninj: A, F, K, N) or embryos injected with spi1.etv6-jak2a ALL (B, G,
L, O), spi1.etv6-jak2a CML (C, H, M), CMV.etv6-jak2a ALL (D, I), or CMV.etv6-jak2a 
CML (E, J) were analyzed by whole-mount in situ hybridization (WISH) for expression of 
the erythroid specific markers gata1 (A-EDQGȕ-embryonic globin (ȕ-e-globin) (N-O) at 24 
hpf or stained with DAF (F-J) or O-dianisidine (K-M) at 52 hpf to detect hemoglobin (F-J). 
Reduced gata1 expression in panel (B), ȕ-e-globin expression in panel (O), and hemoglobin 
in panels (G-H) and (L-M) are indicated with black asterisks, while increased gata1
expression is shown with a black arrow in panels (D) and (E).
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The lymphoid compartment was also investigated by analysis of the expression of the 
lymphoid-specific genes, rag1 (Trede et al., 2001) and ikaros (Willett et al., 1999). In 
embryos injected with the spi1.etv6-jak2a ALL oncogene, expression of rag1 (Fig. 4.5B) and 
ikaros (Fig. 4.5G) was increased compared to that in uninjected embryos (Fig. 4.5A, F). 
However, embryos injected with the three other etv6-jak2a constructs exhibited normal rag1
and ikaros expression patterns (Fig. 4.5C-E, H-J). Further analysis of embryos injected with 
the spi1.etv6-jak2a ALL oncogene at 7 dpf demonstrated strong spi1 expression (Fig. 4.5L)
that was absent in controls (Fig. 4.5K), indicating that the spi1 promoter remains strongly 
active in the thymus of these embryos.
116
Chapter 4.Dissection of alternate ETV6-JAK2 fusions in vivo
Figure 4.5. Characterization of lymphopoiesis in embryos expressing etv6-jak2a fusions.
Uninjected embryos (uninj: A, F, K) or embryos injected with spi1.etv6-jak2a ALL (B, G, L), 
spi1.etv6-jak2a CML (C, H), CMV.etv6-jak2a ALL (D, I), or CMV.etv6-jak2a CML (E, J)
were analyzed by in situ hybridization for expression of the lymphoid specific markers rag1
(A-E) and ikaros (F-J) at 4 dpf and spi1 (K, L) at 7 dpf. Black arrows show the position of the 
thymus in each case, with red arrows indicating rag1+ cells through the embryo in panel B.
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4.5 Biochemical analysis of ETV6-JAK2 variants
We next sought to investigate potential functional differences between the different 
ETV6-JAK2 variants to explain their lineage specificity. To compare their relative activities, 
both forms were immunoprecipitated from transfected HEK293T cell lysates with anti-Flag 
antibody with the resultant immune complexes analyzed by Western blot with anti-
phosphotyrosine antibody as a surrogate marker of activity (Fig. 4.6A). This revealed that 
both fusion proteins were phosphorylated, probably through auto-phosphorylation as occurs 
in mammalian ETV6-JAK2 fusion proteins (Lacronique et al., 2000). Re-probing the blot 
with anti-Flag antibody allowed normalization of the phosphotyrosine band intensity, which 
revealed a greater activity of the ALL variant compared to the CML variant. To assess 
potential biochemical differences further, activation of the downstream STAT3 and STAT5 
was analyzed using relevant luciferase reporters normalized relative to a CMV-Renilla 
control. This indicated that the levels of activation of both STAT3 and STAT5 were slightly 
greater in the CML variant, with the largest difference seen with STAT3 (Fig. 4.6B). The 
relative localization of the two ETV6-JAK2 variants was also analyzed by 
immunohistochemistry with anti-Flag antibody. This identified equivalent cytoplasmic 
expression patterns for both the ALL and CML variants (Fig. 4.6C-E). Finally, the sensitivity 
of each variant to JAK2 inhibitors was investigated. By analysis of phosphotyrosine staining 
in transfected HEK293T cells, both variants showed reduced activity with the inhibitor 
AG490, although the CML variant was more sensitive than the ALL variant (inhibition of 
72% compared to 35%) (Fig. 4.6F). A similar effect was also seen with the alternative 
inhibitor WP1066 (data not shown). Treatment of etv6-jak2a-injected embryos with the JAK2 
inhibitor AG490 largely blunted the expanded posterior intermediate cell mass mediated by 
both variants (Fig. 4.6G). 
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Figure 4.6. Functional properties of etv6-jak2a fusions.
(A) Activity of etv6-jak2a fusions. Lysates from HEK293T cells transfected with the 
LQGLFDWHGFRQVWUXFWVZHUHLPPXQRSUHFLSLWDWHGZLWKĮ-Flag and analyzed by western blot with 
Į-SKRVSKRW\URVLQH Į-S7\U DQG Į-Flag (upper panels), with the relative levels of tyrosine 
phosphorylation (pTyr/Flag) determined by image analysis, with etv6-jak2a ALL set at 100% 
(lower panel). The etv6-jak2a CML protein is indicated with an arrow and the etv6-jak2a 
ALL protein with an arrowhead. (B) Downstream STAT activation by etv6-jak2a fusions. 
HEK293T cells were co-transfected with empty vector, CMV.etv6-jak2a ALL and 
CMV.etv6-jak2a CML as indicated, along with STAT-luciferase and CMV.Renilla 
constructs, with the relative activation of STAT3 (upper panel) or STAT5 (lower panel) 
reporter determined relative to CMV.etv6-jak2a ALL at 100%. (C-E) Localization of etv6-
jak2a fusions. HEK293T cells were transfected with the indicated constructs and co-stained 
ZLWK Į-Flag/Alexa fluor 568nm (red) and DAPI (blue). (F-G) Sensitivity of etv6-jak2a 
fusions to JAK2 inhibitors. HEK293T cells were transfected and analyzed as in panel (A) in 
WKHDEVHQFHRUSUHVHQFHRIȝ0$*F). Alternatively, zebrafish were injected with the 
LQGLFDWHGFRQVWUXFWVZLWKRUZLWKRXWȝ0$*DQGVFRUHGIRUSRVWHULRULQWHUPHGLDWHFHOO
mass expansion (G).
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4.6 Discussion
It has previously been shown that zebrafish are susceptible to the pathological actions 
of a number of genes implicated in hematologic malignancies and diseases, including MYC,
RUNX1-CBF, JAK2 and STAT5 (Kalev-Zylinska et al., 2002; Langenau et al., 2003; Ma et 
al., 2009; Ma et al., 2007; Lewis et al., 2006), as well as a zebrafish etv6-jak2a fusion gene 
corresponding to the ETV6-JAK2 oncogene found in atypical CML (Onnebo et al., 2005) 
(Table 4.1). Collectively this work has demonstrated that zebrafish represents a suitable 
model organism for the study of leukemic oncogenes. In this Chapter, advantage has been 
taken of this model to investigate two fundamental unanswered questions regarding ETV6-
JAK2 fusions. Firstly, are there any intrinsic differences between the alternative forms of 
ETV6-JAK2 seen in lymphoid and myeloid leukemia that contribute to the type of 
malignancy induced? This was examined by directly comparing versions of etv6-jak2a
derived from T-cell ALL and atypical CML. Secondly, is ETV6-JAK2 a leukemia-specific 
oncogene, or is this association simply the result of being expressed in cells of this lineage 
via the ETV6 promoter? This question was investigated by comparing white blood cell-
specific expression with ubiquitous expression of the alternative etv6-jak2a fusions. The 
results presented shed considerable light on both questions. 
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Table 4.1. Summary of consequences of JAK2 perturbation in zebrafish.
pICM: posterior intermediate cell mass; HSC: hematopoietic stem cells; HPC: hematopoietic 
progenitor cells
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Cell population Marker / 
assay
stat5.1ca jak2aca etv6-jak2a ALL etv6-jak2a CML
HSC/HPC pICM Ĺ ± Ĺ Ĺ
early myeloid 
+  lymphoid
spi1 Ĺ Ĺ ± Ĺ
late myeloid lyz/
l-plastin
Ĺ Ĺ ± Ļ
Late myeloid mmp9/
mpo
Ĺ Ĺ ± Ĺ
early erythroid gata1 Ĺ Ĺ Ļ Ļ
late erythroid Ǻ-e-globin/
Hb
Ĺ Ĺ Ļ Ļ
lymphoid rag1/
ikaros
Ļ nt Ĺ ±
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Expression of the T-cell ALL-derived zebrafish etv6-jak2a gene under the control of 
the white blood cell-specific spi1 promoter resulted in an expansion of the posterior 
intermediate cell mass, increased numbers of white blood cells in the circulation and anemia. 
Further analysis using in situ hybridization with lineage-specific markers revealed a later 
expansion of lymphoid cells. The late latency of the lymphoid phenotypes is consistent with 
the ontogeny of lymphoid development in zebrafish, which commences at around 3.5 dpf 
(Trede et al., 2004), and is a consequence of the conserved ability of the spi1 promoter to 
mediate expression in early lymphoid lineages (Busslinger et al., 2004). The CML-derived 
etv6-jak2a oncogene also resulted in elevated numbers of white blood cells and anemia. 
However, in this case there was a decrease in mature myeloid cells suggesting a block in 
myelopoiesis, as well as an increase in the number of immature erythroid cells, but no effects 
on cells of the lymphoid lineage. Collectively, this suggests that while both CML and ALL 
versions of etv6-jak2a can exert a potent proliferative effect on early hematopoietic cells, 
different cell lineages are susceptible in each case. In contrast, the effects on the erythroid 
lineage were similar to those of the CML-derived fusion, with an increase in immature 
erythroid cells but with manifest anemia, suggesting a differentiation block in an erythroid 
progenitor population. This is in contrast to the effects of activating JAK2 mutants that lead 
to enhanced erythropoiesis (Campbell et al., 2006). There are two potential explanations for 
the difference. Firstly, the etv6-jak2a fusions are expressed from the spi1 promoter and so 
will not be expressed in erythroid cells, apart from the earliest precursors, in contrast to the 
JAK2 mutants that are expressed throughout erythropoiesis. Secondly, the activating JAK2 
mutants act via receptor-associated pathways (Staerk et al., 2007), whereas the ETV6-JAK2 
forms lack the domains required for receptor association and are present throughout the 
cytoplasm, as was demonstrated in this Chapter.
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Ubiquitous expression of either etv6-jak2a variant caused some non-hematopoietic 
defects, including vasculature defects and general head and tail defects, which were also 
observed with activating forms of stat5.1 (data not shown), suggesting this is the likely 
downstream pathway. Importantly, however, while ubiquitous expression of either etv6-jak2a
variant resulted in expansion of white blood cells, no other cellular hyperproliferation was 
observed, indicating that the effects of this class of oncogenes are limited to cells of the 
hematopoietic lineage. Activating JAK2 mutations are known to promote cytokine receptor 
hypersensitivity (James et al., 2005; Morgan et al., 2008) and altered regulation of 
downstream pathways (Hookham et al., 2007). Since the majority of cytokine receptors are
expressed on immune and hematopoietic cells, this might provide some explanation for this 
observation. 
Other studies have attempted to investigate the downstream pathways important for 
the effects of ETV6-JAK2. These have identified STAT5 (Schwaller et al., 2000), TYK2 
(Stoiber et al., 2004), SOCS1 (Frantsve et al., 2001), NF-ț% 0DOLQJH HW DO 3,-3K 
(Nguyen et al., 2001), and various MAPK (Ho et al., 2002) as potentially playing a role. 
Several studies have investigated the efficacy of inhibitors that can suppress the effects of 
ETV6-JAK2 (Funakoshi-Tago et al., 2008; Dawson et al., 2010). This Chapter showed that 
both forms of ETV6-JAK2 were sensitive to JAK2 inhibitors, although the ALL form 
appeared slightly less sensitive. This information is clinically significant, and highlights the 
usefulness of zebrafish as a pre-clinical model to dissect these pathways. 
The presence of a complete JH2 domain is the only difference between the two forms, 
and so this region of the fusion oncoprotein must be responsible. The mechanism by which 
this so-called “pseudo-kinase domain” facilitates the effect has remained unknown. This 
domain is known to act as a regulator of JAK kinase activity (Feener et al., 2004; Saharinen 
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et al., 2002) with mutation of this domain leading to myeloproliferative disorders in humans, 
mice, fish and flies (Luo et al., 1997; Ma et al., 2009; Ma et al., 2007; De Keersmaecker et 
al., 2006; Shide et al., 2008). Consistent with this, the ALL version that lacks the JH2 domain 
showed greater activity, which is in accordance with other studies on human ETV6-JAK2 
fusions (Barahmand-Pour et al., 1998). Somewhat surprisingly, however, the CML version 
showed greater STAT activation, particularly of STAT3, which represents a novel 
downstream target for ETV6-JAK2. Analysis of the conserved tyrosine residues within the 
JH2 domain which are unique to the CML-derived ETV6-JAK2 provide a potential 
mechanism to explain this difference (Fig. 4.7). One of these, Y570, has the sequence 
DYG(E/Q)(V/L) which is in good agreement with consensus STAT5 docking sites (May et 
al., 1996; Pezet et al., 1997). Another, at Y637 has the sequence YLK(R/K), which fits the 
alternative STAT3 site of Y-hydrophobic-basic-large hydrophilic (Ward et al., 1999). 
Recently, the JH2 domain was also found to possess both tyrosine and serine kinase activity 
(Ungureanu et al., 2011), which might also contribute to the differential levels of STAT 
activation – and potentially the phenotypic differences – observed. It is worth noting that 
activating JH2 domain mutants of JAK2 have also been identified in human lymphoid 
disorders (Mullighan et al., 2009).
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Figure 4.7. Proposed mechanism underpinning different responses of alternate ETV6-
JAK2 fusions
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5.1 Introduction
There is considerable evidence that a range of ETV6 variants are produced in vivo.
For example, alternatively spliced isoforms of ETV6, generated through exon skipping, have 
been reported in human mononuclear cells. These isoforms lack different ETV6 functional 
domains and work antagonistically on full-length ETV6, with the ratio of these isoforms a 
key determinant in regulating the transcriptional balance to either promote or repress
proliferation (Sasaki et al., 2004). Other studies have shown that introduction of ETV6 
mutants lacking either the PNT or ETS domain were able to block ETV6-induced erythroid 
differentiation in mouse erythroleukemia (MEL) cells, while mutations lacking the ETS 
domain were able to overcome the growth-suppressive effects of ETV6 in Ras-transformed 
NIH3T3 cells (Waga et al., 2003; Sasaki et al., 2004).
In disease settings, ETV6 abnormalities are not restricted to translocations or 
deletions. Thus, MDS patients that progress to leukemia frequently show expression of ETV6 
mutants lacking the ETS domain (Sasaki et al., 2004). Furthermore, recurrent mutations of 
ETV6, including point mutations, in-frame or frame-shift insertions and deletions affecting 
either the PNT or ETS domains have been reported in cases of AML (Doorn-Khosrovani et
al., 2005; Silva et al., 2008), childhood B-ALL (Zhang et al., 2011) and early immature adult 
T-ALL (Van Vlierberghe et al., 2011). Truncated proteins corresponding to these mutants 
were unable to repress transcription and abolished the transrepression activity of full-length
ETV6 in vitro (Doorn-Khosrovani et al., 2005; Van Vlierberghe et al., 2011). 
These studies have led to the hypothesis that one of the pathogenic mechanisms 
involved in leukemogenesis is via production of truncated forms of ETV6 that interfere 
dominantly with normal ETV6 function. This Chapter sought to directly investigate this 
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possibility with truncated ETV6 proteins analysed in vitro for mechanistic studies and in 
zebrafish embryos to study the effects on hematopoiesis in vivo.
5.2 Results
5.2.1 Construction and expression of truncated etv6 variants
Sequences encoding Flag-tagged versions of full-length zebrafish etv6 (etv6-FL) and 
truncated etv6 forms corresponding to amino acids 1-324, thereby deleting the ETS domain 
(etv6-ǻ(76, and amino acids 324-444, thereby deleting the PNT domain (etv6-ǻ317ZHUH
amplified and cloned into the pCS2+ vector (Fig. 5.1A). After sequence verification, these 
constructs were introduced into human 293T cells to confirm the various etv6 proteins were 
expressed. Western blot analysis of total cell lysates using anti-Flag identified a single band 
with the expected molecular weight for both etv6-FL and etv6-ǻ(767KHHWY-ǻ317IRUP
ran at a higher molecular weight than expected, although sequencing confirmed it was the 
correct sequence (Fig. 5.1B).
5.2.2 DNA-binding capacity of ETV6 
Although zebrafish etv6 showed strong sequence homology with mammalian ETV6, 
it was important to confirm it showed functional conservation. To analyse the DNA binding 
properties of zebrafish etv6, an electrophoretic mobility shift assay (EMSA) was performed 
using an E74 binding site probe with nuclear extracts prepared from HEK293T cells 
expressing Flag-tagged zebrafish etv6-FL. Some binding was observed in extracts from 
untransfected cells, which is not unexpected given the ubiquitous nature of ETS transcription 
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factors. However, significantly more binding was observed in extracts from HEK293T cells 
transfected with a vector expressing zebrafish etv6-FL, with a parallel Western blot with anti-
Flag confirming expression of the Flag-etv6-FL (Fig. 5.1C).
5.2.3 Transcriptional properties of truncated etv6 variants
Having established that zebrafish etv6 was able to bind to a typical ETS site, an ETV6 
reporter based on the rat Mmp3 promoter that contains consensus ETS site (Mmp3-
luciferase) was used to analyse the transcriptional properties of zebrafish etv6. Consistent 
with the repressional property of mammalian ETV6, a decrease in luciferase activity was 
observed when the reporter was co-transfected with a vector expressing zebrafish etv6-FL in 
comparison to an empty vector. In contrast, neither expression of etv6-ǻ(76 QRU of etv6-
ǻ317VXSpressed luciferase activity. Moreover, co-expression of etv6-ǻ(76RUHWY-ǻ317
with etv6-FL blunted the transcriptional repression effects of etv6-FL (Fig. 5.1D). This 
suggests that both truncated forms can act as dominant-negative regulators of normal etv6 
function, as suggested for the mammalian equivalents.
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Figure 5.1. Construction, expression and functional analysis of truncated forms of 
zebrafish etv6.
(A) Schematic representation of constructs expressing Flag-tagged zebrafish full-length etv6 
(etv6-FL) and truncated etv6 forms (etv6-ǻ(76DQGHWY-ǻ3176HJPHQWVFRUUHVSRQGLQJWR
Flag (green), PNT (orange) and ETS (red) domains, relative amino acids numbers and
predicted sizes of the encoded proteins are indicated.
(B) Expression of Flag-tagged etv6 forms in human 293T cells. Total cell lysates from 293T 
cells transfected with vectors expressing Flag-tagged etv6-FL, etv6-ǻ(76 Dnd etv6-ǻ317
were subjected to Western blot analysis with Į-)ODJDQGĮ-GAPDH antibodies, the latter as a 
loading control.
(C) Binding of zebrafish etv6 to a conserved ETS site. Nuclear extracts from HEK293T cells 
transfected with a vector expressing Flag-tagged etv6-FL or untransfected cells were 
subjected to EMSA using E74 binding site probe, with a parallel Western blot with Į-Flag 
confirming expression of zebrafish etv6-FL.
(D) Effect of etv6 isoforms on transcription. HEK293T cells were co-transfected with the 
Mmp3-luciferase reporter and Renilla-luciferase, along with vectors expressing Flag-tagged 
etv6-FL, etv6-ǻ(76DQGHWY-ǻ317DORQHRULQFRPELQDWLRQFirefly luciferase activity was 
normalised for transfection efficiency using Renilla luciferase and expressed relative to no 
etv6, with error bars indicating the standard deviation from triplicate experiment (*: p < 0.05; 
n/s: not significant).
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5.2.4 Molecular analysis of hematological compartments
To investigate the function of truncated isoforms of ETV6 in vivo, zebrafish embryos 
were microinjected with in vitro transcribed RNA encoding etv6-FL, etv6-ǻ(76HWY-ǻ317
or mock RNA. RT-PCR analysis on pooled embryos using forward Flag primer and reverse 
primers for exon III and exon VII confirmed the stability of injected etv6-FL, etv6-ǻ(76DQG
etv6-ǻ317mRNAs, respectively, to at least 5 dpf (data not shown). Injected embryos were 
subsequently examined for any hematologic perturbation using specific blood lineage 
markers.
At 20 hpf, increased expression of scl was observed in the rostral LPM in embryos 
injected with etv6-ǻ(76DQGHWY-ǻ317FRPSDUHG to those injected with etv6-FL or control 
embryos (Fig. 5.2A-D, O). In contrast, the caudal LPM scl+ population was significantly 
depleted in etv6-ǻ(76DQGHWY-ǻ317HPEU\RV )LJ(-H, P). The expression of gata1
was also decreased in etv6-ǻ(76 DQG HWY6-ǻ317 HPEU\RV EXW VLJQLILFDQWO\ LQFUHDVHG LQ
etv6-FL embryos at the same time point relative to control embryos (Fig. 5.2I-L, Q). In 
contrast, co-injection of the same concentration of etv6-FL with either etv6-ǻ(76or etv6-
ǻ317led to decreased gata1 expression compared to controls (Fig. 5.2I-J, M-N, Q).
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Figure 5.2. Truncated isoforms of zebrafish etv6 disrupt primitive HSC and erythroid 
compartments.
WISH analysis of indicated control embryos (Co) and embryos injected with mRNA 
encoding different isoforms of etv6 (etv6-FL, etv6-ǻ(76DQGHWY-ǻ317IRUWKHH[SUHVVLRQ
of dorsal scl (A-D), caudal scl (E-H) and total gata1 (I-N), with quantitation of dorsal scl (O), 
caudal scl (P) and gata1 (Q) at 20 hpf presented as mean relative area of expression ± SEM 
(*: p < 0.05).
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At 5 dpf, etv6-ǻ(76DQGHWY-ǻ317HPEU\RVVKRZHGDQRYHUDOOGHFUHDVHLQc-myb
expression and O-dianisidine staining but an expanded lyz+ compartment. In contrast, etv6-
FL embryos showed increased expression of c-myb but reduced lyz+ cells relative to controls 
(Fig. 5.3A-L, Q). The lymphoid compartments was also investigated by analysis of ikaros
expression at 5 dpf, which was increased in etv6-ǻ(76 DQG HWY-ǻ317 HPEU\RV EXW
decreased in etv6-FL embryos compared to controls (Fig. 5.3M-P, R).
139
Chapter 5. Functional analysis of truncated isoforms of ETV6
Figure 5.3. Truncated isoforms of zebrafish etv6 disrupt definitive hematopoiesis.
A-H, M-P, R. WISH analysis of indicated control embryos (Co) and embryos injected with 
mRNA encoding different isoforms of etv6 (etv6-FL, etv6-ǻ(76 DQG HWY-ǻ317 IRU WKH
expression of c-myb (A-H) and ikaros (M-P) at 5 dpf, with the area of ikaros staining
quantified relative to eye size, and expressed as mean ± SEM  (R) 
I-H, Q. Analysis of embryos for Hb with O-dianisidine and WISH for the expression of lyz (I-
H), with the number of lyz+ cells represented as mean ± SEM (Q) (*: p < 0.05).
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5.3 Discussion 
Alternative isoforms of many proteins exist, including transcription factors, and these
can exert antagonistic biological effects. For example, two isoforms of RUNX1, RUNX 1a 
and 1b, exhibit antagonistic effects, with RUNX1a able to stimulate myeloid proliferation and 
inhibit cell differentiation in murine myeloid cells treated with G-CSF while RUNX1b 
antagonised these effects (Tanaka et al., 1995). In hematopoietic cells, five different 
alternatively spliced mRNAs encoding distinct isoforms of ETV6 have been reported, which 
includes those lacking either the PNT, central or ETS domains (Sasaki et al., 2004). In vitro
studies have shown that isoforms that lack either PNT or ETS domain lose their trans-
repressional abilities and can also dominantly interfere with ETV6-induced transcriptional 
repression. This is relevant clinically with expression of truncated ETV6 isoforms observed 
in certain leukemias often as a result of specific mutations (Doorn-Khosrovani et al., 2005).  
However, there are no data confirming the antagonistic effects of truncated ETV6 proteins in 
vivo. This Chapter has taken advantage of the zebrafish model, and especially the elucidation 
of a role for ETV6 in zebrafish hematopoiesis (Chapter 3), to investigate the effects of 
truncated ETV6 proteins.
Deletion mutants of zebrafish etv6 lacking either the PNT or ETS domain, etv6-ǻ317
and etv6-ǻ(76 FRXOG QRW UHSUHVV WUDQVFULSWLRQ DQG GRPLQDQWO\ LQWHUIHUHG ZLWK the 
transcriptional repression by full-length etv6. These results confirms that these two truncated 
constructs can act as dominant negative isoforms of etv6 in vitro in agreement with other 
studies (Doorn-Khosrovani et al., 2005; Sasaki et al., 2004). It has been proposed that ETV6-
ǻ(76FDQ LQWHUIHUHZLWK(79via heterodimerization through its PNT domain, which can 
result in changing of the subcellular localisation or disruption of DNA binding activity of 
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ETV6.  In contrast, ETV6-ǻ317may compete with ETV6 for binding to DNA, but is not 
able to bind to corepressors such as mSin3A (Sasaki et al., 2004).
Embryos injected with truncated forms of etv6 showed a similar disruption of early 
and definitive hematopoiesis to etv6 morphant embryos, as identified by increased rostral scl
expression and decreased caudal scl and gata1 expression at 20 hpf, as well as decreased c-
myb and lyz but increased ikaros expression by 5 dpf. Coinjection of etv6-ǻ317RU HWY-
ǻ(76ZLWKHWY-FL decreased expression of gata1 at 20 hpf. This is the first study showing a
dominant negative effect of truncated forms of ETV6 on normal ETV6 function in vivo.
These data provide an explanation for those cases of AML (Doorn-Khosrovani et al., 2005), 
ALL (Zhang et al., 2011; Van Vlierberghe et al., 2011) and MDS (Sasaki et al., 2004) in 
which heterozygous mutations of ETV6 leading to truncated products have been identified
adding to our understanding of leukemia etiology.
143
Chapter 6.Perpective and future directions
Chapter 6
Perspective and future directions
144
Chapter 6.Perpective and future directions
6.1 Overview
Chromosomal translocations involving fusions of the human ETV6 gene occur 
frequently in hematological malignancies, including alternate fusions involving JAK2 
observed in myeloid and lymphoid cancers. In addition, the ETV6 gene can be deleted or 
mutated to yield truncated isoforms. Moreover, a complete understanding of the normal 
function of ETV6 has remained incomplete partly due to the embryonic lethality of Etv6-
knockout mice. Therefore, further studies into ETV6 and its disruption were warranted. This 
Thesis has employed zebrafish as a model to increase our understanding of ETV6 function 
and its perturbation during embryogenesis. Specifically, it has used this model to (i) 
investigate the role of ETV6; (ii) analyze the effect of atypical CML and T-cell ALL-derived 
ETV6-JAK2 fusions; (iii) determine the consequences of truncated isoforms of ETV6.
6.2 Characterization and role of ETV6 in development
Chapter 3 investigated the role of ETV6 during embryonic development. 
Bioinformatics analysis in zebrafish revealed a single conserved etv6 orthologue, which was 
found to be expressed in hematopoietic, vascular and some other tissues. Morpholino-
mediated gene knockdown of etv6 revealed a complex contribution of this gene toward 
embryonic hematopoiesis and _ to a lesser extent _ vessel development. During primitive 
hematopoiesis, etv6 knockdown resulted in reduced levels of progenitor cells, erythrocytes
and macrophages, but increased numbers of incompletely differentiated heterophils. During 
definitive hematopoiesis, etv6 knockdown decreased hematopoietic stem cells, erythrocytes 
and myeloid cells, but resulted in enhanced lymphopoiesis. The data presented in this Chapter 
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suggested that ETV6 plays a wider and more complex role in hematopoiesis than previously 
thought, impacting on the development of multiple lineages. 
This study used morpholinos to knockdown etv6 in zebrafish embryos. Such gene 
knockdowns are transient, with efficient knockdown typically in the first 5-7 days of 
development (Nasevicius and Ekker, 2000; Bill et al., 2009). Therefore, studying later effects 
including in adults would require the generation of germline mutants through technologies 
such as TILLING (Moens et al., 2008) or genome editing with TALEN (Bedell et al., 2012) 
or CRISPR (Hwang et al., 2013) with the resultant mutations present at all stages of 
development. Such approaches can also circumvent potential off-target effects of 
morpholinos (Hruscha et al., 2013). Mutant etv6 lines would also facilitate the identification 
of genes regulated by etv6 in vivo using next generation sequencing approaches.
There is mounting evidence that the closely-related ETV7 is also involved in 
hematopoiesis. Thus, ETV7 has been reported to be involved in RBC development with loss 
of hemoglobinised RBCs in circulation following knockdown of zebrafish etv7 (Quintana et 
al., 2013). In addition, overexpression of ETV7 was shown to hinder monocytic 
differentiation in human U937 cell line (Kawagoe et al., 2004). However, unlike ETV6, 
ETV7 is frequently upregulated in human cancer, and is not a target of chromosomal 
translocations (Quintana and Grosveld, 2011).  Moreover, ETV7 can interact with ETV6 
through the PNT domain and relieve the inhibitory effect of ETV6 on Ras-induced cellular 
transformation (Kawagoe et al., 2004). These findings, together with the observed down 
regulation of etv7 in etv6 morphant embryos in this study, suggest a complex and potentially 
antagonistic interplay between these proteins. Close investigation of hematopoiesis in fish 
carrying mutated etv6 or etv7 or both would provide interesting insights in this regard.
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The etv6 morphant embryos showed subtle vessel defects, consistent with another 
report (Roukens et al., 2010). However, more severe defects have been reported in the 
absence of Etv6 during mouse yolk sac angiogenesis (Wang et al., 1997) and Xenopus arterial 
formation (Ciau-Uitz et al., 2010). More studies are warranted to understand these species 
differences. For example, other ETS family members should be considered for the possibility 
of compensation.
6.3 Molecular dissection of ETV6-JAK2 in zebrafish
Having established a role for etv6 in zebrafish hematopoiesis, Chapter 4 dissected
alternate atypical CML and T-ALL derived ETV6-JAK2 fusions. Injection of the T-cell 
ALL-derived etv6-jak2a significantly perturbed lymphopoiesis with a lesser effect on 
myelopoiesis in zebrafish embryos. In contrast, injection of the atypical CML-derived tel-
jak2a resulted in significant disruption of the myeloid compartment. However, both fusion 
forms showed similar effects on the erythroid lineage, with an increase in immature erythroid 
cells and decease in differentiated hemoglobinised erythrocytes. These phenotypes were 
observed regardless of whether expressed in a white blood cell-specific or ubiquitous manner, 
with no overt cellular proliferation outside of the hematopoietic cells, indicating that ETV6-
JAK2 represents a leukemic-specific oncogene. Functional studies revealed subtle molecular 
differences between the alternative forms, with the ALL variant showing higher activity, but 
reduced downstream STAT activation and decreased sensitivity to JAK2 inhibition, although 
JAK2 activity was required to mediate the effects of both variants on zebrafish 
hematopoiesis. This Chapter provided clear evidence that the molecular structure of 
alternative ETV6-JAK2 fusions likely contributes to the etiology of disease, and further 
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suggested that this class of oncogene exerts its effects in a cell lineage-specific manner, 
which may be due to differences in downstream signalling in different cell types.
This Chapter demonstrated that zebrafish were susceptible to the hematopoietic 
perturbation of T-ALL and CML derived ETV6-JAK2. Other studies have also observed 
hematological malignancies induced by over-expression of MYC (Gutierrez et al., 2014) and 
the leukemogenic fusion ETV6-RUNX1 (Sabaawy et al., 2006). Collectively, these studies 
consolidate zebrafish as a useful model system for the study of leukemogenesis and related
disorders.
Notably, this study used fusion genes constructed using the zebrafish etv6 and jak2a
genes, rather than using human or mouse sequences. A few other studies also have used 
zebrafish analogues of mammalian oncogenes to induce hematological disruption in 
zebrafish. For example, constitutive activation of zebrafish jak2a (Ma et al., 2009), or 
overexpression of zebrafish spi1 (Sun et al., 2013) and eena (Le et al., 2008) were able to 
induce polycythemia vera, AML and MPD, respectively. These studies collectively 
demonstrate that zebrafish orthologues of oncogenes are functional and able to produce 
similar hematological consequences to those observed in mammals and suggest that 
identification of new oncogenes in zebrafish via mutagenesis screening is likely to provide 
clinically-relevant insights.
However, in this study only the transient expression of etv6-jak2a was investigated. In 
order to understand its effects in a more clinically relevant setting, stable transgenic lines 
would be preferred. Unfortunately, attempts in this regard were unsuccessful largely because 
of the high incidence of mortality observed in injected embryos (data not shown). However, 
transgenic mice expressing T-ALL ETV6-JAK2 in the lymphoid lineage have been produced, 
with these mice developing fetal T-cell leukemia at 4-22 weeks of age (Carron et al., 2000). 
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This suggests that appropriately tissue-restricted etv6-jak2a transgenic zebrafish might also 
be viable. Recently, genome editing via homology directly repair has been successfully used 
for insertion of short sequences, such as loxP sites and hemagglutin (HA) tags (Bedell et al., 
2012; Chang et al., 2013; Hruscha et al., 2013), as well as entire reading frames, such as 
EGFP (Zu et al., 2013) and Gal4 (Auer et al., 2014) into the zebrafish genome. These 
methods could easily be applied to knock-in the appropriate segment jak2a at the relevant site 
within the etv6 locus to produce stable transgenic line. These could be employed for a range 
of studies, including understanding the effects in adult zebrafish as well as to identify 
modifier genes.
6.4 Molecular analysis of dominant negative isoforms of ETV6
Chapter 5 investigated truncated forms of ETV6 lacking either the PNT or ETS 
domain, as observed in leukemia and MPN.  Both mutants lost their transrepressional activity 
and interfered with the repression function of etv6-FL in vitro. It has been proposed that 
ETV6-ǻ(76FDQLQWHUIHUHZLWK(79-FL through heterodimerization and possible alteration
of subcellular localisation (Sasaki et al., 2004). To investigate the possibility of 
heterodimerization, immunoprecipitation of cells cotransfected with differently tagged etv6-
FL and truncated isoforms followed by Western blot could be performed. In addition, to 
identify possible changes in subcellular localisation of these isoforms immunohistochemistry 
would be informative. Competition between etv6-ǻ317with etv6-FL in binding to DNA has 
also been proposed, which would be further investigated using EMSA.
Injection of either etv6 mutant into zebrafish mimicked etv6 knockdown, resulting in 
reduced levels of progenitor cells and erythrocytes during primitive hematopoiesis. During 
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definitive hematopoiesis these mutants reduced c-myb+ cells but enhanced monocytic and 
lymphocytic populations. In contrast, expression of etv6-FL increased primitive progenitor 
cells and erythrocytes and reduced definitive monocytes and lymphocytes. However, when 
truncated forms were co-injected with etv6-FL, decreased erythroid populations were 
observed. This study extends observations that the loss of PNT or ETS domains of ETV6 can 
result in a dominant negative effect on ETV6 function. This further attests to a potential role 
for these mutations in the etiology of leukemia. This could be further explored by introducing 
both single and bi-allelic truncating mutations of etv6 corresponding to those in MDS, AML 
and ALL into zebrafish through genome editing with CRISPR.
6.5 Final conclusion
ETV6 is a transcription factor with high sequence homology across vertebrates,
including in zebrafish. ETV6 is widely expressed during embryonic development, with 
higher level of expression in hematopoietic tissues, where it plays a broad role in 
hematopoiesis, impacting on the development of multiple lineages. Frequent chromosomal 
translocations involving ETV6 has been reported in leukemia, including alternate atypical 
CML and T-ALL derived ETV6-JAK2 fusions.  These fusions represent leukemic-specific 
oncogenes which exert their effects in a cell lineage-specific manner. The molecular structure 
of these alternative fusions as well as differences in downstream signalling likely contributes 
to the etiology of disease. ETV6 can be also mutated to yield truncated isoforms which can 
dominantly interferes with normal ETV6 function to produce leukemia.
This study contributes to our understanding of hematopoiesis regulation with 
particular attention to the role ETV6 and its perturbation, which in turn has expanded our 
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knowledge about leukemia etiology. This study also further validates zebrafish as a useful 
model system for the study of both hematopoiesis and leukemogenesis, including drug 
screens application to identify compounds able to reverse the effects of ETV6-fusion 
oncoproteins and/or ETV6 truncations.
151
References
References
152
References
Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid 
progenitor that gives rise to all myeloid lineages. Nature 2000; 404: 193-197.
Alghisi E, Distel M, Malagola M, Anelli V, Santoriello C, Herwig L, Krudewig A, 
Henkel C, Russo D, Mione M. Targeting oncogene expression to endothelial cells induces 
proliferation of the myelo-erythroid lineage by repressing the notch pathway. Leukemia 
2013; 11: 229-241.
Artitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a 
source of proteins for healing and tissue regeneration. Thromb Haemost 2004; 91: 4-15.
Auer TO, Duroure K, De Cian A, Concordet J-P, Del Bene F. Highly efficient 
CRISPR/Cas9-mediated knock-in in zebrafish by homology-independent DNA repair. 
Genome Res 2014; 24: 142-153.
Baens M, Peeters P, Guo C, Aerssens J, Marynen P. Genomic organization of TEL: 
the human ETS-variant gene 6. Genome Res 1996; 6: 404-413.
Baker S, Rane S, Reddy E. Hematopoietic cytokine receptor signaling. Oncogene 
2007; 26: 6724-6737.
Barahmand-Pour F, Meinke A, Groner B, Decker T. Jak2-Stat5 interactions analyzed 
in yeast. J Biol Chem 1998; 273: 12567-12575.
Barbouti A, Ahlgren T, Johansson B, Höglund M, Lassen C, Turesson I, Mitelman F, 
Fioretos T. Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia 
in blast crisis treated with imatinib mesylate. Br J Haematol 2003; 122: 85-93.
Bassuk AG, Leiden JM. The role of Ets transcription factors in the development and 
function of the mammalian immune system. Adv. Imm 1997; 64: 65-104.
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, 
Bench AJ, Boyd EM, Curtin N. Acquired mutation of the tyrosine kinase JAK2 in human 
myeloproliferative disorders. The Lancet 2005; 365: 1054-1061.
Beckmann J, Scheitza S, Wernet P, Fischer JC, Giebel B. Asymmetric cell division 
within the human hematopoietic stem and progenitor cell compartment: identification of 
asymmetrically segregating proteins. Blood 2007; 109: 5494-5501.
Bedell VM, Wang Y, Campbell JM, Poshusta TL, Starker CG, Krug II RG, Tan W, 
Penheiter SG, Ma AC, Leung AY. In vivo genome editing using a high-efficiency TALEN 
system. Nature 2012; 491: 114-118.
Belloni E, Trubia M, Mancini M, Derme V, Nanni M, Lahortiga I, Riccioni R, 
Confalonieri S, Lo-Coco F, Di Fiore PP. A new complex rearrangement involving the ETV6, 
LOC115548, and MN1 genes in a case of acute myeloid leukemia. Genes Chromosomes 
Cancer 2004; 41: 272-277.
Bennett CM, Kanki JP, Rhodes J, Liu TX, Paw BH, Kieran MW, Langenau DM, 
Delahaye-Brown A, Zon LI, Fleming MD. Myelopoiesis in the zebrafish, Danio rerio. Blood 
2001; 98: 643-651.
153
References
Berman JN, Kanki JP, Look AT. Zebrafish as a model for myelopoiesis during 
embryogenesis. Exp Hematol 2005; 33: 997-1006.
Bertrand JY, Kim AD, Teng S, Traver D. CD41+ cmyb+ precursors colonize the 
zebrafish pronephros by a novel migration route to initiate adult hematopoiesis. Development 
2008; 135: 1853-1862.
Bertrand JY, Kim AD, Violette EP, Stachura DL, Cisson JL, Traver D. Definitive 
hematopoiesis initiates through a committed erythromyeloid progenitor in the zebrafish 
embryo. Development 2007; 134: 4147-4156.
Bettelli E, Korn T, Kuchroo VK. Th17: the third member of the effector T cell trilogy. 
Curr Opin Immunol 2007; 19: 652-657.
Beumer K, Bhattacharyya G, Bibikova M, Trautman JK, Carroll D. Efficient gene 
targeting in Drosophila with zinc-finger nucleases. Genetics 2006; 172: 2391-2403.
Beverloo HB, Panagopoulos I, Isaksson M, van Wering E, van Drunen E, de Klein A, 
Johansson B, Slater R. Fusion of the homeobox gene HLXB9 and the ETV6 gene in infant 
acute myeloid leukemias with the t (7; 12)(q36; p13). Cancer Res 2001; 61: 5374-5377.
Bibikova M, Carroll D, Segal DJ, Trautman JK, Smith J, Kim YG, Chandrasegaran S. 
Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. 
Mol Cell Biol 2001; 21: 289-297.
Bibikova M, Golic M, Golic KG, Carroll D. Targeted chromosomal cleavage and 
mutagenesis in Drosophila using zinc-finger nucleases. Genetics 2002; 161: 1169-1175.
Bill BR, Petzold AM, Clark KJ, Schimmenti LA, Ekker SC. A primer for morpholino 
use in zebrafish. Zebrafish 2009; 6: 69-77.
Blackburn JS, Liu S, Raiser DM, Martinez SA, Feng H, Meeker ND, Gentry J, 
Neuberg D, Look AT, Ramaswamy S. Notch signaling expands a pre-malignant pool of T-
cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell 
frequency. Leukemia 2012; 26: 2069-2078.
Blom B, Spits H. Development of human lymphoid cells. Annu Rev Immunol 2006; 
24: 287-320.
Boccuni P, MacGrogan D, Scandura JM, Nimer SD. The human L (3) MBT 
polycomb group protein is a transcriptional repressor and interacts physically and 
functionally with TEL (ETV6). J Biol Chem 2003; 278: 15412-15420.
Bohlander SK. ETV6: a versatile player in leukemogenesis. In: Semin Cancer Biol 
2005; 15: 162-174.
Bolli N, Payne EM, Grabher C, Lee J-S, Johnston AB, Falini B, Kanki JP, Look AT. 
Expression of the cytoplasmic NPM1 mutant (NPMc+) causes the expansion of 
hematopoietic cells in zebrafish. Blood 2010; 115: 3329-3340.
Bousquet M, Quelen C, De Mas V, Duchayne E, Roquefeuil B, Delsol G, Laurent G, 
Dastugue N, Brousset P. The t (8; 9)(p22; p24) translocation in atypical chronic myeloid 
leukaemia yields a new PCM1-JAK2 fusion gene. Oncogene 2005; 24: 7248-7252.
154
References
Brendolan A, Rosado MM, Carsetti R, Selleri L, Dear TN. Development and function 
of the mammalian spleen. Bioessays 2007; 29: 166-177.
Brownlie A, Donovan A, Pratt SJ, Paw BH, Oates AC, Brugnara C, Witkowska HE, 
Sassa S, Zon LI. Positional cloning of the zebrafish sauternes gene: a model for congenital 
sideroblastic anaemia. Nat Genet 1998; 20: 244-250.
Brownlie A, Hersey C, Oates AC, Paw BH, Falick AM, Witkowska HE, Flint J, 
Higgs D, Jessen J, Bahary N. Characterization of embryonic globin genes of the zebrafish. 
Dev. Biol. 2003; 255: 48-61.
Buijs A, Sherr S, van Baal S, van Bezouw S, Van der Plas D, Geurts vKA, Riegman 
P, Lekanne DR, Zwarthoff E, Hagemeijer A. Translocation (12; 22)(p13; q11) in 
myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 
gene on 22q11. Oncogene 1995; 10: 1511-1519.
Buijs A, Van Rompaey L, Molijn AC, Davis JN, Vertegaal ACO, Potter MD, Adams 
C, Van Baal S, Zwarthoff EC, Roussel MF. The MN1-TEL fusion protein, encoded by the 
translocation (12; 22) (p13; q11) in myeloid leukemia, is a transcription factor with 
transforming activity. Mol Cell Biol 2000; 20: 9281-9293.
Burns CE, DeBlasio T, Zhou Y, Zhang J, Zon L, Nimer SD. Isolation and 
characterization of runxa and runxb, zebrafish members of the runt family of transcriptional 
regulators. Exp Hematol 2002; 30: 1381-1389.
Busslinger M. Transcriptional control of early B cell development 1. Annu Rev 
Immunol 2004; 22: 55-79.
Cade L, Reyon D, Hwang WY, Tsai SQ, Patel S, Khayter C, Joung JK, Sander JD, 
Peterson RT, Yeh J-RJ. Highly efficient generation of heritable zebrafish gene mutations 
using homo-and heterodimeric TALENs. Nucleic Acids Res 2012; 40: 8001-8010.
Campbell PJ, Griesshammer M, Döhner K, Döhner H, Kusec R, Hasselbalch HC, 
Larsen TS, Pallisgaard N, Giraudier S, Le Bousse-Kerdilès M-C. V617F mutation in JAK2 is 
associated with poorer survival in idiopathic myelofibrosis. Blood 2006; 107: 2098-2100.
Cardone M, Kandilci A, Carella C, Nilsson JA, Brennan JA, Sirma S, Ozbek U, Boyd 
K, Cleveland JL, Grosveld GC. The novel ETS factor TEL2 cooperates with Myc in B 
lymphomagenesis. Mol Cell Biol 2005; 25: 2395-2405.
Carella C, Potter M, Bonten J, Rehg JE, Neale G, Grosveld GC. The ETS factor TEL2 
is a hematopoietic oncoprotein. Blood 2006; 107: 1124-1132.
Carroll M, Tomasson M, Barker G, Golub T, Gilliland D. The Tel platelet-derived 
growth factor receptor (PDGF-beta-R) fusion in chronic myelomonocytic leukemia is a 
transforming protein that self-associates and activates PDGF-beta-R kinase-dependent 
signaling pathways. Proc Natl Acad Sci USA 1996; 93: 14845-14850.
Carron C, Cormier F, Janin A, Lacronique V, Giovannini M, Daniel M-T, Bernard O, 
Ghysdael J. TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 2000; 95: 3891-
3899.
155
References
Cave H, Cacheux V, Raynaud S, Brunie G, Bakkus M, Cochaux P, Preudhomme C, 
Lai J, Vilmer E, Grandchamp B. ETV6 is the target of chromosome 12p deletions in t (12; 
21) childhood acute lymphocytic leukemia. Leukemia 1997; 11: 1459-1464.
Cavenagh J. White blood cells. Surgery (Oxford) 2007; 25: 61-64.
Cazzaniga G, Daniotti M, Tosi S, Giudici G, Aloisi A, Pogliani E, Kearney L, Biondi 
A. The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic 
leukemia case. Cancer Res 2001; 61: 4666-4670.
Cazzaniga G, Tosi S, Aloisi A, Giudici G, Daniotti M, Pioltelli P, Kearney L, Biondi 
A. The tyrosine kinase abl-related gene ARG Is Fused to ETV6 in an AML-M4Eo Patient 
With a t(1; 12)(q25; p13): molecular cloning of both reciprocal transcripts. Blood 1999; 94: 
4370-4373.
Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in 
BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J 
Immunol 1997; 159: 4720-4728.
Chakrabarti SR, Nucifora G. The leukemia-associated gene TEL encodes a 
transcription repressor which associates with SMRT and mSin3A. Biochem Biophys Res 
Commun 1999; 264: 871-877.
Chang N, Sun C, Gao L, Zhu D, Xu X, Zhu X, Xiong J-W, Xi JJ. Genome editing 
with RNA-guided Cas9 nuclease in zebrafish embryos. Cell Res. 2013; 23: 465-472.
Chase A, Reiter A, Burci L, Cazzaniga G, Biondi A, Pickard J, Roberts IAG, 
Goldman JM, Cross NCP. Fusion of ETV6 to the caudal-related homeobox gene CDX2 in 
acute myeloid leukemia with the t(12; 13)(p13; q12). Blood 1999; 93: 1025-1031.
Chen AT, Zon LI. Zebrafish blood stem cells. J Cell Biochem 2009; 108: 35-42.
Chen B, Zhao W, Jin J, Xue Y, Cheng X, Chen X, Cui J, Chen Z, Cao Q, Yang G. 
Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and 
comparison with those in Western countries. Leukemia 2005; 19: 767-775.
Chen J, Jette C, Kanki J, Aster J, Look A, Griffin J. NOTCH1-induced T-cell 
leukemia in transgenic zebrafish. Leukemia 2007b; 21: 462-471.
Chen S, Xue Y, Zhu X, Wu Y, Pan J. Minimally differentiated acute myeloid 
leukemia with t (12; 22)(p13; q11) translocation showing primary multidrug resistance and 
expressing multiple multidrug-resistant proteins. Acta Haematol 2007a; 118: 38-41.
Ciau-Uitz A, Pinheiro P, Gupta R, Enver T, Patient R. Tel1/ETV6 specifies blood 
stem cells through the agency of VEGF signaling. Dev Cell 2010; 18: 569-578.
Cools J, Bilhou-Nabera C, Wlodarska I, Cabrol C, Talmant P, Bernard P, Hagemeijer 
A, Marynen P. Fusion of a novel gene, BTL, to ETV6 in acute myeloid leukemias with at (4; 
12)(q11-q12; p13). Blood 1999; 94: 1820-1824.
Cools J, Mentens N, Odero MD, Peeters P, Wlodarska I, Delforge M, Hagemeijer A, 
Marynen P. Evidence for position effects as a variantETV6-mediated leukemogenic 
156
References
mechanism in myeloid leukemias with a t(4; 12)(q11-q12; p13) or t (5; 12)(q31; p13). Blood 
2002; 99: 1776-1784.
Corey DR, Abrams JM. Morpholino antisense oligonucleotides: tools for 
investigating vertebrate development. Genome Biol 2001; 2: 1015.1-1015.3.
Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Verstovsek 
S, Rios MB, Shan J, Kantarjian HM. Staging of chronic myeloid leukemia in the imatinib era. 
Cancer 2006; 106: 1306-1315.
Crosier PS, Bardsley A, Horsfield JA, Krassowska AK, Lavallie ER, Collins-Racie 
LA, Postlethwait JH, Yan YL, Mccoy JM, Crosier KE. In situ hybridization screen in 
zebrafish for the selection of genes encoding secreted proteins. Dev Dyn 2001; 222: 637-644.
Cunningham L, Finckbeiner S, Hyde RK, Southall N, Marugan J, Yedavalli VR, 
Dehdashti SJ, Reinhold WC, Alemu L, Zhao L. Identification of benzodiazepine Ro5-3335 as 
an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1–
&%)ȕLQWHUDFWLRQ3URF1DWO$FDG6FL86$-14597.
Curtis C, Grand F, Waghorn K, Sahoo T, George J, Cross N. A novel ETV6-
PDGFRB fusion transcript missed by standard screening in a patient with an imatinib 
responsive chronic myeloproliferative disease. Leukemia 2007; 21: 1839-1841.
Davidson AJ, Ernst P, Wang Y, Dekens MPS, Kingsley PD, Palis J, Korsmeyer SJ, 
Daley GQ, Zon LI. cdx4 mutants fail to specify blood progenitors and can be rescued by 
multiple hox genes. Nature 2003; 425: 300-306.
Davidson AJ, Zon LI. The ‘definitive’ (and ‘primitive’) guide to zebrafish 
hematopoiesis. Oncogene 2004; 23: 7233-7246.
Dawson MA, Curry JE, Barber K, Beer PA, Graham B, Lyons JF, Richardson CJ, 
Scott MA, Smyth T, Squires MS. AT9283, a potent inhibitor of the Aurora kinases and Jak2, 
has therapeutic potential in myeloproliferative disorders. Br J Haematol 2010; 150: 46-57.
De Braekeleer E, Douet-Guilbert N, Morel F, Le Bris M-J, Basinko A, De Braekeleer 
M. ETV6 fusion genes in hematological malignancies: a review. Leuk Res 2012; 36: 945-961.
de Graaf CA, Metcalf D. Thrombopoietin and hematopoietic stem cells. Cell Cycle 
2011; 10: 1582-1589.
De Keersmaecker K, Cools J. Chronic myeloproliferative disorders: a tyrosine kinase 
tale. Leukemia 2005; 20: 200-205.
Detrich Hr, Kieran MW, Chan FY, Barone LM, Yee K, Rundstadler JA, Pratt S, 
Ransom D, Zon LI. Intraembryonic hematopoietic cell migration during vertebrate 
development. Proc Natl Acad Sci USA 1995; 92: 10713-10717.
Dittmer J, Nordheim A. Ets transcription factors and human disease. Biochim 
Biophys Acta 1998; 1377: F1-F11.
Donaldson LW, Petersen JM, Graves BJ, McIntosh LP. Solution structure of the ETS 
domain from murine Ets-1: a winged helix-turn-helix DNA binding motif. EMBO J 1996; 15: 
125-134.
157
References
Dooley KA, Davidson AJ, Zon LI. Zebrafish scl functions independently in 
hematopoietic and endothelial development. Dev Biol. 2005; 277: 522-536.
Doorn-Khosrovani SBvWv, Spensberger D, de Knegt Y, Tang M, Löwenberg B, 
Delwel R. Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 
protein in acute myeloid leukemia. Oncogene 2005; 24: 4129-4137.
Downing JR. The AML1-ETO chimaeric transcription factor in acute myeloid 
leukaemia: biology and clinical significance. Br J Haematol 1999; 106: 296-308.
Doyon Y, McCammon JM, Miller JC, Faraji F, Ngo C, Katibah GE, Amora R, 
Hocking TD, Zhang L, Rebar EJ. Heritable targeted gene disruption in zebrafish using 
designed zinc-finger nucleases. Nat Biotechnol 2008; 26: 702-708.
Eguchi Ishimae M, Eguchi M, Maki K, Porcher C, Shimizu R, Yamamoto M, Mitani 
K. Leukemia related transcription factor TEL/ETV6 expands erythroid precursors and 
stimulates hemoglobin synthesis. Cancer Sci 2009; 100: 689-697.
Eguchi M, Eguchi-Ishimae M, Tojo A, Morishita K, Suzuki K, Sato Y, Kudoh S, 
Tanaka K, Setoyama M, Nagamura F. Fusion of ETV6 to neurotrophin-3 receptor TRKC in 
acute myeloid leukemia with t (12; 15)(p13; q25). Blood 1999; 93: 1355-1363.
Eguchi-Ishimae M, Eguchi M, Maki K, Porcher C, Shimizu R, Yamamoto M, Mitani 
K. Leukemia-related transcription factor TEL/ETV6 expands erythroid precursors and 
stimulates hemoglobin synthesis. Cancer Sci 2009; 100: 689-697.
Enoch S, Leaper DJ. Basic science of wound healing. Surgery (Oxford) 2005; 23: 37-
42.
Enver T, Greaves M. Loops, lineage, and leukemia. Cell 1998; 94: 9-12.
Erben P, Gosenca D, Müller MC, Reinhard J, Score J, del Valle F, Walz C, Mix J, 
Metzgeroth G, Ernst T. Screening for diverse PDGFRA or PDGFRB fusion genes is 
facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. 
Haematologica 2010; 95: 738-744.
Falcone FH, Zillikens D, Gibbs BF. The 21st century renaissance of the basophil? 
Current insights into its role in allergic responses and innate immunity. Exp Dermatol 2006; 
15: 855-864.
Fears S, Chakrabarti S, Nucifora G, Rowley J. Differential expression of TCL1 during 
pre-B-cell acute lymphoblastic leukemia progression. Cancer Genet Cytogenet 2002; 135: 
110-119.
Feener EP, Rosario F, Dunn SL, Stancheva Z, Myers MG. Tyrosine phosphorylation 
of Jak2 in the JH2 domain inhibits cytokine signaling. Mol Cell Biol 2004; 24: 4968-4978.
Feng H, Langenau DM, Madge JA, Quinkertz A, Gutierrez A, Neuberg DS, Kanki JP, 
Thomas Look A. Heat-shock induction of T-cell lymphoma/leukaemia in conditional 
Cre/lox-regulated transgenic zebrafish. Br J Haematol 2007; 138: 169-175.
Feng H, Stachura DL, White RM, Gutierrez A, Zhang L, Sanda T, Jette CA, Testa JR, 
Neuberg DS, Langenau DM. T-lymphoblastic lymphoma cells express high levels of BCL2, 
158
References
S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell 2010; 18: 
353-366.
Fenrick R, Amann JM, Lutterbach B, Wang L, Westendorf JJ, Downing JR, Hiebert 
SW. Both TEL and AML-1 contribute repression domains to the t (12; 21) fusion protein. 
Mol Cell Biol 1999; 19: 6566-6574.
Fenrick R, Wang L, Nip J, Amann JM, Rooney RJ, Walker-Daniels J, Crawford HC, 
Hulboy DL, Kinch MS, Matrisian LM. TEL, a putative tumor suppressor, modulates cell 
growth and cell morphology of ras-transformed cells while repressing the transcription of 
stromelysin-1. Mol Cell Biol 2000; 20: 5828-5839.
Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan-Halevy I, Wang Y, 
Kantarjian HM, Priebe W. WP1066 disrupts Janus kinase-2 and induces caspase-dependent 
apoptosis in acute myelogenous leukemia cells. Cancer Res 2007; 67: 11291-11299.
Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, Ariola C, Fodale 
V, Clappier E, Paoloni F. Somatically acquired JAK1 mutations in adult acute lymphoblastic 
leukemia. J Exp Med 2008; 205: 751-758.
Foley JE, Maeder ML, Pearlberg J, Joung JK, Peterson RT, Yeh JRJ. Targeted 
mutagenesis in zebrafish using customized zinc-finger nucleases. Nat Protoc 2009; 4: 1855-
1868.
Foley JE, Yeh J-RJ, Maeder ML, Reyon D, Sander JD, Peterson RT, Joung JK. Rapid 
mutation of endogenous zebrafish genes using zinc finger nucleases made by Oligomerized 
Pool ENgineering (OPEN). PLoS One 2009; 4: e4348.
Forghieri F, Morselli M, Potenza L, Maccaferri M, Pedrazzi L, Paolini A, Bonacorsi 
G, Artusi T, Giacobbi F, Corradini G. Chronic eosinophilic leukaemia with ETV6-NTRK3 
fusion transcript in an elderly patient affected with pancreatic carcinoma. Eur J Haematol 
2011; 86: 352-355.
Forrester AM, Grabher C, McBride ER, Boyd ER, Vigerstad MH, Edgar A, Kai FB, 
Da’as SI, Payne E, Look AT. NUP98-HOXA9-transgenic zebrafish develop a 
myeloproliferative neoplasm and provide new insight into mechanisms of myeloid 
leukaemogenesis. Br J Haematol 2011; 155: 167-181.
Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilliland DG. Socs-1 inhibits TEL-
JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase 
activity and induction of proteasome-mediated degradation. Mol Cell Biol 2001; 21: 3547-
3557.
Fry TJ, Mackall CL. The many faces of IL-7: from lymphopoiesis to peripheral T cell 
maintenance. J Immunol 2005; 174: 6571-6576.
Funakoshi-Tago M, Tago K, Nishizawa C, Takahashi K, Mashino T, Iwata S, Inoue 
H, Sonoda Y, Kasahara T. Licochalcone A is a potent inhibitor of TEL-Jak2-mediated 
transformation through the specific inhibition of Stat3 activation. Biochem pharmacol 2008; 
76: 1681-1693.
159
References
Galloway JL, Wingert RA, Thisse C, Thisse B, Zon LI. Loss of gata1 but not gata2 
converts erythropoiesis to myelopoiesis in zebrafish embryos. Dev Cell 2005; 8: 109-116.
Gering M, Rodaway A, Göttgens B, Patient R, Green A. The SCL gene specifies 
haemangioblast development from early mesoderm. EMBO J 1998; 17: 4029-4045.
Gill G. Regulation of the initiation of eukaryotic transcription. Essays in biochemistry 
2001; 37: 33-44.
Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, Morgan 
E, Raimondi SC, Rowley JD, Gilliland DG. Fusion of the TEL gene on 12p13 to the AML1 
gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1995; 92: 4917-
4921.
Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a 
novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5; 12) chromosomal 
translocation. Cell 1994; 77: 307-316.
Golub TR, Goga A, Barker GF, Afar D, McLaughlin J, Bohlander SK, Rowley JD, 
Witte ON, Gilliland DG. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL 
in human leukemia. Mol Cell Biol 1996; 16: 4107-4116.
Gouilleux-Gruart V, Gouilleux F, Desaint C, Claisse J, Capiod J-C, Delobel J, Weber-
Nordt R, Dusanter-Fourt I, Dreyfus F, Groner B. STAT-related transcription factors are 
constitutively activated in peripheral blood cells from acute leukemia patients. Blood 1996; 
87: 1692-1697.
Graves BJ, Petersen JM. Specificity within the ets family of transcription factors. Adv 
Cancer Res 1998; 75: 1-57.
Griesinger F, Janke A, Podleschny M, Bohlander SK. Identification of an ETV6–
ABL2 fusion transcript in combination with an ETV6 point mutation in a T-cell acute 
lymphoblastic leukaemia cell line. Br J Haematol 2002; 119: 454-458.
Grimshaw SJ, Mott HR, Stott KM, Nielsen PR, Evetts KA, Hopkins LJ, Nietlispach 
D, Owen D. Structure of the sterile motif (SAM) domain of the Saccharomyces cerevisiae 
mitogen-activated protein kinase pathway-modulating protein STE50 and analysis of its 
interaction with the STE11 SAM. J Biol Chem 2004; 279: 2192-2201.
Grover A, Mancini E, Moore S, Mead AJ, Atkinson D, Rasmussen KD, O’Carroll D, 
Jacobsen SEW, Nerlov C. Erythropoietin guides multipotent hematopoietic progenitor cells 
toward an erythroid fate. J Exp Med 2014; 211: 181-188.
Guidez F, Petrie K, Ford AM, Lu H, Bennett CA, MacGregor A, Hannemann J, Ito Y, 
Ghysdael J, Greaves M. Recruitment of the nuclear receptor corepressor N-CoR by the TEL 
moiety of the childhood leukemia–associated TEL-AML1 oncoprotein. Blood 2000; 96: 
2557-2561.
Gutierrez A, Grebliunaite R, Feng H, Kozakewich E, Zhu S, Guo F, Payne E, 
Mansour M, Dahlberg SE, Neuberg DS. Pten mediates Myc oncogene dependence in a 
conditional zebrafish model of T cell acute lymphoblastic leukemia. JEM 2011; 208: 1595-
1603.
160
References
Gutierrez A, Pan L, Groen RW, Baleydier F, Kentsis A, Marineau J, Grebliunaite R, 
Kozakewich E, Reed C, Pflumio F. Phenothiazines induce PP2A-mediated apoptosis in T cell 
acute lymphoblastic leukemia. J Clin Invest 2014; 124: 644-655.
Hagman J, Lukin K. Transcription factors drive B cell development. Curr Opin 
Immunol 2006; 18: 127-134.
Hansen JD, Zapata AG. Lymphocyte development in fish and amphibians. Immunol 
Rev 1998; 166: 199-220.
Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver 
CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T 
helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-1132.
Hartenstein V. Blood cells and blood cell development in the animal kingdom. Annu 
Rev Cell Dev Biol 2006; 22: 677-712.
Hauer J, Tosi S, Schuster FR, Harbott J, Kolb HJ, Borkhardt A. Graft versus leukemia 
effect after haploidentical HSCT in a MLL-negative infant AML with HLXB9/ETV6 
rearrangement. Pediatr Blood Cancer 2008; 50: 921-923.
Hiebert SW, Sun W, Davis JN, Golub T, Shurtleff S, Buijs A, Downing JR, Grosveld 
G, Roussell M, Gilliland DG. The t (12; 21) translocation converts AML-1B from an 
activator to a repressor of transcription. Mol Cell Biol 1996; 16: 1349-1355.
Ho JM-Y, Beattie BK, Squire JA, Frank DA, Barber DL. Fusion of the ets 
transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood 1999; 93: 
4354-4364.
Ho JM-Y, Nguyen MH-H, Dierov JK, Badger KM, Beattie BK, Tartaro P, Haq R, 
Zanke BW, Carroll MP, Barber DL. TEL-JAK2 constitutively activates the extracellular 
signal–regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 
signaling pathways. Blood 2002; 100: 1438-1448.
Hock H, Meade E, Medeiros S, Schindler JW, Valk PJM, Fujiwara Y, Orkin SH. 
Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival. 
Genes Dev 2004; 18: 2336-2341.
Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC, Vainchenker W, Percy MJ, 
McMullin MF, Constantinescu SN, Johnston JA. The myeloproliferative disorder–associated 
JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. 
Blood 2007; 109: 4924-4929.
Hosoya N, Qiao Y, Hangaishi A, Wang L, Nannya Y, Sanada M, Kurokawa M, Chiba 
S, Hirai H, Ogawa S. Identification of a SRC-like tyrosine kinase gene, FRK, fused with 
ETV6 in a patient with acute myelogenous leukemia carrying at (6; 12)(q21; p13) 
translocation. Genes Chromosome Cancer 2005; 42: 269-279.
Hruscha A, Krawitz P, Rechenberg A, Heinrich V, Hecht J, Haass C, Schmid B. 
Efficient CRISPR/Cas9 genome editing with low off-target effects in zebrafish. Development 
2013; 140: 4982-4987.
161
References
Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev 
Biochem 2000; 69: 373-398.
Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JJ, 
Joung JK. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol 
2013; 31: 227-229.
Iijima Y, Ito T, Oikawa T, Eguchi M, Eguchi-Ishimae M, Kamada N, Kishi K, Asano 
S, Sakaki Y, Sato Y. A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), 
identified in an AML-M3 cell line with at (1; 12)(q25; p13) translocation. Blood 2000; 95: 
2126-2131.
Ing VW. The etiology and management of leukopenia. Can Fam Physician 1984; 30: 
1835-1839.
Irvin BJ, Wood LD, Wang L, Fenrick R, Sansam CG, Packham G, Kinch M, Yang E, 
Hiebert SW. TEL, a putative tumor suppressor, induces apoptosis and represses transcription 
of Bcl-XL. J Biol Chem 2003; 278: 46378-47386.
James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau F, Lacout C, Garçon L, 
Raslova H, Berger R, Bennaceur-Griscelli A. A unique clonal JAK2 mutation leading to 
constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
Janknecht R, Nordheim A. Gene regulation by Ets proteins. Biochim Biophys Acta, 
Reviews on cancer 1993; 1155: 346-356.
Janssen H, Wlodarska I, Mecucci C, Hagemeijer A, Vandenberghe P, Marynen P, 
Cools J. Fusion of ETV6 to GOT1 in a case with myelodysplastic syndrome and t (10; 
12)(q24; p13). Haematologica 2006; 91: 949-951.
Janz T, Johnson R, Rubenstein S. Anemia in the emergency department: evaluation 
and treatment. Emerg Med Pract 2013; 15: 1-15.
Jensen FB. The dual roles of red blood cells in tissue oxygen delivery: oxygen carriers 
and regulators of local blood flow. J Exp Biol 2009; 212: 3387-3393.
Jeong EG, Kim MS, Nam HK, Min CK, Lee S, Chung YJ, Yoo NJ, Lee SH. Somatic 
mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res 2008; 
14: 3716-3721.
Jin H, Sood R, Xu J, Zhen F, English MA, Liu PP, Wen Z. Definitive hematopoietic 
stem/progenitor cells manifest distinct differentiation output in the zebrafish VDA and PBI. 
Development 2009; 136: 647-654.
Jin H, Xu J, Wen Z. Migratory path of definitive hematopoietic stem/progenitor cells 
during zebrafish development. Blood 2007; 109: 5208-5214.
Jousset C, Carron C, Boureux A, Quang CT, Oury C, Dusanter-Fourt I, Charon M, 
Levin J, Bernard O, Ghysdael J. A domain of TEL conserved in a subset of ETS proteins 
defines a specific oligomerization interface essential to the mitogenic properties of the TEL–
PDGFR oncoprotein. EMBO J 1997; 16: 69-82.
162
References
Jowett T. Double in Situ hybridization techniques in zebrafish. Methods 2001; 23: 
345-358.
Kalev-Zylinska ML, Horsfield JA, Flores MVC, Postlethwait JH, Vitas MR, Baas 
AM, Crosier PS, Crosier KE. Runx1 is required for zebrafish blood and vessel development 
and expression of a human RUNX1-CBF2T1 transgene advances a model for studies of 
leukemogenesis. Development 2002; 129: 2015-2030.
Kamizono S, Hanada T, Yasukawa H, Minoguchi S, Kato R, Minoguchi M, Hattori 
K, Hatakeyama S, Yada M, Morita S. The SOCS box of SOCS-1 accelerates ubiquitin-
dependent proteolysis of TEL-JAK2. J Biol Chem2001; 276: 12530-12538.
Kari G, Rodeck U, Dicker AP. Zebrafish: an emerging model system for human 
disease and drug discovery. Clin Pharmacol Ther 2007; 82: 70-80.
Karin M. Too many transcription factors: positive and negative interactions. New Biol 
1990; 2: 126-131.
Kastner P, Dupuis A, Gaub M-P, Herbrecht R, Lutz P, Chan S. Function of Ikaros as a 
tumor suppressor in B cell acute lymphoblastic leukemia. Am J Blood Res 2013; 3: 1-13.
Katsura Y, Suzukawa K, Nanmoku T, Nemoto N, Machino T, Obara N, Okoshi Y, 
Mukai HY, Hasegawa Y, Kojima H. Myelodysplastic syndrome accompanied by basophilia 
and eosinophilia with t (5; 12)(q31; p13). Cancer Gent Cytogenet 2007; 178: 85-88.
Kawagoe H, Potter M, Ellis J, Grosveld GC. TEL2, an ETS factor expressed in 
human leukemia, regulates monocytic differentiation of U937 cells and blocks the inhibitory 
effect of TEL1 on ras-induced cellular transformation. Cancer Res 2004; 64: 6091-6100.
Kelly JC, Shahbazi N, Scheerle J, Jahn J, Suchen S, Christacos NC, Mowrey PN, Witt 
MH, Hostetter A, Meloni-Ehrig AM. Insertion (12; 9)(p13; q34q34): a cryptic rearrangement 
involving ABL1/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid 
leukemia. Cancer Gent Cytogenet 2009; 192: 36-39.
Kim CA, Phillips ML, Kim W, Gingery M, Tran HH, Robinson MA, Faham S, Bowie 
JU. Polymerization of the SAM domain of TEL in leukemogenesis and transcriptional 
repression. EMBO J 2001; 20: 4173-4182.
Kissa K, Murayama E, Zapata A, Cortés A, Perret E, Machu C, Herbomel P. Live 
imaging of emerging hematopoietic stem cells and early thymus colonization. Blood 2008; 
111: 1147-1156.
Kisseleva T, Bhattacharya S, Braunstein J, Schindler C. Signaling through the 
JAK/STAT pathway, recent advances and future challenges. Gene 2002; 285: 1-24.
Kisucka J, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, 
Ruggeri ZM, Jain RK, Folkman J, Wagner DD. Platelets and platelet adhesion support 
angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci USA 2006; 103: 
855-860.
Kiyoi H, Yamaji S, Kojima S, Naoe T. JAK3 mutations occur in acute 
megakaryoblastic leukemia both in Down syndrome children and non-Down syndrome 
adults. Leukemia 2007; 21: 574-576.
163
References
Knezevich SR, McFadden DE, Tao W, Lim JF, Sorensen PHB. A novel ETV6-
NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998; 18: 184-187.
Kobayashi H, Montgomery K, Bohlander S, Adra C, Lim B, Kucherlapati R, Donis-
Keller H, Holt M, Le Beau M, Rowley J. Fluorescence in situ hybridization mapping of 
translocations and deletions involving the short arm of human chromosome 12 in malignant 
hematologic diseases. Blood 1994; 84: 3473-3482.
Kobayashi M, Nishikawa K, Yamamoto M. Hematopoietic regulatory domain of 
gata1 gene is positively regulated by GATA1 protein in zebrafish embryos. Development 
2001; 128: 2341-2350.
Kodandapani R, Pio F, Ni CZ, Piccialli G, Klemsz M, McKercher S, Maki RA, Ely 
KR. A new pattern for helix-turn-helix recognition revealed by the PU. 1 ETS-domain-DNA 
complex. Nature 1996; 380: 456-460.
Kondo M, Weissman IL, Akashi K. Identification of clonogenic common lymphoid 
progenitors in mouse bone marrow. Cell 1997; 91: 661-672.
Kralik JM, Kranewitter W, Boesmueller H, Marschon R, Tschurtschenthaler G, 
Rumpold H, Wiesinger K, Erdel M, Petzer AL, Webersinke G. Characterization of a newly 
identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia. Diagn Pathol 2011; 6: 
19.
Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR, Tichelli A, 
Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. 
N Eng J Med 2005; 352: 1779-1790.
Krause L, Przemeck G, de Angelis MH, Bohlander S. The OSTL gene encodes for a 
conserved RING finger protein which interacts with HAX1 and SIVA: Possible role in B cell 
signaling and survival. Blood 2003; 102: 848a.
Kuchenbauer F, Schoch C, Holler E, Haferlach T, Hiddemann W, Schnittger S. A rare 
case of acute myeloid leukemia with a CHIC2-ETV6 fusiongen and multiple other molecular 
aberrations. Leukemia 2005; 19: 2366-2368.
Kuno Y, Abe A, Emi N, Iida M, Yokozawa T, Towatari M, Tanimoto M, Saito H. 
Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with 
t (9; 12)(q22; p12). Blood 2001; 97: 1050-1055.
La Starza R, Trubia M, Testoni N, Ottaviani E, Belloni E, Crescenzi B, Martelli M, 
Flandrin G, Pelicci PG, Mecucci C. Clonal eosinophils are a morphologic hallmark of 
ETV6/ABL1 positive acute myeloid leukemia. Haematologica 2002; 87: 789-794.
Lacronique V, Boureux A, Della Valle V, Poirel H, Quang CT, Mauchauffé M, 
Berthou C, Lessard M, Berger R, Ghysdael J. A TEL-JAK2 fusion protein with constitutive 
kinase activity in human leukemia. Science 1997; 278: 1309-1312.
Lacronique V, Boureux A, Monni R, Dumon S, Mauchauffé M, Mayeux P, Gouilleux 
F, Berger R, Gisselbrecht S, Ghysdael J. Transforming properties of chimeric TEL-JAK 
proteins in Ba/F3 cells. Blood 2000; 95: 2076-2083.
164
References
Lam EYN, Hall CJ, Crosier PS, Crosier KE, Flores MV. Live imaging of Runx1 
expression in the dorsal aorta tracks the emergence of blood progenitors from endothelial 
cells. Blood 2010; 116: 909-914.
Langenau D, Keefe M, Storer N, Jette C, Smith A, Ceol C, Bourque C, Look A, Zon 
L. Co-injection strategies to modify radiation sensitivity and tumor initiation in transgenic 
Zebrafish. Oncogene 2008; 27: 4242-4248.
Langenau DM, Feng H, Berghmans S, Kanki JP, Kutok JL, Look AT. Cre/lox-
regulated transgenic zebrafish model with conditional myc-induced T cell acute 
lymphoblastic leukemia. Proc Natl Acad Sci USA 2005; 102: 6068-6073.
Langenau DM, Traver D, Ferrando AA, Kutok JL, Aster JC, Kanki JP, Lin S, 
Prochownik E, Trede NS, Zon LI. Myc-induced T cell leukemia in transgenic zebrafish. 
Science 2003; 299: 887-890.
Latchman DS. Transcription factors: an overview. Int J Biochem Cell Biol 1997; 29: 
1305-1312.
Le Guyader D, Redd MJ, Colucci-Guyon E, Murayama E, Kissa K, Briolat V, 
Mordelet E, Zapata A, Shinomiya H, Herbomel P. Origins and unconventional behavior of 
neutrophils in developing zebrafish. Blood 2008; 111: 132-141.
Le H-Y, Zhang Y, Liu H, Ma L-H, Jin Y, Huang Q-H, Chen Y, Deng M, Chen Z, 
Chen S-J. eena Promotes myeloid proliferation through stimulating ERK1/2 phosphorylation 
in zebrafish. J Biol Chem2008; 283: 17652-17661.
Le X, Langenau DM, Keefe MD, Kutok JL, Neuberg DS, Zon LI. Heat shock-
inducible Cre/Lox approaches to induce diverse types of tumors and hyperplasia in transgenic 
zebrafish. Proc Natl Acad Sci USA 2007; 104: 9410-9415.
Lee J, Kim Y, Soung Y, Han K, Kim S, Rhim H, Min W, Nam S, Park W, Lee J. The 
JAK2 V617F mutation in de novo acute myelogenous leukemias. Oncogene 2005; 25: 1434-
1436.
Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol 
1998; 16: 293-322.
Levy DE, Darnell J. Stats: transcriptional control and biological impact. Nat Rev Mol 
Cell Biol 2002; 3: 651-662.
Lewis RS, Stephenson SE, Ward AC. Constitutive activation of zebrafish Stat5 
expands hematopoietic cell populations in vivo. Exp Hematol 2006; 34: 179-187.
Liao EC, Paw BH, Oates AC, Pratt SJ, Postlethwait JH, Zon LI. SCL/Tal-1
transcription factor acts downstream of cloche to specify hematopoietic and vascular 
progenitors in zebrafish. Genes Dev 1998; 12: 621-626.
Lieschke GJ, Oates AC, Crowhurst MO, Ward AC, Layton JE. Morphologic and 
functional characterization of granulocytes and macrophages in embryonic and adult 
zebrafish. Blood 2001; 98: 3087-3096.
165
References
Lieschke GJ, Oates AC, Paw BH, Thompson MA, Hall NE, Ward AC, Ho RK, Zon 
LI, Layton JE. Zebrafish SPI-1 (PU. 1) marks a site of myeloid development independent of 
primitive erythropoiesis: implications for axial patterning. Dev Biol 2002; 246: 274-295.
Liongue C, Hall CJ, O'Connell BA, Crosier P, Ward AC. Zebrafish granulocyte 
colony-stimulating factor receptor signaling promotes myelopoiesis and myeloid cell 
migration. Blood 2009; 113: 2535-2546.
Liu F, Wen Z. Cloning and expression pattern of the lysozyme C gene in zebrafish. 
Mech Dev 2002; 113: 69-72.
Long Q, Meng A, Wang H, Jessen JR, Farrell MJ, Lin S. GATA-1 expression pattern 
can be recapitulated in living transgenic zebrafish using GFP reporter gene. Development 
1997; 124: 4105-4111.
Lopez RG, Carron C, Ghysdael J. v-SRC specifically regulates the nucleo-
cytoplasmic delocalization of the major isoform of TEL (ETV6). J Biol Chem2003; 278: 
41316-41325.
Lopez RG, Carron C, Oury C, Gardellin P, Bernard O, Ghysdael J. TEL is a 
sequence-specific transcriptional repressor. J Biol Chem1999; 274: 30132-30138.
Lu X, Harris C, Cooley L, Margolin J, Steuber P, Sheldon M, Rao P, Lau C. The 
utility of spectral karyotyping in the cytogenetic analysis of newly diagnosed pediatric acute 
lymphoblastic leukemia. Leukemia 2002; 16: 2222-2227.
Luo H, Rose P, Barber D, Hanratty WP, Lee S, Roberts TM, D'Andrea AD, Dearolf 
CR. Mutation in the Jak kinase JH2 domain hyperactivates Drosophila and mammalian Jak-
Stat pathways. Mol Cell Biol 1997; 17: 1562-1571.
Ma AC, Fan A, Ward AC, Liongue C, Lewis RS, Cheng SH, Chan PK, Yip S-F, 
Liang R, Leung AY. A novel zebrafish jak2a (V581F) model shared features of human JAK2 
(V617F) polycythemia vera. Exp Hematol 2009; 37: 1379-1386. e1374.
Ma AC, Ward AC, Liang R, Leung AY. The role of jak2a in zebrafish hematopoiesis. 
Blood 2007; 110: 1824-1830.
Malinge S, Monni R, Bernard O, Penard-Lacronique V. Activation of the NF-ț%
pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the 
DFFXPXODWLRQRIDQWLDSRSWRWLF ,$3SURWHLQV DQG LQYROYHV ,..Į2QFRJHQH-
3597.
Malone A, Langabeer S, O’Marcaigh A, Storey L, Bacon CL, Smith OP. A Doctor (s) 
dilemma: ETV6-ABL1 positive acute lymphoblastic leukaemia. Br J Haematol 2010; 151: 
101-102.
Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat 
Immunol 2001; 2: 816-822.
May P, Gerhartz C, Heesel B, Welte T, Doppler W, Graeve L, Horn F, Heinrich PC. 
Comparative study on the phosphotyrosine motifs of different cytokine receptors involved in 
STAT5 activation. FEBS lett 1996; 394: 221-226.
166
References
McCullough KC, Summerfield A. Basic concepts of immune response and defense 
development. ILAR J 2005; 46: 230-240.
McGrath KE, Koniski AD, Malik J, Palis J. Circulation is established in a stepwise 
pattern in the mammalian embryo. Blood 2003; 101: 1669-1676.
Melnick A, Carlile GW, McConnell MJ, Polinger A, Hiebert SW, Licht JD. AML-
1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the 
promyelocytic leukemia zinc finger protein. Blood 2000; 96: 3939-3947.
Meng A, Tang H, Ong BA, Farrell MJ, Lin S. Promoter analysis in living zebrafish 
embryos identifies a cis-acting motif required for neuronal expression of GATA-2. Proc Natl 
Acad Sci USA 1997; 94: 6267-6272.
Meng X, Noyes MB, Zhu LJ, Lawson ND, Wolfe SA. Targeted gene inactivation in 
zebrafish using engineered zinc-finger nucleases. Nat biotechnol 2008; 26: 695-701.
Metcalf D. The molecular biology and functions of the granulocyte-macrophage 
colony-stimulating factors. Blood 1986; 67: 257-267.
Metcalf D, Begley C, Johnson G, Nicola N, Lopez A, Williamson D. Effects of 
purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult 
mice. Blood 1986; 68: 46-57.
Mizgirev IV, Revskoy S. A new zebrafish model for experimental leukemia therapy. 
Cancer Biol Ther 2010; 9: 895-902.
Moens CB, Donn TM, Wolf-Saxon ER, Ma TP. Reverse genetics in zebrafish by 
TILLING. Brief Funct Genomic Proteomic 2008; 7: 454-459.
Monni R, Santos SC, Mauchauffe M, Berger R, Ghysdael J, Gouilleux F, Gisselbrecht 
S, Bernard O, Penard-Lacronique V. The TEL-Jak2 oncoprotein induces Socs1 expression 
and altered cytokine response in Ba/F3 cells. Oncogene 2001; 20: 849-858.
Montecino-Rodriguez E, Dorshkind K. Evolving patterns of lymphopoiesis from 
embryogenesis through senescence. Immunity 2006; 24: 659-662.
Montpetit A, Sinnett D. Comparative analysis of the ETV6 gene in vertebrate 
genomes from pu erfish to human. Oncogene 2001; 20: 3437-3442.
Morgan KJ, Gilliland DG. A role for JAK2 mutations in myeloproliferative diseases. 
Annu Rev Med 2008; 59: 213-222.
Mosmann TR, Cherwinski H, Bond M, Giedlin M, Coffman R. Two types of murine 
helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted 
proteins. J Immunol 1986; 136: 2348-23457.
Mueller BU, Pabst T, Osato M, Asou N, Johansen LM, Minden MD, Behre G, 
Hiddemann W, Ito Y, Tenen DG. Heterozygous PU. 1 mutations are associated with acute 
myeloid leukemia. Blood 2002; 100: 998-1007.
167
References
Mullighan CG, Zhang J, Harvey RC, Collins-Underwood JR, Schulman BA, Phillips 
LA, Tasian SK, Loh ML, Su X, Liu W. JAK mutations in high-risk childhood acute 
lymphoblastic leukemia. Proc Natl Acad Sci USA 2009; 106: 9414-9418.
Murati A, Adelaide J, Gelsi-Boyer V, Etienne A, Remy V, Fezoui H, Sainty D, Xerri 
L, Vey N, Olschwang S. t (5; 12)(q23–31; p13) with ETV6-ACSL6 gene fusion in 
polycythemia vera. Leukemia 2006; 20: 1175-1178.
Murayama E, Kissa K, Zapata A, Mordelet E, Briolat V, Lin HF, Handin RI, 
Herbomel P. Tracing hematopoietic precursor migration to successive hematopoietic organs 
during zebrafish development. Immunity 2006; 25: 963-975.
Nakamura F, Nakamura Y, Maki K, Sato Y, Mitani K. Cloning and characterization 
of the novel chimeric gene TEL/PTPRR in acute myelogenous leukemia with inv 
(12)(p13q13). Cancer Res 2005; 65: 6612-6621.
Nakamura Y, Nakazato H, Sato Y, Furusawa S, Mitani K. Expression of the 
TEL/EVI1 fusion transcript in a patient with chronic myelogenous leukemia with t (3; 
12)(q26; p13). Am J Hematol 2002; 69: 80-82.
Nakazato H, Shiozaki H, Zhou M, Nakatsu M, Motoji T, Mizoguchi H, Miyawaki S, 
Sato Y. TEL/MN1 fusion in a de novo acute myeloid leukaemia-M2 patient who showed 
strong resistance to treatment. Br J Haematol 2001; 113: 1076-1089.
Nand R, Bryke C, Kroft SH, Divgi A, Bredeson C, Atallah E. Myeloproliferative 
disorder with eosinophilia and ETV6–ABL gene rearrangement: Efficacy of second-
generation tyrosine kinase inhibitors. Leuk Res 2009; 33: 1144-1146.
Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate 
chromatin structure and transcription. Cell 2002; 108: 475-487.
Nguyen MH-H, Ho JM-Y, Beattie BK, Barber DL. TEL-JAK2 mediates constitutive 
DFWLYDWLRQ RI WKH SKRVSKDWLG\OLQRVLWRO ƍ-kinase/protein kinase B signaling pathway. J Biol 
Chem 2001; 276: 32704-32713.
Nishimura Y, Wada H, Mori A, Takatsuka H, Tamura A, Fujimori Y, Okamoto T, 
Takemoto Y, Kakishita E. Detection of ETV6/MDS1/Evi-1 chimeric transcripts in a patient 
with acute myelocytic leukemia and t (3; 12)(q26; p13). Int J Hematol 2000; 72: 108-109.
Nofrini V, Berchicci L, La Starza R, Gorello P, Di Giacomo D, Arcioni F, Pierini V, 
Crescenzi B, Romoli S, Matteucci C. MN1-ETV6 IXVLRQJHQHDULVLQJIURP0'6:LWKTí
Leuk Res 2011; 35: e123-e126.
Nordentoft I, JRGENSEN P. The acetyltransferase 60 kDa trans-acting regulatory 
protein of HIV type 1-interacting protein (Tip60) interacts with the translocation E26 
transforming-specific leukaemia gene (TEL) and functions as a transcriptional co-repressor. 
Biochem J 2003; 374: 165-173.
O’Sullivan LA, Noor SM, Trengove MC, Lewis RS, Liongue C, Sprigg NS, 
Nicholson SE, Ward AC. Suppressor of cytokine signaling 1 regulates embryonic 
myelopoiesis independently of its effects on T cell development. J Immunol 2011; 186: 4751-
4761.
168
References
Oates AC, Brownlie A, Pratt SJ, Irvine DV, Liao EC, Paw BH, Dorian KJ, Johnson 
SL, Postlethwait JH, Zon LI. Gene duplication of zebrafish JAK2 homologs is accompanied 
by divergent embryonic expression patterns: only jak2a is expressed during erythropoiesis. 
Blood 1999; 94: 2622-2636.
Odero MD, Carlson K, Calasanz MJ, Lahortiga I, Chinwalla V, Rowley JD. 
Identification of new translocations involving ETV6 in hematologic malignancies by 
fluorescence in situ hybridization and spectral karyotyping. Genes Chromosomes Cancer 
2001; 31: 134-142.
Odero MD, Vizmanos JL, Román JP, Lahortiga I, Panizo C, Calasanz MJ, Zeleznik 
Le NJ, Rowley JD, Novo FJ. A novel gene, MDS2, is fused to ETV6/TEL in at (1; 12)(p36. 
1; p13) in a patient with myelodysplastic syndrome. Genes Chromosomes Cancer 2002; 35: 
11-19.
Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. 
Gene 2003; 303: 11-34.
Okuda K, Golub T, Gilliland D, Griffin J. p210BCR/ABL, p190BCR/ABL, and 
TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. 
Oncogene 1996; 13: 1147-1152.
Onnebo S, Condron MM, McPhee DO, Lieschke GJ, Ward AC. Hematopoietic 
perturbation in zebrafish expressing a tel-jak2a fusion. Exp Hematol 2005; 33: 182-188.
Orkin SH. Transcription factors and hematopoietic development. J Biol Chem1995; 
270: 4955-4958.
Orkin SH. Diversification of haematopoietic stem cells to specific lineages. Nat Rev 
Genet 2000; 1: 57-64.
Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 
2008; 132: 631-644.
O'Sullivan LA, Liongue C, Lewis RS, Stephenson SE, Ward AC. Cytokine receptor 
signaling through the Jak–Stat–Socs pathway in disease. Mol Immunol 2007; 44: 2497-2506.
Otsubo K, Kanegane H, Eguchi M, Eguchi-Ishimae M, Tamura K, Nomura K, Abe A, 
Ishii E, Miyawaki T. ETV6–ARNT fusion in a patient with childhood T lymphoblastic 
leukemia. Cancer Gent Cytogenet 2010; 202: 22-26.
Paffett-Lugassy N, Hsia N, Fraenkel PG, Paw B, Leshinsky I, Barut B, Bahary N, 
Caro J, Handin R, Zon LI. Functional conservation of erythropoietin signaling in zebrafish. 
Blood 2007; 110: 2718-2726.
Paik EJ, Zon LI. Hematopoietic development in the zebrafish. Int J Dev Biol 2010; 
54: 1127-1137.
Palis J, Yoder MC. Yolk-sac hematopoiesis: The first blood cells of mouse and man. 
Exp Hematol 2001; 29: 927-936.
Panagopoulos I, Strömbeck B, Isaksson M, Heldrup J, Olofsson T, Johansson B. 
Fusion of ETV6 with an intronic sequence of the BAZ2A gene in a paediatric pre-B acute 
169
References
lymphoblastic leukaemia with a cryptic chromosome 12 rearrangement. Br J Haematol 2006; 
133: 270-275.
Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM. The novel 
activation of ABL by fusion to an ets-related gene, TEL. Cancer Res 1995; 55: 34-38.
Patel N, Goff LK, Clark T, Ford AM, Foot N, Lillington D, Hing S, Pritchard Jones 
K, Jones LK, Saha V. Expression profile of wild type ETV6 in childhood acute leukaemia. Br 
J Haematol 2003; 122: 94-98.
Patterson LJ, Gering M, Eckfeldt CE, Green AR, Verfaillie CM, Ekker SC, Patient R. 
The transcription factors Scl and Lmo2 act together during development of the hemangioblast 
in zebrafish. Blood 2007; 109: 2389-2398.
Peeters P, Raynaud SD, Cools J, Wlodarska I, Grosgeorge J, Philip P, Monpoux F, 
Van Rompaey L, Baens M, Van den Berghe H. Fusion of TEL, the ETS-variant gene 6 
(ETV6), to the receptor-associated kinase JAK2 as a result of t (9; 12) in a lymphoid and t (9; 
15; 12) in a myeloid leukemia. Blood 1997; 90: 2535-2540.
Peeters P, Wlodarska I, Baens M, Criel A, Selleslag D, Hagemeijer A, Van den 
Berghe H, Marynen P. Fusion of ETV6 to MDS1/EVI1 as a result of t (3; 12)(q26; p13) in 
myeloproliferative disorders. Cancer Res 1997b; 57: 564-569.
Penas EMM, Cools J, Algenstaedt P, Hinz K, Seeger D, Schafhausen P, Schilling G, 
Marynen P, Hossfeld DK, Dierlamm J. A novel cryptic translocation t (12; 17)(p13; p12–
p13) in a secondary acute myeloid leukemia results in a fusion of the ETV6 gene and the 
antisense strand of the PER1 gene. Genes Chromosomes Cancer 2003; 37: 79-83.
Pezet A, Ferrag F, Kelly PA, Edery M. Tyrosine docking sites of the rat prolactin 
receptor required for association and activation of stat5. J Biol Chem1997; 272: 25043-
25050.
PietilÄ I, Vainio S. The embryonic aorta gonad mesonephros region as a generator of 
haematopoietic stem cells. Apmis 2005; 113: 804-812.
Pietras EM, Warr MR, Passegué E. Cell cycle regulation in hematopoietic stem cells. 
JCB 2011; 195: 709-720.
Poirel H, Oury C, Carron C, Duprez E, Laabi Y, Tsapis A, Romana SP, Mauchauffe 
M, Le Coniat M, Berger R. The TEL gene products: nuclear phosphoproteins with DNA 
binding properties. Oncogene 1997; 14: 349-357.
Pokharel M. Leukemia: a review article. IJARPB 2012; 2: 397-407.0
Potter MD, Buijs A, Kreider B, van Rompaey L, Grosveld GC. Identification and 
characterization of a new human ETS-family transcription factor, TEL2, that is expressed in 
hematopoietic tissues and can associate with TEL1/ETV6. Blood 2000; 95: 3341-3348.
Qiao Y, Ogawa S, Hangaishi A, Yuji K, Izutsu K, Kunisato A, Imai Y, Wang L, 
Hosoya N, Nannya Y. Identification of a novel fusion gene, TTL, fused to ETV6 in acute 
lymphoblastic leukemia with t (12; 13)(p13; q14), and its implication in leukemogenesis. 
Leukemia 2003; 17: 1112-1120.
170
References
Quintana AM, Picchione F, Geltink RIK, Taylor MR, Grosveld GC. Zebrafish etv7 
regulates red blood cell development through the cholesterol synthesis pathway. Dis Model 
Mech 2014; 7: 265-270.
Rawat VP, Cusan M, Deshpande A, Hiddemann W, Quintanilla-Martinez L, 
Humphries RK, Bohlander SK, Feuring-Buske M, Buske C. Ectopic expression of the 
homeobox gene Cdx2 is the transforming event in a mouse model of t (12; 13)(p13; q12) 
acute myeloid leukemia. Proc Natl Acad Sci USA 2004; 101: 817-822.
Raynaud S, Cave H, Baens M, Bastard C, Cacheux V, Grosgeorge J, Guidal-Giroux 
C, Guo C, Vilmer E, Marynen P. The 12; 21 translocation involving TEL and deletion of the 
other TEL allele: two frequently associated alterations found in childhood acute 
lymphoblastic leukemia. Blood 1996; 87: 2891-2899.
Robb L. Cytokine receptors and hematopoietic differentiation. Oncogene 2007; 26: 
6715-6723.
Rodriguez P. Characterization of hematopoietic transcription factor complexes in 
erythroid cells. 2006.
Romana S, Mauchauffe M, Le Coniat M, Chumakov I, Le Paslier D, Berger R, 
Bernard O. The t (12; 21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. 
Blood 1995a; 85: 3662-3670.
Romana S, Poirel H, Leconiat M, Flexor M, Mauchauffe M, Jonveaux P, Macintyre 
E, Berger R, Bernard O. High frequency of t (12; 21) in childhood B-lineage acute 
lymphoblastic leukemia. Blood 1995b; 86: 4263-4269.
Rompaey L, Potter M, Adams C, Grosveld G. Tel induces a G1 arrest and suppresses 
Ras-induced transformation. Oncogene 2000; 19: 5244-5250.
Rottapel R, Ilangumaran S, Neale C, La Rose J, Ho J, Nguyen M, Barber D, Dubreuil 
P, de Sepulveda P. The tumor suppressor activity of SOCS-1. Oncogene 2002; 21: 4351-
4362.
Roukens MG, Alloul-Ramdhani M, Baan B, Kobayashi K, Peterson-Maduro J, van 
Dam H, Schulte-Merker S, Baker DA. Control of endothelial sprouting by a Tel-CtBP 
complex. Nat Cell Biol 2010; 12: 933-942.
Sabaawy HE, Azuma M, Embree LJ, Tsai H-J, Starost MF, Hickstein DD. TEL-
AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia. Proc 
Natl Acad Sci USA 2006; 103: 15166-15171.
Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of 
basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of 
signal transduction. J Biol Chem 2002; 277: 47954-47963.
Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by 
its pseudokinase domain. Mol Cell Biol 2000; 20: 3387-3395.
Saharinen P, Vihinen M, Silvennoinen O. Autoinhibition of Jak2 tyrosine kinase is 
dependent on specific regions in its pseudokinase domain. Mol Biol Cell 2003; 14: 1448-
1459.
171
References
Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune 
tolerance. Cell 2008; 133: 775-787.
Sakurai T, Yamada T, Kihara-Negishi F, Teramoto S, Sato Y, Izawa T, Oikawa T. 
Effects of overexpression of the Ets family transcription factor TEL on cell growth and 
differentiation of K562 cells. Int J Oncol 2003; 22: 1327-1333.
Salomon-Nguyen F, Della-Valle V, Mauchauffé M, Busson-Le Coniat M, Ghysdael J, 
Berger R, Bernard OA. The t (1; 12)(q21; p13) translocation of human acute myeloblastic 
leukemia results in a TEL-ARNT fusion. Proc Natl Acad Sci USA 2000; 97: 6757-6762.
Sasaki K, Nakamura Y, Maki K, Waga K, Nakamura F, Arai H, Imai Y, Hirai H, 
Mitani K. Functional analysis of a dominant-QHJDWLYHǻ(767(/(79 LVRIRUP%LRFKHP
Biophys Res Commun 2004; 317: 1128-1137.
Sato Y, Suto Y, Pietenpol J, Golub T, Gilliland D, Davis E, Le Beau M, Roberts J, 
Vogelstein B, Rowley J. TEL and KIP1 define the smallest region of deletions on 12p13 in 
hematopoietic malignancies. Blood 1995; 86: 1525-1533.
Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to 
cytokines. J Biol Chem 2007; 282: 20059-20063.
Schindler CW. Series introduction. JAK-STAT signaling in human disease. J Clin 
Invest 2002; 109: 1133-1137.
Schlenner SM, Rodewald HR. Early T cell development and the pitfalls of potential. 
Trends Immunol 2010; 31: 303-310.
Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS, Peeters P, 
Van Rompaey L, Van Etten RA, Ilaria R. Transformation of hematopoietic cell lines to 
growth-factor independence and induction of a fatal myelo-and lymphoproliferative disease 
in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 1998; 17: 5321-5333.
Schwaller J, Parganas E, Wang D, Cain D, Aster JC, Williams IR, Lee C-K, Gerthner 
R, Kitamura T, Frantsve J. Stat5 is essential for the myelo-and lymphoproliferative disease 
induced by TEL/JAK2. Mol Cell 2000; 6: 693-704.
Sharrocks AD, Brown AL, Ling Y, Yates PR. The ETS-domain transcription factor 
family. Int J Biochem Cell Biol 1997; 29: 1371-1387.
Shen L-J, Chen F-Y, Zhang Y, Cao L-F, Kuang Y, Zhong M, Wang T, Zhong H. 
MYCN transgenic zebrafish model with the characterization of acute myeloid leukemia and 
altered hematopoiesis. PLoS One 2013; 8: e59070.
Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K, Oku S, Abe 
H, Katayose KS, Kubuki Y. Development of ET, primary myelofibrosis and PV in mice 
expressing JAK2 V617F. Leukemia 2007; 22: 87-95.
Shizuru JA, Negrin RS, Weissman IL. Hematopoietic stem and progenitor cells: 
clinical and preclinical regeneration of the hematolymphoid system. Annu Rev Med 2005; 
56: 509-538.
172
References
Shurtleff S, Buijs A, Behm F, Rubnitz J, Raimondi S, Hancock M, Chan GCF, Pui 
CH, Grosveld G, Downing J. TEL/AML1 fusion resulting from a cryptic t (12; 21) is the 
most common genetic lesion in pediatric ALL and defines a subgroup of patients with an
excellent prognosis. Leukemia 1995; 9: 1985-1989.
Silva F, Morolli B, Storlazzi C, Zagaria A, Impera L, Klein B, Vrieling H, Kluin-
Nelemans H, Giphart-Gassler M. ETV6 mutations and loss in AML-M0. Leukemia 2008; 22: 
1639-1643.
Smith AC, Raimondi AR, Salthouse CD, Ignatius MS, Blackburn JS, Mizgirev IV, 
Storer NY, de Jong JL, Chen AT, Zhou Y. High-throughput cell transplantation establishes 
that tumor-initiating cells are abundant in zebrafish T-cell acute lymphoblastic leukemia. 
Blood 2010; 115: 3296-3303.
Sorrells S, Toruno C, Stewart RA, Jette C. Analysis of apoptosis in zebrafish embryos 
by whole-mount immunofluorescence to detect activated Caspase 3. JoVE 2013: e51060-
e51060.
Spiekermann K, Pau M, Schwab R, Schmieja K, Franzrahe S, Hiddemann W. 
Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with 
protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor 
cells. Exp Hematol 2002; 30: 262-271.
Staerk J, Kallin A, Royer Y, Diaconu C-C, Dusa A, Demoulin J-B, Vainchenker W, 
Constantinescu S. JAK2, the JAK2 V617F mutant and cytokine receptors. Pathologie 
Biologie 2007; 55: 88-91.
Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland 
DG, Tefferi A. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in 
both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood 2005; 
106: 1207-1209.
Stoiber D, Kovacic B, Schuster C, Schellack C, Karaghiosoff M, Kreibich R, Weisz 
E, Artwohl M, Kleine OC, Muller M. TYK2 is a key regulator of the surveillance of B 
lymphoid tumors J Clin Invest 2004; 114: 1650-1658.
Strehl S, König M, Dworzak M, Kalwak K, Haas O. PAX5/ETV6 fusion defines 
cytogenetic entity dic (9; 12)(p13; p13). Leukemia 2003; 17: 1121-1123.
Strehl S, Nebral K, König M, Harbott J, Strobl H, Ratei R, Struski S, Bielorai B, 
Lessard M, Zimmermann M. ETV6-NCOA2: a novel fusion gene in acute leukemia 
associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 
mutations. Clinical Cancer Res 2008; 14: 977-983.
Struski S, Mauvieux L, Gervais C, Hélias C, Liu KL, Lessard M. ETV6/GOT1 fusion 
in a case of t (10; 12)(q24; p13)-positive myelodysplastic syndrome. Haematologica 2008; 
93: 467-468.
Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and 
properties. Antisense Nucleic Acid Drug Dev 1997; 7: 187-195.
173
References
Sun J LW, Li L, Chen J, Wu M, Zhang Y, Leung AY, Zhang W, Wen Z, Liao W. 
Suppression of Pu.1 function results in expanded myelopoiesis in zebrafish. Leukemia 2013; 
27: 1913-1917.
Suto Y, Sato Y, Smith SD, Rowley JD, Bohlander SK. A t (6; 12)(q23; p13) results in 
the fusion of ETV6 to a novel gene, STL, in a B cell ALL cell line. Genes Chromosomes 
Cancer 1997; 18: 254-268.
Takahashi W, Sasaki K, Komatsu N, Mitani K. TEL/ETV6 accelerates erythroid 
differentiation and inhibits megakaryocytic maturation in a human leukemia cell line UT-
7/GM. Cancer Sci 2005; 96: 340-348.
Taketani T, Taki T, Sako M, Ishii T, Yamaguchi S, Hayashi Y.  MNX1–ETV6 fusion 
gene in an acute megakaryoblastic leukemia and expression of the MNX1 gene in leukemia 
and normal B cell lines. Cancer Gent Cytogenet 2008; 186: 115-119.
Takizawa H, Boettcher S, Manz MG. Demand-adapted regulation of early 
hematopoiesis in infection and inflammation. Blood 2012; 119: 2991-3002.
Tanaka H, Takeuchi M, Takeda Y, Sakai S, Abe D, Ohwada C, Sakaida E, Shimizu 
N, Saito Y, Miyagi S. Identification of a novel TEL–Lyn fusion gene in primary 
myelofibrosis. Leukemia 2009; 24: 197-200.
Tanaka T, Tanaka K, Ogawa S, Kurokawa M, Mitani K, Nishida J, Shibata Y, Yazaki 
Y, Hirai H. An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell 
differentiation and transcriptional activation antagonistically by two alternative spliced forms. 
EMBO J 1995; 14: 341-350.
Taniguchi T. Cytokine signaling through nonreceptor protein tyrosine kinases. 
Science 1995; 268: 251-255.
Tefferi A, Vardiman J. Classification and diagnosis of myeloproliferative neoplasms: 
the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. 
Leukemia 2007; 22: 14-22.
Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Eng J Med 2009; 361: 1872-
1885.
Thompson MA, Ransom DG, Pratt SJ, MacLennan H, Kieran MW, Detrich III HW, 
Vail B, Huber TL, Paw B, Brownlie AJ. The cloche and spadetail genes differentially affect 
hematopoiesis and vasculogenesis. Dev Biol 1998; 197: 248-269.
Tokita K, Maki K, Tadokoro J, Nakamura Y, Arai Y, Sasaki K, Eguchi-Ishimae M, 
Eguchi M, Mitani K. Chronic idiopathic myelofibrosis expressing a novel type of TEL-
PDGFRB chimaera responded to imatinib mesylate therapy. Leukemia 2006; 21: 190-192.
Traver D, Paw BH, Poss KD, Penberthy WT, Lin S, Zon LI. Transplantation and in 
vivo imaging of multilineage engraftment in zebrafish bloodless mutants. Nat Immunol 2003; 
4: 1238-1246.
Trede NS, Langenau DM, Traver D, Look AT, Zon LI. The use of zebrafish to 
understand immunity. Immunity 2004; 20: 367-379.
174
References
Trede NS, Zapata A, Zon LI. Fishing for lymphoid genes. Trends Immunol 2001; 22: 
302-307.
Turner DL, Weintraub H. Expression of achaete-scute homolog 3 in Xenopus 
embryos converts ectodermal cells to a neural fate. Genes Dev 1994; 8: 1434-1447.
Ungureanu D, Wu J, Pekkala T, Niranjan Y, Young C, Jensen ON, Xu CF, Neubert 
TA, Skoda RC, Hubbard SR. The pseudokinase domain of JAK2 is a dual-specificity protein 
kinase that negatively regulates cytokine signalling. Nat Struct Mol Biol 2011; 18: 971-976.
Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with 
engineered zinc finger nucleases. Nat Rev Genet 2010; 11: 636-646.
van de Geijn G-JM, Gits J, Touw IP. Distinct activities of suppressor of cytokine 
signaling (SOCS) proteins and involvement of the SOCS box in controlling G-CSF signaling. 
J. Leukoc. Biol 2004; 76: 237-244.
van Doorn SBW, Khosrovani DS, de Knegt Y, Tang M, Löwenberg B, Delwel R. 
Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in 
acute myeloid leukemia. Oncogene 2005; 24: 4129-4137.
Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, Haydu JE, Rigo I, 
Hadler M, Tosello V, Della Gatta G, Paietta E, Racevskis J. ETV6 mutations in early 
immature human T cell leukemias. J Exp Med 2011; 208: 2571-2579.
van Wely K, Meester-Smoor M, Janssen M, Aarnoudse A, Grosveld G, Zwarthoff E. 
The MN1-TEL myeloid leukemia-associated fusion protein has a dominant-negative effect on 
RAR-RXR-mediated transcription. Oncogene 2007; 26: 5733-5740.
van Wely KH, Molijn AC, Buijs A, Meester-Smoor MA, Aarnoudse AJ, Hellemons 
A, den Besten P, Grosveld GC, Zwarthoff EC. The MN1 oncoprotein synergizes with 
coactivators RAC3 and p300 in RAR-RXR-mediated transcription. Oncogene 2003; 22: 699-
709.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, 
Le Beau MM, Hellström-Lindberg E, Tefferi A. The 2008 revision of the World Health 
Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and 
important changes. Blood 2009; 114: 937-951.
Verduzco D, Amatruda JF. Analysis of Cell Proliferation, Senescence and Cell Death 
in Zebrafish Embryos. Methods in cell biology 2011; 101: 19-38.
Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ, 
Kantarjian H, Priebe W, Estrov Z. WP1066, a novel JAK2 inhibitor, suppresses proliferation 
and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin 
Cancer Res 2008; 14: 788-796.
von Bergh AR, van Drunen E, van Wering ER, van Zutven LJ, Hainmann I,
Lönnerholm G, Meijerink JP, Pieters R, Beverloo HB. High incidence of t (7; 12)(q36; p13) 
in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of 
HLXB9. Genes Chromosomes Cancer 2006; 45: 731-739.
175
References
Vu H, Xinh P, Masuda M, Motoji T, Toyoda A, Sakaki Y, Tokunaga K, Sato Y. 
FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and at (12; 
13)(p13; q12) translocation. Leukemia 2006; 20: 1414-1421.
Waga K, Nakamura Y, Maki K, Arai H, Yamagata T, Sasaki K, Kurokawa M, Hirai 
H, Mitani K. Leukemia-related transcription factor TEL accelerates differentiation of Friend 
erythroleukemia cells. Oncogene 2003; 22: 59-68.
Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler 
Thromb Vasc Biol 2003; 23: 2131-2137.
Walters DK, Mercher T, Gu T-L, O'Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, 
Eide CA, Wong MJ. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer 
cell 2006; 10: 65-75.
Walz C, Erben P, Ritter M, Bloor A, Metzgeroth G, Telford N, Haferlach C, 
Haferlach T, Gesk S, Score J. Response of ETV6-FLT3–positive myeloid/lymphoid 
neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood 2011; 118: 
2239-2242.
Wang L, Hiebert SW. TEL contacts multiple co-repressors and specifically associates 
with histone deacetylase-3. Oncogene 2001; 20: 3716-3725.
Wang LC, Kuo F, Fujiwara Y, Gilliland DG, Golub TR, Orkin SH. Yolk sac 
angiogenic defect and intra-embryonic apoptosis in mice lacking the Ets-related factor TEL.
EMBO J 1997; 16: 4374-4383.
Wang LC, Swat W, Fujiwara Y, Davidson L, Visvader J, Kuo F, Alt FW, Gilliland 
DG, Golub TR, Orkin SH. The TEL/ETV6 gene is required specifically for hematopoiesis in 
the bone marrow. Genes Dev 1998; 12: 2392-2402.
Ward AC, Hermans MH, Smith L, van Aesch YM, Schelen AM, Antonissen C, Touw 
IP. Tyrosine-dependent and-independent mechanisms of STAT3 activation by the human 
granulocyte colony-stimulating factor (G-CSF) receptor are differentially utilized depending 
on G-CSF concentration. Blood 1999; 93: 113-124.
Ward AC, McPhee DO, Condron MM, Varma S, Cody SH, Onnebo S, Paw BH, Zon 
LI, Lieschke GJ. The zebrafish spi1 promoter drives myeloid-specific expression in stable 
transgenic fish. Blood 2003; 102: 3238-3240.
Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed 
hematopoiesis. Blood 2000; 95: 19-29.
Weber GJ, Choe SE, Dooley KA, Paffett-Lugassy NN, Zhou Y, Zon LI. Mutant-
specific gene programs in the zebrafish. Blood 2005; 106: 521-530.
Wickramasinghe S, Goerke A, Garcia J, Han B. Designing blood oxygenators. Ann N 
Y Acad Sci. 2003; 984: 502-514.
Wickramasinghe SN, McCullough J. Blood and bone marrow pathology: Elsevier 
Science Limited, Edinburgh, 2003.
176
References
Willett CE, Cherry JJ, Steiner LA. Characterization and expression of the 
recombination activating genes (rag1 and rag2) of zebrafish. Immunogenetics 1997; 45: 394-
404.
Willett CE, Cortes A, Zuasti A, Zapata AG. Early hematopoiesis and developing 
lymphoid organs in the zebrafish. Dev Dyn 1999; 214: 323-336.
Willett CE, Kawasaki H, Amemiya CT, Lin S, Steiner LA. Ikaros expression as a 
marker for lymphoid progenitors during zebrafish development. Dev Dyn 2001; 222: 694-
698.
Wlodarska I, Baens M, Peeters P, Aerssens J, Mecucci C, Brock P, Marynen P, Van
den Berghe H. Biallelic alterations of both ETV6 and CDKN1B genes in at (12; 21) 
childhood acute lymphoblastic leukemia case. Cancer Res 1996; 56: 2655-2661.
Wlodarska I, Marynen P, La Starza R, Mecucci C, Van den Berghe H. The ETV6, 
CDKN1B and D12S178 loci are involved in a segment commonly deleted in various 12p 
aberrations in different hematological malignancies. Cytogenet Genome Res 1996; 72: 229-
235.
Wood LD, Irvin BJ, Nucifora G, Luce KS, Hiebert SW. Small ubiquitin-like modifier 
conjugation regulates nuclear export of TEL, a putative tumor suppressor. Proc Natl Acad Sci 
USA 2003; 100: 3257.
Wright DA, Thibodeau-Beganny S, Sander JD, Winfrey RJ, Hirsh AS, Eichtinger M, 
Fu F, Porteus MH, Dobbs D, Voytas DF. Standardized reagents and protocols for engineering 
zinc finger nucleases by modular assembly. Nat Protoc 2006; 1: 1637-1652.
Xiang Z, Zhao Y, Mitaksov V, Fremont DH, Kasai Y, Molitoris A, Ries RE, Miner 
TL, McLellan MD, DiPersio JF. Identification of somatic JAK1 mutations in patients with 
acute myeloid leukemia. Blood 2008; 111: 4809-4812.
Xiong J-W, Yu Q, Zhang J, Mably JD. An acyltransferase controls the generation of 
hematopoietic and endothelial lineages in zebrafish. Circ Res 2008; 102: 1057-1064.
Xu L, Glass CK, Rosenfeld MG. Coactivator and corepressor complexes in nuclear 
receptor function. Curr Opin Genet Dev1999; 9: 140-147.
Yagasaki F, Jinnai I, Yoshida S, Yokoyama Y, Matsuda A, Kusumoto S, Kobayashi 
H, Terasaki H, Ohyashiki K, Asou N. Fusion of TEL/ETV6 to a novel ACS2 in 
myelodysplastic syndrome and acute myelogenous leukemia with t (5; 12)(q31; p13). Genes 
Chromosomes Cancer 1999; 26: 192-202.
Yagasaki F, Wakao D, Yokoyama Y, Uchida Y, Murohashi I, Kayano H, Taniwaki 
M, Matsuda A, Bessho M. Fusion of ETV6 to fibroblast growth factor receptor 3 in 
peripheral T-cell lymphoma with at (4; 12)(p16; p13) chromosomal translocation. Cancer Res 
2001; 61: 8371-8374.
Yamashita Y, Watanabe S, Miyazato A, Ohya K, Ikeda U, Shimada K, Komatsu N, 
Hatake K, Miura Y, Ozawa K. Tec and Jak2 kinases cooperate to mediate cytokine-driven 
activation of c-fos transcription. Blood 1998; 91: 1496-1507.
177
References
Yeh J-RJ, Munson KM, Chao YL, Peterson QP, MacRae CA, Peterson RT. AML1-
ETO reprograms hematopoietic cell fate by downregulating scl expression. Development
2008; 135: 401-410.
Yeh J-RJ, Munson KM, Elagib KE, Goldfarb AN, Sweetser DA, Peterson RT. 
Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. Nat 
Chem Biol 2009; 5: 236-243.
Yoong S, O’Connell B, Soanes A, Crowhurst MO, Lieschke GJ, Ward AC. 
Characterization of the zebrafish matrix metalloproteinase 9 gene and its developmental 
expression pattern. Gene Expr Patterns 2007; 7: 39-46.
Zaliova M, Meyer C, Cario G, Vaskova M, Marschalek R, Stary J, Zuna J, Trka J. 
TEL/AML1-positive patients lacking TEL exon 5 resemble canonical TEL/AML1 cases. 
Pediatr Blood Cancer 2011; 56: 217-225.
Zhang CD. Analysis of the interaction of TIP60 and PIN1 with the ets family 
transcription factor ETV6. 2005.
Zhang J, Mullighan CG, Harvey RC, Wu G, Chen X, Edmonson M, Buetow KH, 
Carroll WL, Chen I-M, Devidas M. Key pathways are frequently mutated in high-risk 
childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. 
Blood 2011; 118: 3080-3087.
Zhang XY, Rodaway AR. SCL-GFP transgenic zebrafish: In vivo imaging of blood 
and endothelial development and identification of the initial site of definitive hematopoiesis. 
Dev Biol 2007; 307: 179-194.
Zhang Y, Wang J, Wheat J, Chen X, Jin S, Sadrzadeh H, Fathi AT, Peterson RT, 
Kung AL, Sweetser DA. AML1-ETO mediates hematopoietic self-renewal and 
OHXNHPRJHQHVLVWKURXJKD&2;ȕ-catenin signaling pathway. Blood 2013; 121: 4906-4916.
Zhuravleva J, Paggetti J, Martin L, Hammann A, Solary E, Bastie JN, Delva L. 
MOZ/TIF2-induced acute myeloid leukaemia in transgenic fish. Br J Haematol 2008; 143: 
378-382.
Zu Y, Tong X, Wang Z, Liu D, Pan R, Li Z, Hu Y, Luo Z, Huang P, Wu Q. TALEN-
mediated precise genome modification by homologous recombination in zebrafish. Nat 
methods 2013; 10: 329-331.
178
References
179
Supplementary figures
Supplementary figures
180
Supplementary figures
Supplementary Figure 4.1: Non-hematopoietic defects due to ubiquitous expression of 
tel-jak2a fusions.
Light microscopic images of uninjected embryos (uninj: A, D) or embryos injected with 
CMV.tel-jak2a ALL (B, E) or CMV.tel-jak2a CML (C, F) at the times indicated. Disrupted 
brain development in panels B and C is indicated with arrowheads and aggregated pigment 
cells in panels E and F are indicated with asterices.
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Supplementary Figure 4.2: Molecular characterization of non-hematopoietic defects 
caused by ubiquitous expression.
Uninjected embryos (uninj: A, D) or embryos injected with CMV.tel-jak2a ALL (B, E) or 
CMV.tel-jak2a CML (C, F) were analyzed for expression of the brain marker pax2.1 at 24 hpf 
(A-C) and the vascular marker flk1 at 24 hpf (D-F) by in situ hybridization. Embryos injected 
with CMV.tel-jak2a ALL or CMV.tel-jak2a CML had weaker pax2.1 expression in the 
midbrain-hindbrain boundary and optic stalk, as well as less migrating neurons than 
uninjected embryos. Perturbations in flk1 expression in the dorsal aorta and caudal vein in 
injected embryos with tail defects compared to uninjected controls. In addition, there was no 
flk1 expression in the area where the intersomitic vessels normally lie, suggesting they are 
absent and confirming the observations made by visual examination. Labeled structures are 
MHB (midbrain-hindbrain boundary), HN (hindbrain neurons), os (optic stalk), T (thymus), 
da (dorsal aorta), cv (cardial vein) and intersomitic vessels (ISV). 
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